On this page
Quick Reference
Overview and Recommendations
Background
- •Allergic rhinitis (AR) is an IgE-mediated type I hypersensitivity reaction of the nasal mucosa triggered by inhaled allergens; it affects an estimated 400-500 million people worldwide and is the most prevalent allergic disease, with a marked rise over the past decade, especially in children. The condition is a key step in the atopic march: it triples the odds of subsequent asthma (adjusted RR 3.53) and commonly co-occurs with atopic dermatitis and allergic conjunctivitis.
- •The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines classify AR along three axes: symptom frequency (intermittent <4 days/week or <4 weeks; persistent ≥4 days/week and ≥4 weeks), severity (mild with normal sleep and activity; moderate-to-severe with impairment), and trigger exposure (seasonal from outdoor pollens, perennial from indoor allergens). A distinct phenotype, local allergic rhinitis (LAR), accounts for up to 25% of rhinitis patients and is characterized by negative skin prick tests and serum IgE but positive nasal allergen challenge and local IgE production in the nasal mucosa.
- •The pathophysiology unfolds in two phases: an early-phase response driven by mast cell degranulation and histamine release, causing sneezing, itching, and watery rhinorrhea within minutes of allergen exposure; followed by a late-phase response 4-6 hours later, orchestrated by eosinophils, Th2 lymphocytes, and ILC2s, producing persistent nasal congestion and mucosal hyperreactivity. Epithelial barrier dysfunction and neurogenic inflammation (via TRP channels, substance P) amplify and perpetuate this type 2 inflammation.
- •The evolution of treatment has moved from empiric oral antihistamines (first-generation, sedating) to targeted therapy: intranasal corticosteroids (first-line since the 1990s), combination intranasal antihistamine-corticosteroid fixed-dose products (superior to monotherapy), and disease-modifying allergen immunotherapy (AIT). AIT, subcutaneous or sublingual, is the only intervention that reduces the risk of developing asthma (RR 0.40) and provides sustained benefit for years after a minimum 3-year course. Biologics such as tezepelumab (anti-TSLP) and stapokibart (anti-IL-4Rα) are emerging for uncontrolled seasonal disease but remain second-line options.
Evaluation
- •Suspect allergic rhinitis in any patient presenting with the classic symptom quartet: sneezing, nasal itching, clear rhinorrhea, and nasal congestion, especially when triggered by specific allergen exposures (pollen seasons, dust mites, animal dander, mold). Ocular itching, tearing, and redness accompany nasal symptoms in up to 75% of patients, reflecting shared conjunctival mucosal involvement.
- •Ask about the pattern and duration of symptoms: are they seasonal (tree, grass, weed pollens) or perennial (dust mites, pets, cockroach)? Use the ARIA framework to classify as intermittent (<4 days/week or <4 consecutive weeks) versus persistent (≥4 days/week and ≥4 weeks). Elicit impact on sleep, school/work productivity, and daily activities to grade severity as mild or moderate-to-severe.
- •Examine the nasal cavity using anterior rhinoscopy or nasal endoscopy: look for pale, boggy, edematous turbinates with clear, watery secretions. The classic 'allergic salute' (upward rubbing of the nose) produces a horizontal crease across the nasal bridge (allergic crease). Dark circles under the eyes (allergic shiners) and Dennie-Morgan lines are supportive but not specific. Inspect the conjunctivae for injection and chemosis; examine the posterior pharynx for cobblestoning from lymphoid hyperplasia.
- •Order skin prick testing (SPT) with a panel of regionally relevant aeroallergens as the initial test of choice, it is rapid, safe, and provides immediate results. A positive reaction (wheal ≥3 mm larger than negative control) indicates IgE sensitization. An alternative is serum-specific IgE (sIgE) measurement (≥0.35 kU/L positive), useful when antihistamines cannot be withheld or SPT is unavailable; discordance between SPT and sIgE occurs in up to 20% of cases.
- •If SPT and sIgE are negative but clinical suspicion for allergic rhinitis remains high, consider nasal allergen challenge (NAC) to diagnose local allergic rhinitis (LAR). NAC is the gold standard for LAR and should be performed in specialized centers using standardized allergen extracts with subjective symptom scores and objective measures (peak nasal inspiratory flow, acoustic rhinometry).
- •Assess severity using validated instruments: the Total Nasal Symptom Score (TNSS) grades rhinorrhea, congestion, sneezing, and itching each 0-3 (composite ≥5 defines moderate-to-severe); the visual analog scale (VAS) score >5 on a 0-10 scale distinguishes moderate from severe disease per the modified ARIA classification. The minimal clinically important difference for TNSS is 0.55 units, and for PNIF (peak nasal inspiratory flow) it is 5 L/min.
- •Evaluate for comorbidities: screen for asthma (wheezing, chest tightness, nocturnal cough, exertional dyspnea; consider spirometry), allergic conjunctivitis, chronic rhinosinusitis (facial pressure, purulent discharge, hyposmia persisting beyond allergy season), otitis media with effusion (especially in children), and sleep-disordered breathing. In children, ask about snoring, mouth breathing, and school absenteeism.
- •Consider red flags that necessitate urgent evaluation: unilateral nasal obstruction or bloody discharge (suspect nasal mass or foreign body), purulent nasal discharge with facial pain and fever persisting >10 days (acute bacterial sinusitis), new-onset asthma symptoms, or persistent anosmia (consider chronic rhinosinusitis with nasal polyps). Cough as the sole presenting symptom may be asthma or eosinophilic bronchitis.
- •In refractory or atypical cases, nasal cytology (scraping with May-Grünwald-Giemsa staining) can identify eosinophils, mast cells, or neutrophils, helping differentiate from non-allergic rhinitis phenotypes (e.g., NARES). Total IgE and peripheral blood eosinophil count are supportive but not diagnostic. Basophil activation test (BAT) is emerging for LAR diagnosis but lacks standardization. Imaging (paranasal sinus CT) is reserved for suspected complications like chronic rhinosinusitis or nasal polyps.
Management
- •Initiate first-line pharmacotherapy with an intranasal corticosteroid (INCS) for moderate-to-severe or persistent allergic rhinitis: fluticasone propionate 2 sprays (50 µg/spray) each nostril once daily, or mometasone furoate 2 sprays each nostril once daily. For mild intermittent symptoms, a second-generation oral antihistamine (e.g., cetirizine 10 mg daily, loratadine 10 mg daily, fexofenadine 180 mg daily) or INCS monotherapy alone may suffice.
- •If symptoms are not adequately controlled after 2-4 weeks of INCS monotherapy, add an intranasal antihistamine: olopatadine 0.6% 2 sprays each nostril twice daily, or use the fixed-dose combination spray (olopatadine HCl plus mometasone furoate) 1 spray each nostril twice daily, this combination is superior to either constituent alone, with onset of action as early as 15 minutes.
- •For patients with moderate-to-severe persistent symptoms despite combination INCS + intranasal antihistamine, consider a short course (5-7 days) of an oral decongestant (pseudoephedrine 60 mg twice daily) for severe congestion, but avoid prolonged use (>7 days) due to risk of rhinitis medicamentosa. Oral leukotriene receptor antagonists (montelukast 10 mg daily) are second-line options, reserved for patients with comorbid asthma or those intolerant to other agents; monitor for neuropsychiatric events.
- •Refer to an allergist for consideration of allergen immunotherapy (AIT) when pharmacotherapy is inadequate, the patient desires disease modification, or there is a goal to prevent asthma. AIT is the only treatment that alters the natural history of allergic rhinitis; both subcutaneous (SCIT) and sublingual (SLIT) routes are effective. SCIT requires in-clinic injections (weekly build-up then monthly maintenance); SLIT tablets (grass, ragweed, house dust mite, birch) are self-administered daily at home.
- •Recommend a minimum 3-year course of AIT to achieve long-term tolerance and sustained clinical benefit. For children with moderate-to-severe grass or birch pollen AR, AIT reduces the short-term risk of developing asthma by 40% (RR 0.40). Advise patients that adherence is critical, only about one-third complete the recommended 3-year course in real-world settings; shared decision-making improves compliance.
- •For SCIT, administer epinephrine auto-injectors and observe patients for at least 30 minutes after each injection due to risk of systemic anaphylaxis (0.1-0.2% of injections). Contraindications to AIT include uncontrolled asthma, severe immunodeficiency, active malignancy, and use of beta-blockers (relative). SLIT has a better safety profile with mostly local oral itching/swelling; systemic reactions are very rare.
- •Consider biologic therapy in selected patients with uncontrolled seasonal allergic rhinitis despite optimized pharmacotherapy and AIT: tezepelumab (anti-TSLP) 210 mg subcutaneously every 4 weeks, or dupilumab (anti-IL-4Rα) at standard asthma dosing (300 mg every 2 weeks). Biologics are not yet approved for AR as a standalone indication in most countries; use in specialist centers with shared decision-making.
- •Avoid first-generation oral antihistamines (diphenhydramine, chlorpheniramine) due to sedation, psychomotor impairment, and anticholinergic effects, they are no longer recommended for any form of allergic rhinitis. Avoid long-term use of oral decongestants (pseudoephedrine, phenylephrine) beyond 7 days. Avoid systemic corticosteroids for chronic disease due to unacceptable adverse effects.
- •Monitor treatment response using validated symptom scores (TNSS, RQLQ) at each follow-up visit. Assess adherence and address barriers. Evaluate for adverse effects: INCS may cause mild epistaxis (5-10%) or nasal irritation; educate on correct spray technique (aim lateral wall, not septum). For AIT, monitor for local and systemic reactions at each dose.
- •Discharge criteria for acute care: patients presenting with anaphylaxis from AIT or natural exposure should be observed for at least 4-6 hours after epinephrine administration for biphasic reactions. Prescribe epinephrine auto-injector, pause AIT, and reassess risk-benefit before resuming. Refer patients with severe reactions to an allergist for dose adjustment or switch to SLIT.
Board Review — High Yield
- •Allergic salute and allergic crease, The classic horizontal nasal crease from upward rubbing of the nose is a pathognomonic sign of long-standing allergic rhinitis in children.
- •ARIA classification, Classify symptoms as intermittent (<4 days/week or <4 weeks) vs. persistent (≥4 days/week and ≥4 weeks); and mild (normal sleep/activity) vs. moderate-to-severe (impaired sleep/activity). This guides step-up therapy.
- •Local allergic rhinitis (LAR), Up to 25% of rhinitis patients have negative skin prick tests and serum IgE but positive nasal allergen challenge; this phenotype responds to standard pharmacotherapy and AIT.
- •Intranasal corticosteroids are first-line, They suppress the late-phase inflammatory response (eosinophil infiltration) and are more effective than antihistamines for nasal congestion, the dominant symptom in persistent disease.
- •Combination intranasal corticosteroid + antihistamine, Fixed-dose olopatadine-mometasone is superior to either constituent alone, with onset of action as early as 15 minutes; recommended for moderate-severe disease not controlled by monotherapy.
- •Allergen immunotherapy (AIT) reduces asthma risk by 40%, A 3-year course of SCIT or SLIT is the only disease-modifying therapy; in children with grass/birch pollen AR, the RR for developing asthma is 0.40 (95% CI 0.30-0.54).
- •Epinephrine is first-line for anaphylaxis, In AIT-related or natural allergen-induced anaphylaxis, administer 0.3 mg IM (0.15 mg for children) into the anterolateral thigh; do not delay for antihistamines or corticosteroids.
- •Avoid first-generation antihistamines, They cause sedation and psychomotor impairment; second-generation agents (cetirizine, fexofenadine, loratadine) are equally effective and non-sedating.
- •Red flags: unilateral symptoms, purulent discharge, Unilateral nasal obstruction or bloody discharge suggests nasal mass/foreign body; purulent discharge with facial pain >10 days suggests bacterial sinusitis.
- •Atopic march, Allergic rhinitis triples the odds of asthma; screen children with atopic dermatitis or food allergy for AR from age 3 years onward.
Deep Dive — Evidence Details
Definition, Classification & Hypersensitivity Mechanism Type
- ▸AR is a clinically symptomatic disorder and should be distinguished from asymptomatic allergen sensitization. [529]
- ▸The supplied evidence classifies pediatric AR as seasonal or perennial, and as mild or moderate-to-severe. [518,521]
- ▸HDM-associated AR is explicitly described as an IgE-mediated sensitization phenotype; pollen-specific IgE should likewise be interpreted with clinical symptoms. [71,529]
- ▸The supported hypersensitivity category is **Gell–Coombs type I, IgE-mediated immediate hypersensitivity**, although the supplied references do not detail the full cellular pathway. [71,529]
- ▸AR may coexist with asthma, CRS, adenoid hypertrophy, Eustachian-tube dysfunction, OME, sleep disturbance, and psychosocial impairment. [523,524,527,528,531,534,335]
Definition
Within the supplied evidence base, allergic rhinitis (AR) is treated as a clinically expressed allergic airway disorder characterized primarily by nasal symptoms and evaluated using measures such as the Total Nasal Symptom Score (TNSS), with ocular symptoms assessed separately by the Total Ocular Symptom Score (TOSS). [518] AR is distinguished from asymptomatic allergic sensitization: population research classified participants separately as healthy, sensitized, AR, or acute asthma exacerbation, indicating that allergen-specific IgE alone does not establish clinically manifest rhinitis. [529] Pediatric studies also define AR using established ARIA-based clinical criteria, rather than sensitization testing alone. [527][530]
The condition is commonly considered part of the broader allergic-airway spectrum and may coexist with asthma, chronic rhinosinusitis (CRS), adenoid hypertrophy, Eustachian-tube dysfunction, and middle-ear disease. [527][528]C[523][524][534] In children, AR may also occur within an evolving atopic trajectory: a prospective cohort specifically examined progression from infant food allergy to later AR, while another cohort evaluated AR associated with house-dust-mite (HDM) sensitization during preschool years. [334]B2b[71]B2b
Classification
By temporal allergen pattern. The supplied pediatric treatment evidence explicitly distinguishes seasonal and perennial AR. [518] Seasonal AR is evaluated in relation to time-limited exposure to relevant environmental allergens, whereas perennial AR is evaluated as persistent or recurrent disease associated with more continuous exposure; the provided references do not supply a separate diagnostic threshold for duration or exposure frequency. [518]
By clinical severity. Pediatric cohorts use a practical severity distinction of mild versus moderate-to-severe AR. [521]C In the HDM cohort, children were stratified into mild AR and moderate-to-severe AR, and the latter group received standardized 1-year sublingual immunotherapy (SLIT). [521]C The response definition was a greater than 20% reduction in TNSS, demonstrating that symptom-score change can be used to classify treatment response, but this threshold is not a diagnostic definition of AR severity. [521]C
By allergen and sensitization phenotype. HDM-induced AR is identified as AR associated with IgE-mediated sensitization to HDM, and AR-HDM was studied as a distinct preschool phenotype. [71]B2b Pollen-related disease may likewise be characterized by specific IgE sensitization; however, a population study separated Artemisia-sensitized individuals from those with clinically defined Artemisia-related allergic disease, reinforcing the distinction between immunologic sensitization and symptomatic AR. [529] The available evidence therefore supports describing AR by clinically relevant allergen specificity—such as HDM- or pollen-associated disease—only when symptoms and sensitization are interpreted together. [71]B2b[529]
By associated phenotype or multimorbidity. AR may be described alongside comorbid upper-airway or lower-airway disease rather than as an isolated nasal condition. [527][528]C[534] In children with asthma and coexisting AR, fractional exhaled nitric oxide and absolute eosinophil count were assessed longitudinally as markers related to asthma control and exacerbation risk, although these measures do not define AR itself. [527] AR also commonly appears in studies of adenoid hypertrophy and CRS, including a transcriptomic comparison of adenoid hypertrophy with and without AR and an observational study of adenoidectomy in children with both conditions. [528]C[534] Systematic reviews further evaluate AR in relation to objective Eustachian-tube dysfunction, abnormal tympanometry, otitis media with effusion, and other middle-ear outcomes. [523][524]
Hypersensitivity mechanism type
The mechanism represented by the supplied evidence is most consistent with IgE-mediated immediate hypersensitivity (Gell–Coombs type I), particularly for allergen-defined pediatric phenotypes. [71]B2b[529] This interpretation is supported by the explicit use of “IgE-mediated sensitization” for HDM-associated AR and by the measurement of allergen-specific IgE in Artemisia-exposed populations. [71]B2b[529] Nevertheless, the references supplied here do not directly describe the complete cellular sequence of type I hypersensitivity—such as allergen cross-linking of mast-cell-bound IgE, mediator release, or the early- and late-phase inflammatory response—so those mechanistic details should not be presented as findings of these studies.
The evidence also indicates that clinical disease reflects more than sensitization alone. [529] Environmental exposure and host susceptibility both contributed to Artemisia-related sensitization and allergic disease in a large population study, while the preschool HDM study investigated clinical predictors of AR-HDM and CRS persistence. [529][71]B2b Nasal microbiome features, including Haemophilus abundance, were investigated as potential predictors of response to SLIT in children with moderate-to-severe AR; this is a treatment-response biomarker hypothesis, not evidence that the microbiome defines the hypersensitivity type. [521]C
Finally, AR-related inflammation has clinically important consequences beyond nasal symptoms. [523][524][527][528]C[531] Pediatric studies associate AR with middle-ear dysfunction and OME-related outcomes, asthma-related inflammatory monitoring, adenoid hypertrophy, sleep disturbance, and adverse psychosocial effects including impaired sleep, social engagement, emotional wellbeing, existential distress, and social alienation. [523][524][527][528]C[531][335]C4 These associations describe comorbidity and disease burden; they do not alter the primary classification of AR as an IgE-associated, clinically symptomatic allergic rhinitis phenotype when supported by compatible symptoms and relevant sensitization. [71]B2b[529]
| Classification axis | Categories or examples | Evidence-based qualification |
|---|---|---|
| Temporal pattern | Seasonal; perennial | Explicitly used in pediatric AR treatment trials. [518] |
| Clinical severity | Mild; moderate-to-severe | Used in a pediatric HDM-AR cohort. [521]C |
| Allergen phenotype | HDM-associated; pollen-associated, including Artemisia-related disease | Requires interpretation of clinical disease together with relevant IgE sensitization. [71]B2b[529] |
| Mechanism | IgE-mediated immediate hypersensitivity, consistent with type I | Supported by explicit IgE-mediated AR terminology; full pathway is not detailed in the supplied references. [71]B2b[529] |
| Multimorbidity phenotype | AR with asthma, CRS, adenoid hypertrophy, ETD, or OME | Represents associated disease burden rather than a different hypersensitivity class. [523][524][527][528]C[534] |
Pathophysiology & Immune Mechanism
- ▸AR reflects interaction between allergen exposure and host susceptibility; symptoms overlap with non-allergic rhinitis, but the underlying pathophysiology differs. [538,529]
- ▸Dust-mite sublingual immunotherapy reduced IL-4, IL-17, ECP, TARC and VCAM-1 over 6 months in a randomized trial of 300 patients. [536]
- ▸Nasal Corynebacterium depletion was associated with inhalant-allergen polysensitization defined as sensitization to ≥4 allergens. [539]
- ▸Cat sensitization was prominently associated with AR plus asthma, with an odds ratio of 3.743 in a real-world cohort. [542]
- ▸Peripheral-airway dysfunction and exercise-induced bronchoconstriction may occur in children with AR without established asthma; exercise testing used an FEV1 fall of ≥10% as the threshold. [540,543]
- ▸Evidence for probiotics, press-needle therapy and microbiome alterations is evolving; current studies do not establish these as definitive causal mechanisms. [535,539,544]
Overview
Allergic rhinitis (AR) is an allergen-associated inflammatory disorder of the upper airway. The supplied evidence distinguishes AR from non-allergic rhinitis, which may produce overlapping symptoms but has different pathophysiology and treatment implications. [538] In clinical research, AR has been defined using symptoms such as nasal itching, congestion, sneezing, rhinorrhea, ocular symptoms and overall discomfort, with confirmation by allergen testing or equivalent diagnostic assessment. [538]
Allergen exposure and host susceptibility
Disease expression reflects interaction between environmental exposure and host susceptibility rather than exposure alone. In a population study of Artemisia-exposed individuals, participants were classified as healthy, sensitized, affected by AR, or experiencing acute asthma exacerbation; the study specifically evaluated the relative contributions of regional pollen exposure and individual susceptibility. [529] This supports a model in which high pollen exposure increases the opportunity for sensitization or symptoms, while host factors determine whether exposure progresses to clinically relevant AR. [529]
Sensitization burden may influence disease phenotype and airway comorbidity. In adults, polysensitization was categorized as sensitization to ≥4 inhalant allergens, and nasal Corynebacterium depletion was investigated in relation to this phenotype. [539] In a real-world cohort, polysensitization, family history of AR or asthma, younger age, cat ownership and cat-specific IgE were associated with AR accompanied by asthma; cat sensitization remained a prominent independent factor, with an odds ratio of 3.743. [542] These findings support an association between broader allergen recognition or specific animal-dander sensitization and a more extensive allergic-airway phenotype, although they do not establish causality. [539][542]
Type 2 and inflammatory pathways
The provided interventional evidence identifies several inflammatory mediators associated with AR activity and response to allergen immunotherapy. In a randomized trial of 300 dust-mite-sensitized patients treated for 6 months, conventional therapy plus sublingual dust-mite drops produced greater reductions than conventional therapy alone in interleukin-4 (IL-4), interleukin-17 (IL-17), eosinophil cationic protein (ECP), thymus and activation-regulated chemokine (TARC) and vascular cell adhesion molecule-1 (VCAM-1), alongside improved symptoms and lower adverse-reaction rates. [536] IL-4 is consistent with type 2 immune activity, while ECP reflects eosinophil activation; the trial also implicates IL-17, TARC and VCAM-1 in the inflammatory profile that accompanies dust-mite AR. [536] Because the abstract reports treatment-associated changes rather than cellular or tissue-level mechanistic experiments, these biomarkers should be interpreted as correlates and potential therapeutic-response markers rather than proven independent drivers. [536]
Microbial communities may modify allergic inflammation. A cross-sectional adult study examined nasal microbiota in relation to inhalant-allergen polysensitization and specifically reported an association between nasal Corynebacterium depletion and polysensitization. [539] Separately, integrated 16S rRNA sequencing and untargeted metabolomics of supragingival plaque compared 35 patients with AR with 35 healthy individuals and identified differences in oral microbial composition and associated metabolic pathways. [134]B3b These findings suggest that upper-airway and oral microbial alterations may accompany AR and could influence immune or metabolic signaling, but the observational designs cannot determine whether dysbiosis causes AR, results from AR, or reflects treatment and environmental differences. [134]B3b[539]
An updated umbrella review and meta-analysis of randomized trials evaluated probiotics as immunomodulatory interventions in adults and children with AR, including effects on total IgE, antigen-specific IgE, eosinophil counts, rhinitis symptoms and quality of life. [544] The supplied abstract indicates that evidence has been inconsistent and that random-effects synthesis was used; therefore, probiotics should be regarded as a potential immune-modifying approach under investigation rather than a defined mechanism of AR. [544]
Airway-wide consequences and comorbidity
AR may represent part of a broader allergic-airway process. In children with moderate-to-severe persistent AR but no asthma diagnosis, impulse oscillometry was used to assess peripheral airway function, reflecting concern that lower-airway involvement can occur without overt asthma symptoms. [543] A related study evaluated exercise-induced bronchoconstriction in 62 non-asthmatic children aged 6–18 years receiving early subcutaneous allergen immunotherapy; the diagnostic threshold was a fall in FEV1 of ≥10% after exercise. [540] In children with coexisting asthma and AR, serial fractional exhaled nitric oxide and absolute eosinophil counts were assessed to distinguish asthma exacerbation from control, reinforcing the clinical relevance of shared eosinophilic/type 2 airway inflammation. [527]
AR is also linked clinically with adjacent airway and middle-ear dysfunction. A pediatric systematic review and meta-analysis evaluated AR, allergic sensitization, Eustachian tube dysfunction, abnormal tympanometry and otitis media with effusion, reflecting a proposed pathway from nasal inflammation to Eustachian-tube and middle-ear dysfunction. [524] In preschool children with chronic rhinosinusitis symptoms, a five-year multi-omics cohort assessed HDM-specific IgE sensitization and predictors of persistent disease, highlighting the potential role of early allergic sensitization in chronic upper-airway trajectories. [71]B2b
Therapeutic modulation of immune mechanisms
Sublingual dust-mite immunotherapy reduced multiple inflammatory biomarkers beyond conventional treatment alone, providing clinical evidence that allergen-specific immune modulation can alter the inflammatory profile of AR. [536] Press-needle therapy has also been evaluated in a systematic review and meta-analysis of pediatric randomized controlled trials, including comparisons of press-needle therapy alone or combined with medication against medication alone; however, the supplied abstract does not provide the pooled effect estimates or biomarker findings needed to define its immune mechanism. [535] Biologic treatment is used in children with severe AR and comorbid allergic asthma, with omalizumab and dupilumab evaluated in a retrospective cohort for early response prediction; this reflects targeting of type 2 disease biology, although the supplied evidence concerns response prediction rather than AR pathogenesis itself. [336]B2b Omalizumab targets free IgE, but a case report of bullous erythema multiforme after treatment illustrates that immune-directed therapy can rarely produce serious immune-mediated adverse reactions. [546]C
Environmental disruption may amplify aeroallergen-related disease. A systematic review of flooding-related dermatoses included environmental aeroallergen-induced exacerbations among its mechanistic categories, indicating that post-disaster environmental change can worsen allergic disease expression. [537] Overall, current evidence supports AR as an interaction among allergen exposure, susceptible host immune responses, eosinophilic and chemokine-associated inflammation, microbial ecology and airway-wide comorbidity, while several associations remain insufficient to establish causation. [529][536][539][542][543][544]
| Feature | Evidence and interpretation |
|---|---|
| Allergen exposure and susceptibility | Artemisia exposure and host susceptibility were evaluated as separate contributors to sensitization, AR and asthma exacerbation. [529] |
| Type 2/eosinophilic inflammation | IL-4 and ECP decreased with dust-mite sublingual immunotherapy; IL-17, TARC and VCAM-1 also decreased. [536] |
| Microbiome | Nasal Corynebacterium depletion was associated with polysensitization; oral microbiome and metabolome differences were reported in AR. [134]B3b[539] |
| Lower-airway involvement | Impulse oscillometry and exercise testing identified potential peripheral-airway abnormalities in children with AR without diagnosed asthma. [540][543] |
| Adjacent-organ effects | Pediatric evidence evaluated associations among AR, allergic sensitization, Eustachian-tube dysfunction and otitis media with effusion. [524] |
Epidemiology, Etiology & Risk Factors
- ▸AR prevalence is reported to be increasing worldwide, but estimates depend on population, diagnostic criteria, allergen exposure, and healthcare access [552].
- ▸Important risk patterns include personal atopy, infantile food allergy, house-dust-mite or inhalant-allergen sensitization, polysensitization, and family history [334, 539, 542].
- ▸Cat-dander sensitization was strongly associated with asthma comorbidity among patients with AR, with OR **3.743** in one real-world study [542].
- ▸Microbiome associations with polysensitization and SLIT response are preliminary and do not prove causation [521, 539].
- ▸AR commonly coexists with asthma and may be associated with sinonasal, eustachian-tube, and middle-ear disease [523, 524, 542, 547].
Epidemiology
Allergic rhinitis (AR) is a common IgE-mediated upper-airway disorder whose prevalence is reported to be increasing worldwide, although the magnitude of prevalence varies according to age, geography, allergen exposure, diagnostic criteria, and healthcare access [552]. In a prospective study of 1150 patients with clinically suspected AR, diagnosis was confirmed using clinical assessment together with allergen testing; the study evaluated nasal itching, congestion, sneezing, rhinorrhea, ocular symptoms, and overall discomfort as potential predictors of AR [538]. These findings support symptom-based recognition as an approach to earlier detection, but symptoms overlap with non-allergic rhinitis and do not replace objective confirmation by skin-prick testing or serum-specific IgE measurement [538].
AR is frequently part of an atopic multimorbidity pattern. In a multicentre cohort of adults undergoing septorhinoplasty, 57% had AR, while chronic sinusitis and obstructive sleep apnoea were each reported in 22%; this surgical cohort is not population-representative but illustrates the high burden of AR among patients seeking tertiary nasal care [547]. Among children receiving sublingual immunotherapy (SLIT), 954 of 1208 participants had AR, and most of the cohort also had asthma, demonstrating substantial coexistence of upper- and lower-airway allergic disease in real-world pediatric allergy practice [525].
Seasonal AR represents an important healthcare and economic burden. A Japanese nationwide claims analysis identified patients with spring AR by an AR diagnosis plus prescriptions covering at least 14 days in each of two consecutive spring pollen seasons; the study compared spring, summer, and autumn disease using healthcare utilization and prescription-drug costs [552]. The study population was drawn from 2018–2019, years characterized by heavy pollen dispersal and preceding the COVID-19 pandemic [552].
Etiology and biologic mechanisms
AR results from allergen-specific immune responses to inhaled environmental allergens; the reviewed studies chiefly concern house-dust mite, pollen, cat dander, and other inhalant allergens [334]B2b[538][539][542][552]. The infantile atopic march is an important developmental pathway: children with food allergy (FA) during infancy may subsequently develop AR, although progression is not universal [334]B2b. A prospective cohort followed 447 infants aged 0–2 years with positive food-allergen testing to age 6 years and used clinical/questionnaire variables and machine-learning models to identify predictors of later AR [334]B2b.
House-dust-mite sensitization is clinically relevant in early childhood. A five-year prospective multi-omics cohort enrolled children aged 4–8 years with chronic-rhinosinusitis symptoms, with or without IgE-mediated house-dust-mite sensitization, and evaluated predictors of persistent disease and later AR attributable to house dust mite [71]B2b. This study addresses a selected symptomatic population and should not be interpreted as a population prevalence estimate [71]B2b.
The nasal microbiome may modify allergic sensitization and treatment response, but current evidence is associative rather than causal. In adults, depletion of nasal Corynebacterium was associated with polysensitization to inhalant allergens in a cross-sectional study of 278 participants categorized from zero to ≥4 sensitizations [539]. In children with AR, a prospective study of 63 patients and 40 healthy controls examined Haemophilus abundance as a potential biomarker of response to one year of house-dust-mite SLIT; moderate-to-severe patients were classified as responders when total nasal symptom score decreased by >20% [521]C. These findings suggest that microbial composition may be linked to sensitization burden or immunotherapy response, but they do not establish microbiome changes as a primary cause of AR [521]C[539].
Established and associated risk factors
The strongest risk patterns supported by the reviewed evidence are personal atopy, early-life food allergy, allergen sensitization, polysensitization, and family history of allergic disease [334]B2b[538][539][542]. In a real-world study of 1367 patients with AR, including 213 with comorbid asthma, family history of AR or asthma, higher symptom burden, polysensitization, cat ownership, cat-specific IgE, and age <18 years were associated with AR plus asthma; cat-dander sensitization remained the prominent factor, with an odds ratio of 3.743 [542]. This result concerns asthma comorbidity among people who already have AR and should not be interpreted as a general risk estimate for developing AR [542].
Maternal and perinatal factors may also influence offspring allergic risk. A nationwide Taiwanese cohort of 2,743,735 live births from 2004–2020 compared children of mothers with no depression or antidepressant use, depression without antidepressant use, and depression with antidepressant use, and followed offspring for atopic dermatitis, AR, and asthma [550]. The study was designed to assess associations with maternal depression and antidepressant exposure; such observational associations may be affected by familial, behavioral, healthcare-use, and other confounding factors [550].
Environmental disruption may exacerbate aeroallergen-related disease. A systematic review of 12 epidemiologic studies from multiple countries, encompassing more than 71 million patient encounters, identified environmental aeroallergen-induced exacerbations among post-flood dermatologic and public-health outcomes in the context of climate-related flooding [537]. This evidence supports flooding and related environmental change as potential modifiers of aeroallergen exposure or symptom severity, rather than as proven primary causes of AR [537].
Comorbidities and modifiers
AR is associated clinically with asthma and may coexist with chronic rhinosinusitis, eustachian-tube dysfunction, and middle-ear disease [523][524][542][547]. Systematic reviews evaluated objective eustachian-tube or middle-ear dysfunction and pediatric otitis media with effusion in relation to AR or allergic sensitization, but the available evidence was heterogeneous and dependent on operational definitions and study size [523][524]. Immunosuppression is a separate risk context for chronic rhinosinusitis: a retrospective cohort investigated new CRS after rituximab-associated B-cell depletion and hypogammaglobulinemia, excluding patients with pre-existing CRS [549]. This does not establish rituximab as an AR risk factor [549].
Several reviewed studies do not provide direct epidemiologic evidence for AR. Research on childhood lung-function trajectories, persistent asthma airflow limitation, obesity in severe asthma, and exercise-induced bronchoconstriction in children with AR primarily addresses lower-airway outcomes or treatment populations rather than AR incidence or causation [548][522][541][540]. Similarly, studies of intranasal corticosteroid tolerability and adherence address management rather than etiology; unpleasant post-nasal drip and nasal irritation may impair treatment compliance [520].
| Factor or context | Evidence and interpretation |
|---|---|
| Infantile food allergy | Prospective follow-up examined predictors of AR by age 6 years; progression is not universal [334]B2b. |
| Inhalant-allergen sensitization | Polysensitization was associated with asthma comorbidity; nasal Corynebacterium depletion was associated with polysensitization [539][542]. |
| Cat exposure/sensitization | Cat ownership and cat-specific IgE were associated with AR plus asthma; cat sensitization was the prominent factor [542]. |
| Family history | Family history of AR or asthma was associated with AR plus asthma [542]. |
| Environmental flooding | Systematic-review evidence supports aeroallergen-related exacerbations after flooding, not proven AR causation [537]. |
| Maternal depression/antidepressant use | A nationwide birth cohort evaluated associations with offspring allergic disease; observational confounding remains relevant [550]. |
| Immunosuppression | Rituximab-related B-cell depletion and hypogammaglobulinemia were studied as risk contexts for CRS, not AR [549]. |
Clinical Presentation
- ▸The four cardinal nasal manifestations are nasal obstruction, rhinorrhea, sneezing, and nasal itching. [555]
- ▸Ocular symptoms are an important associated feature and are commonly evaluated with the TOSS. [518]
- ▸Pediatric AR may be seasonal or perennial and is frequently associated with reduced quality of life and underdiagnosis. [518][62]
- ▸Severity is heterogeneous; a greater than 20% TNSS reduction has been used to define response in pediatric moderate-severe AR. [521]
- ▸Assess for asthma, eczema, conjunctivitis, ear disease, chronic rhinosinusitis symptoms, and polysensitization because allergic multimorbidity is common. [58][72][524][559]
Core symptom pattern
Allergic rhinitis (AR) is a chronic inflammatory upper-airway disorder and is described as an IgE-mediated condition that can impair quality of life and extend across the respiratory tract under the “one airway, one disease” model. [59]A1b In children, AR is considered the most common chronic disease, although it is frequently undiagnosed. [518] Pediatric AR may occur in seasonal or perennial forms, reflecting exposure to aeroallergens over particular periods or throughout the year. [518]
The characteristic nasal symptom cluster comprises nasal obstruction, rhinorrhea, sneezing, and nasal itching. [555]C These symptoms may occur together, but their relative severity varies among individuals and across rhinitis subtypes. [555]C Nasal obstruction represents impaired nasal airflow, whereas rhinorrhea, sneezing, and itching reflect the irritative and secretory components of the disorder. [555]C Symptom burden is commonly quantified with the Total Nasal Symptom Score (TNSS), which incorporates these four key nasal manifestations. [518][555]C
Ocular involvement is an important component of the clinical picture. [518] Eye symptoms are assessed separately with the Total Ocular Symptom Score (TOSS), indicating that pediatric AR may present as a combined nasal and ocular syndrome rather than isolated nasal disease. [518] The effect on daily functioning and well-being can be clinically substantial; pediatric studies evaluate AR-related health status with the Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ), while broader pediatric allergy literature identifies reduced quality of life as a frequent consequence of AR. [518][62]A1a
Severity and variability
Clinical severity is heterogeneous, ranging from mild disease to moderate-severe disease. [521]C In a pediatric cohort undergoing house-dust-mite sublingual immunotherapy, response was defined as a greater than 20% reduction in TNSS, illustrating the use of symptom change as a clinically meaningful measure of severity and treatment response. [521]C A separate prediction study reported that approximately 30%–40% of patients receiving sublingual immunotherapy may show a poor response, emphasizing that symptom persistence and treatment response are variable. [554]
The symptom profile is not uniform across rhinitis phenotypes. [555]C A systematic review of adult rhinitis cohorts specifically evaluated baseline nasal obstruction, rhinorrhea, sneezing, and itching across allergic and other rhinitis subtypes, supporting the use of symptom pattern—rather than any single symptom alone—in clinical characterization. [555]C Environmental context may also influence nasal function: a systematic review identified mucociliary clearance, mucosal hydration, epithelial tight-junction integrity, and local immune responses as key components of nasal mucosal defense, while noting that the effects of chronic high humidity and heat remain incompletely synthesized. [557]
Associated airway and allergic disease
AR commonly coexists with asthma, particularly in children with broader allergic multimorbidity. [58]A1b[62]A1a The coexistence of AR and asthma is linked to type 2-driven airway inflammation and altered epithelial–immune interactions. [58]A1b In children with asthma, a cumulative allergic burden incorporating AR, atopic dermatitis, food allergy, drug allergy, and family history was investigated in relation to lung function, reflecting the clinical importance of documenting allergic comorbidities rather than treating AR as an isolated condition. [558]
Allergen sensitization patterns may differ according to lower-airway involvement. [72]C4 In a large pediatric study of AR and asthma, house-dust-mite sensitization was prominent, accounting for 41% of sensitization in the reported cohort, while cat and other allergen co-sensitization patterns were evaluated as potential markers of airway phenotype. [72]C4 Longitudinal population data also reported increased allergic symptoms and sensitization to mites, pollen, and animal allergens over a decade, together with increases in asthma, AR, conjunctivitis, and eczema comorbidity. [559]
Upper-airway disease may be associated with ear and sinonasal manifestations. [524] A systematic review specifically evaluated the relationship between pediatric AR or allergic sensitization and otitis media with effusion, Eustachian-tube dysfunction, abnormal tympanometry, and middle-ear dysfunction. [524] This supports assessment for hearing, ear-pressure, or middle-ear symptoms when a child with AR has persistent nasal disease or related complaints. [524] Chronic rhinosinusitis is another upper-airway condition considered alongside AR in evidence evaluating probiotic interventions, although the available reference does not establish that AR symptoms alone identify chronic rhinosinusitis. [553]
Pediatric and multimorbidity context
AR may occur alongside atopic dermatitis and other allergic disorders. [526][532][556] Nationwide data in children with PFAPA found an association with allergic, but not autoimmune, comorbidities, indicating that recurrent inflammatory presentations may coexist with an allergic disease burden. [526] Congenital ichthyosis, characterized by impaired skin-barrier function, has also been associated with increased allergic disorders, providing additional context when AR occurs in a child with significant barrier disease. [556]
Clinical assessment should therefore document the four cardinal nasal symptoms, ocular symptoms, timing and persistence of exposure-related complaints, functional or quality-of-life effects, asthma and eczema history, ear symptoms, and known sensitizations. [518][555]C[524][559] Treatment studies in children evaluate TNSS, TOSS, adverse effects, and quality-of-life outcomes, reinforcing these domains as the principal clinical measures for describing presentation and follow-up. [518] Evidence for probiotics and nasal saline irrigation concerns symptom management rather than a distinct clinical phenotype; these interventions have been studied in pediatric AR, with saline trials including isotonic 0.9% and hypertonic greater than 0.9% solutions. [62]A1a[519] Intranasal corticosteroid delivery may be limited by post-nasal drip and nasal irritation, symptoms that can affect adherence and should be elicited during review. [520]
| Domain | Relevant findings or measures |
|---|---|
| Nasal | Obstruction, rhinorrhea, sneezing, itching; TNSS [555]C |
| Ocular | Eye symptoms; TOSS [518] |
| Burden | Quality-of-life impairment; RQLQ or related instruments [518][62]A1a |
| Comorbidity | Asthma, eczema, conjunctivitis, ear/middle-ear disease, chronic rhinosinusitis [58]A1b[524][559] |
| Sensitization and exposure | Mites, pollen, animal allergens, and other co-sensitizations [72]C4[559] |
Diagnosis & Immunodiagnostics
- ▸SPT (≥3mm) or sIgE (≥0.35 kU/L) confirms sensitization.
- ▸Nasal allergen challenge is gold standard for LAR when systemic tests negative.
Diagnosis combines clinical history with positive skin prick test (wheal ≥3mm) or serum specific IgE (≥0.35 kU/L) [1]A1c[13]A1c. Nasal allergen challenge (NAC) is gold standard for local allergic rhinitis (LAR) when systemic tests are negative [201]D5. Supportive labs: total IgE, nasal cytology (eosinophils), basophil activation test (BAT), molecular diagnostics for component‑resolved testing [27]D5[92]D5. Imaging not routine; CT reserved for complications.
Diagnostic algorithm:
- History/physical suggestive of AR.
- SPT or sIgE → if positive, diagnose AR, classify severity.
- If SPT/sIgE negative but high suspicion, perform NAC → if positive, diagnose LAR.
- Negative NAC effectively rules out IgE‑mediated rhinitis.
- Consider molecular diagnostics in polysensitized patients.
- Refractory cases: nasal cytology, BAT, immunodeficiency workup.
Pearl: In any patient with persistent rhinitis symptoms and negative skin prick test/serum IgE, consider nasal allergen challenge to identify local allergic rhinitis, a treatable phenotype that responds to standard AR pharmacotherapy and allergen immunotherapy [104]D5[123]D5.
Severity, Grading & Risk Stratification
- ▸Grade AR using symptoms, sleep, activity, school/work function, quality of life, and medication requirements; sensitization alone is insufficient. [555][538]
- ▸Use **mild** versus **moderate-to-severe** impairment pragmatically, while recording intermittent or persistent duration separately. [560][562]
- ▸In children, include developmental and school-related effects and consider lower-airway assessment even without established asthma. [518][540]
- ▸Polysensitization, comorbid asthma, chronic sinonasal disease, and persistent treatment need increase clinical complexity but are not independent severity grades. [273][560][71]
- ▸Biomarkers and microbiome signatures remain investigational for risk prediction or treatment response. [274][521][539]
Scope and principles
Allergic rhinitis (AR) severity should be graded by the patient’s symptom burden, functional impairment, disease control, and treatment requirement rather than by sensitization alone. Current evidence supports a multidimensional approach because AR symptoms vary substantially among phenotypes and individuals; nasal obstruction, rhinorrhea, sneezing, and itching do not contribute equally in every rhinitis subtype. [555]C Symptom-based visual analogue scale (VAS) assessment—including nasal symptoms, ocular symptoms, and overall discomfort—has also been investigated as a tool for distinguishing AR from non-allergic rhinitis, although symptom scores do not replace objective confirmation of IgE-mediated sensitization. [538]
Practical severity grading
A practical clinical classification is:
- Mild AR: symptoms are present but cause little or no sleep disturbance, limitation of daily activities, impairment of school or work, or troublesome quality-of-life deterioration. [555]C
- Moderate-to-severe AR: symptoms produce clinically meaningful impairment in sleep, daily activities, school or work, quality of life, or require regular pharmacotherapy for control. [560][562]
- Uncontrolled or high-burden AR: persistent symptoms despite appropriate treatment, frequent need for rescue medication, substantial ocular involvement, or clinically important lower-airway comorbidity. This category is clinically useful but is not a universally standardized disease grade in the cited literature. [560][562]
Duration should be recorded separately as intermittent or persistent, because symptom frequency alone does not fully capture severity. The cited studies include both seasonal and perennial AR, and treatment trials commonly identify moderate-to-severe disease as the population most likely to require continuous medication or allergen immunotherapy. [518][560][562]
Severity assessment should include the four principal nasal symptoms—obstruction, rhinorrhea, sneezing, and itching—plus ocular symptoms, sleep, activity limitation, school/work performance, and rescue-medication use. [555]C[538] TNSS, total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life measures, VAS, and combined symptom–medication scores are established research and clinical outcome domains, but no single score should be interpreted in isolation. [518][555]C[562]
Pediatric considerations
In children younger than 12 years, oral antihistamines and leukotriene receptor antagonists have been evaluated in randomized trials for seasonal and perennial AR, with outcomes including TNSS, TOSS, quality of life, and adverse events. [518] Pediatric severity should therefore incorporate age-appropriate effects on sleep, concentration, school attendance, play, and caregiver-reported burden, in addition to symptom scores. [518][562]
Children with moderate-to-severe disease may be candidates for allergen immunotherapy when clinically appropriate. In Canadian children and adolescents aged 5–17 years with moderate-to-severe tree-pollen AR or rhinoconjunctivitis, a phase III trial assessed daily tree SLIT-tablet therapy over up to 52 weeks using a combined symptom and medication endpoint. [562] In children with moderate-to-severe house-dust-mite AR, a prospective cohort used a >20% reduction in TNSS to define response to 1 year of SLIT, illustrating one research-based response threshold rather than a universal grading rule. [521]C
Risk stratification
Risk stratification should identify factors associated with greater morbidity, treatment complexity, or progression:
- Comorbid asthma or lower-airway involvement. Moderate-to-severe HDM AR trials included patients with and without controlled asthma, and SLIT reduced symptoms and rescue-medication requirements in that treatment context. [560] Exercise-induced bronchoconstriction was detected in non-asthmatic children with moderate-to-severe persistent AR receiving early subcutaneous immunotherapy, indicating that lower-airway assessment may be relevant even when asthma has not been diagnosed. [540]
- Polysensitization or multiple clinically relevant allergens. Polysensitization is reported in approximately 80% of allergic patients in a systematic review, and multiallergen immunotherapy was associated with lower combined symptom and medication scores than placebo in pooled studies. [273]B2a In adults, polysensitization was categorized as ≥4 inhalant sensitizations and was examined in relation to nasal microbiome composition. [539] Sensitization burden may help guide exposure assessment and immunotherapy planning, but it should not substitute for clinical relevance.
- Persistent disease and structural or inflammatory burden. Periostin has been described as a downstream marker of IL-4/IL-13-driven type 2 inflammation, epithelial-barrier disruption, eosinophil recruitment, and tissue remodeling; current evidence supports its investigation as a potential severity or response biomarker, not routine standalone grading. [274]D5
- Risk of chronic upper-airway disease. In preschool children with chronic rhinosinusitis symptoms, a 5-year prospective study evaluated HDM sensitization and clinical and multi-omics predictors of persistent disease, supporting longitudinal follow-up when AR coexists with chronic sinonasal symptoms. [71]B2b
- Atopic progression. A prospective cohort of 447 infants with food allergy followed to age 6 years developed predictive models for later AR, demonstrating risk-prediction research relevant to the atopic march rather than severity grading after AR is established. [334]B2b
Modifiers and limitations
Seasonality and unusual aeroallergen exposure can alter symptom burden. Prospective monitoring linked birch-rust spore exposure with upper-airway symptoms in a subarctic setting, suggesting that exposure calendars should reflect local aeroallergens rather than pollen alone. [565] Nasal microbiome findings, including Haemophilus abundance and Corynebacterium depletion, are emerging associations with treatment response or polysensitization, but they are not validated severity grades. [521]C[539]
Several cited studies do not establish AR severity categories directly. Septorhinoplasty outcomes in adults with nasal obstruction, glucocorticoid effects on non-traumatic olfactory disorders, vitamin D evidence across allergic diseases, severe-asthma obesity outcomes, and persistent airflow limitation in asthma provide contextual information about comorbidity or related airway disease but should not be used to grade AR itself. [547][563][564][541][522] Press-needle therapy and homeopathic-treatment trials address treatment efficacy rather than validated severity classification. [535][561]
| Domain | Findings supporting greater burden or risk | Evidence |
|---|---|---|
| Symptoms | Prominent obstruction, rhinorrhea, sneezing, itching, or ocular symptoms | [555]C[538] |
| Function | Sleep, daily activities, school/work, or quality-of-life impairment | [555]C[562] |
| Treatment need | Regular therapy, persistent symptoms, or frequent rescue medication | [560][562] |
| Comorbidity | Asthma, exercise-induced bronchoconstriction, or chronic rhinosinusitis symptoms | [540][560][71]B2b |
| Sensitization | Multiple clinically relevant allergens, particularly ≥4 inhalant sensitizations | [273]B2a[539] |
| Pediatric response research | >20% TNSS reduction used as a study-defined SLIT response threshold | [521]C |
Acute Management & Anaphylaxis Pathway
- ▸Suspected anaphylaxis requires emergency assessment and protocol-based epinephrine treatment; routine allergic-rhinitis medicines are not emergency substitutes. [568][518][520]
- ▸Oral antihistamines and leukotriene receptor antagonists were studied in children aged **<12 years**, but the supplied abstract does not provide comparative effect estimates or identify a preferred agent. [518]
- ▸A fluticasone nasal-adaptor trial was small (**16 participants per group**) and used **3-week** treatment periods. [520]
- ▸Pooled adherence to intranasal corticosteroids and oral antihistamines was **43%** across **12 studies** and **191,103 adults**. [290]
- ▸Accelerated SCIT is a supervised protocol intervention, not acute rescue therapy; the cited regimen used **6** one-strength injections followed by **4** maximum-tolerated-dose injections. [209]
Scope and triage
This pathway distinguishes an acute flare of allergic rhinitis from suspected anaphylaxis. The supplied evidence evaluates symptomatic allergic-rhinitis treatment, immunotherapy safety, adherence, and anaphylaxis epidemiology; it does not provide validated emergency drug doses, observation durations, or diagnostic cut-offs for anaphylaxis. [518][209]A1b[290]B2a[568]
Suspected anaphylaxis requires emergency assessment rather than escalation of routine rhinitis therapy. In a nationwide study, anaphylaxis diagnoses were confirmed by chart review using World Allergy Organization criteria and documented epinephrine treatment, supporting epinephrine-treated, criteria-based case identification as the relevant emergency framework. [568] The provided references do not specify the epinephrine route, dose, repeat interval, airway protocol, fluid strategy, or monitoring duration; these details should therefore follow the local emergency/anaphylaxis protocol rather than be inferred from allergic-rhinitis evidence. [568]
Acute allergic-rhinitis management
For children, oral antihistamines and leukotriene receptor antagonists have been evaluated in randomized trials involving patients aged <12 years with seasonal or perennial allergic rhinitis. The network meta-analysis assessed total nasal symptom score, total ocular symptom score, rhinoconjunctivitis quality of life, adverse events, and serious adverse events; treatment selection should therefore consider both symptom targets and safety. [518] The supplied abstract does not report comparative effect estimates or identify a single preferred oral agent, so no medication should be labelled superior on the basis of this reference alone. [518]
Intranasal corticosteroids remain a relevant administration option in allergic rhinitis, but unpleasant sensations—including post-nasal drip and nasal irritation—may undermine use. A crossover trial in allergic-rhinitis participants compared standard fluticasone nasal spray with a fluticasone metered-dose inhaler plus a nasal adaptor, with each treatment used for 3 weeks; the study was small, enrolling 16 participants per group, so device-related conclusions should be interpreted cautiously. [520]
Adherence is a central component of acute and ongoing control. A systematic review of 12 studies involving 191,103 adults found pooled adherence to prescribed intranasal corticosteroids and oral antihistamines of 43%, with substantial heterogeneity; self-reported adherence was consistently higher than pharmacy-refill estimates. [290]B2a At each acute review, confirm the prescribed product, dosing schedule, administration technique, tolerability, and whether the patient is actually obtaining and using treatment. The supplied evidence does not establish a universal adherence target or a validated acute step-up algorithm. [290]B2a
Immunotherapy is not acute rescue treatment
Allergen immunotherapy is a disease-modifying strategy rather than an immediate treatment for acute nasal symptoms or anaphylaxis. A systematic review of 35 economic evaluations found that 32 (91%) concluded immunotherapy was cost-effective versus symptomatic pharmacotherapy, although methodological heterogeneity required narrative synthesis. [218]B2a Pediatric real-world SLIT data included 1,208 patients aged 3–17 years, while a separate cohort evaluated one-year house-dust-mite SLIT in children with moderate-to-severe disease; these studies address longitudinal response, not emergency relief. [525][521]C
Accelerated subcutaneous immunotherapy should be administered only within an appropriately supervised service. In the PERFECT multicentre study, adolescents and adults with allergic rhinitis or rhinoconjunctivitis, with or without asthma, were randomized to an optimized one-strength or standard house-dust-mite regimen; the accelerated regimen used 6 injections at one strength followed by 4 injections at the maximum tolerated dose, whereas the standard regimen used 14 injections across three strengths. [209]A1b These findings concern safety and tolerability of a defined protocol and do not support unsupervised dose escalation or use during an acute reaction. [209]A1b
Anaphylaxis pathway
- Treat suspected anaphylaxis as an emergency and activate emergency services or the institutional emergency response. The anaphylaxis evidence base supplied here is based on World Allergy Organization criteria and documented epinephrine treatment. [568]
- Stop or remove the suspected trigger when feasible without delaying emergency care, and assess airway, breathing, circulation, mental status, and progression. The supplied references do not provide operational thresholds or dosing instructions for these steps. [568]
- Use emergency epinephrine according to the applicable local anaphylaxis protocol; do not rely on oral antihistamines, leukotriene receptor antagonists, intranasal corticosteroids, or allergen immunotherapy as substitutes for emergency treatment. The provided allergic-rhinitis studies evaluate symptom control or longer-term treatment and do not establish them as anaphylaxis therapy. [518][520][209]A1b[568]
- Continue emergency monitoring and escalation according to local policy, particularly when respiratory or circulatory compromise, asthma, or recurrent symptoms are present. The supplied references identify anaphylaxis as occurring across diverse clinical contexts and examine comorbidity burden, but do not define observation or discharge criteria. [568]
- After stabilization, document the suspected trigger, treatment, response, comorbidities, and follow-up plan; review rhinitis control separately, including medication adherence and tolerability. The evidence supports evaluating adherence and adverse events as distinct outcomes from acute emergency treatment. [518][290]B2a
Evidence limitations
None of the supplied abstracts provides an acute anaphylaxis dosing table, validated emergency triage thresholds, or comparative acute-treatment algorithm. Local emergency guidance and specialist assessment are therefore essential for those decisions. [568]
| Clinical situation | Action supported by the supplied evidence | Evidence boundary |
|---|---|---|
| Acute allergic-rhinitis symptoms without systemic emergency features | Review prescribed oral therapy or intranasal corticosteroid use, tolerability, technique, and adherence. [518][520][290]B2a | No universal step-up algorithm or preferred oral agent is reported. [518][290]B2a |
| Suspected anaphylaxis | Activate emergency care and administer epinephrine according to the local anaphylaxis protocol. [568] | Dose, route, repeat interval, airway management, fluids, and observation duration are not specified in the supplied references. [568] |
| Considering allergen immunotherapy | Refer for supervised specialist assessment; do not use immunotherapy as acute rescue. [209]A1b[218]B2a[521]C[525] | The cited studies address safety, cost-effectiveness, or longitudinal outcomes rather than emergency symptom relief. [209]A1b[218]B2a[521]C[525] |
Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics
- ▸The strongest supplied disease-modifying evidence concerns HDM SLIT, including the 300 IR tablet studied for approximately 12 months and evaluated for rescue-medication and corticosteroid sparing. [560]
- ▸SLIT response is heterogeneous; approximately 30–40% of patients may respond poorly, and prediction tools remain investigational. [554]
- ▸Multiallergen AIT reduced combined symptom-medication scores versus placebo in polysensitized patients, but allergen selection remains clinically debated. [273]
- ▸SCIT requires structured safety assessment because asthma/AR comorbidity and high allergen-specific IgE were associated with systemic reactions in children. [576]
- ▸Biologics should primarily be selected for approved severe-asthma or specialist indications; evidence for omalizumab as routine AR treatment remains insufficient in the supplied abstracts. [573][336][577]
Treatment goals and selection
Long-term management should be individualized according to the clinically relevant allergen, disease severity, treatment response, comorbid asthma or conjunctivitis, age, adherence, and risk of immunotherapy reactions. The supplied evidence supports allergen immunotherapy (AIT) as the principal disease-modifying strategy, while biologics are mainly supported in patients with severe type-2 airway disease or selected seasonal allergic rhinitis (AR) populations. [560][562][573][577]
Allergen avoidance should be targeted rather than indiscriminate: treatment decisions should follow confirmation that sensitization is clinically relevant to symptoms. A prospective study of 1,150 patients with suspected AR evaluated symptom-based prediction against final diagnosis, highlighting the potential role of structured symptom assessment before confirmatory testing. [538] Children with infant food allergy represent a population at risk for later AR; a prospective cohort of 447 infants followed to age 6 years developed predictive models for future AR onset, although the supplied evidence does not establish an avoidance intervention that prevents this progression. [334]B2b
Sublingual immunotherapy
For moderate-to-severe house-dust-mite (HDM) AR, the 300 IR HDM SLIT tablet was studied for approximately 12 months in a large randomized controlled trial including patients with and without controlled asthma. Participants could use antihistamines, intranasal corticosteroids, or oral corticosteroids stepwise for intolerable nasal or ocular symptoms; the post hoc analysis assessed the proportion of patients and treatment days requiring rescue medication, including corticosteroid use. [560] This evidence supports evaluating HDM SLIT when persistent HDM-driven disease remains burdensome despite pharmacotherapy, with particular interest in reducing corticosteroid exposure; the supplied abstract does not provide the numerical steroid-sparing estimates. [560]
A randomized trial of 300 HDM-sensitized patients compared conventional treatment with conventional treatment plus sublingual HDM drops for 6 months. The combination group had greater reductions in IL-4, IL-17, eosinophil cationic protein, thymus and activation-regulated chemokine, and vascular cell adhesion molecule-1, together with improved symptoms, lower reported adverse-reaction rates, and improved pulmonary-function measures. [536] These biomarker findings are supportive but should not replace symptom-based assessment of clinical benefit. [536]
Tree-pollen SLIT tablets are another age-specific option. In a phase III trial, Canadian children and adolescents aged 5–17 years with moderate-to-severe tree-pollen AR and/or conjunctivitis received daily tree SLIT tablet or placebo for up to 52 weeks, with free access to symptom-relieving medication; the primary outcome was the pollen-season total combined score combining daily symptoms and medication use. [562]
Response to SLIT is variable: a prediction study notes that approximately 30–40% of patients may show poor response and developed a clinical, environmental, and immune-inflammatory nomogram in 346 treated patients. [554] Nasal microbiome findings are preliminary: in a prospective pediatric cohort, one-year HDM SLIT responders were defined by a >20% reduction in TNSS, with 25 responders and 15 nonresponders analyzed for Haemophilus abundance and dynamics. [521]C These biomarkers and prediction tools remain investigational rather than routine treatment-selection requirements. [521]C[554]
Subcutaneous and multiallergen immunotherapy
SCIT may improve health-related quality of life in children and parental caregivers; a prospective study compared 12-month changes in validated quality-of-life measures between children receiving SCIT and standard pharmacotherapy, while examining relationships between symptom and quality-of-life improvement. [575] Safety assessment is essential: among 250 children receiving 9,244 HDM-SCIT injections, allergic asthma and AR comorbidity and high allergen-specific IgE were identified as risk factors for systemic reactions. [576]C
A systematic review and meta-analysis of 7 randomized and 7 nonrandomized studies found that multiallergen AIT significantly reduced combined symptom-medication scores versus placebo, with an SMD of −3.75 (95% CI −5.85 to −1.65; p<0.001). The review specifically addressed polysensitized patients, in whom multiallergen formulations remain debated; formulation choice should therefore prioritize allergens demonstrably linked to symptoms rather than sensitization alone. [273]B2a
Lower-airway surveillance during immunotherapy
AR may coexist with clinically subtle lower-airway abnormalities. In non-asthmatic children with moderate-to-severe persistent AR receiving early SCIT, exercise-provocation testing was used to assess exercise-induced bronchoconstriction, defined as a ≥10% fall in FEV1. [540] A separate case-control study used impulse oscillometry in 69 such children and 65 healthy controls to investigate peripheral airway dysfunction during early immunotherapy. [543] These findings support asking about exertional symptoms and considering objective lower-airway assessment when clinically indicated, without diagnosing asthma solely from AR. [540][543]
Biologics
Omalizumab was evaluated in a randomized double-blind trial of 60 patients with cypress-pollen seasonal AR and total IgE <100 IU/mL. Participants received a single monthly-dose intervention of either 150 mg or 300 mg, administered within 5 days before pollen-season onset; the study compared daily symptom and medication outcomes. [573] The supplied evidence establishes evaluation of dose individualization in low-IgE disease but does not provide the comparative efficacy results; omalizumab should therefore be reserved for specialist-directed cases rather than used routinely for uncomplicated AR. [573]
For children with moderate-to-severe allergic asthma and comorbid AR, a retrospective cohort of 246 patients receiving omalizumab or dupilumab developed a nomogram for early response at 16 weeks. [336]B2b Dupilumab targets IL-4/IL-13 receptor signaling and was examined in the prospective, three-year REVEAL real-world registry in patients aged ≥12 years initiating treatment for asthma. [577] Biologic choice should be driven primarily by the approved severe-asthma indication and phenotype; AR improvement may be an associated benefit rather than the sole reason for treatment. [336]B2b[577]
Evidence concerning biologic response modifiers remains observational. A registry study evaluated obesity in 525 patients with severe asthma and its influence on biologic response and clinical remission. [541] Mechanistically, a systematic review of 223 studies linked IL-4/IL-13, IL-1β/IL-6/IL-17A, STAT6, NF-κB, and NLRP3 pathways to macrophage polarization in AR inflammation, but these findings do not yet establish a macrophage-targeted biologic for clinical AR care. [574]
Duration, monitoring, and evidence limitations
Longitudinal pediatric real-world evidence followed 1,208 children aged 3–17 years receiving individualized liquid-drop SLIT, with assessments at months 6, 12, 18, 24, and 36; the cohort included 954 patients with AR and evaluated clinically meaningful quality-of-life response. [525] A separate five-year prospective cohort of preschool children assessed predictors of persistent chronic rhinosinusitis and later HDM-related AR, with 117 participants completing follow-up. [71]B2b These studies support prolonged follow-up, adherence review, and reassessment of comorbid airway disease, but prediction models and biomarkers should complement—not replace—clinical response, safety monitoring, and shared decision-making. [71]B2b[521]C[525]
| Strategy | Population/evidence | Practical implication |
|---|---|---|
| HDM SLIT tablet | Moderate-to-severe HDM AR; 300 IR; approximately 12 months | Consider for disease modification and potential corticosteroid sparing. [560] |
| HDM SLIT drops | 300 patients; 6-month randomized trial | Symptom, inflammatory-marker, adverse-reaction, and pulmonary-function improvements were reported. [536] |
| Tree SLIT tablet | Children aged 5–17 years with moderate-to-severe tree AR/conjunctivitis; up to 52 weeks | Assess seasonal total combined symptom-medication outcomes. [562] |
| SCIT | Pediatric AR/asthma cohorts; 9,244 injections analyzed | Use specialist supervision and systemic-reaction risk assessment. [576]C |
| Multiallergen AIT | Polysensitized AR; 7 RCTs and 7 nonrandomized studies | Benefit versus placebo reported, but formulation selection remains debated. [273]B2a |
| Biologics | Selected seasonal AR or severe asthma with comorbid AR | Specialist use; evidence and approvals are stronger for severe asthma than isolated AR. [336]B2b[573][577] |
Immunodeficiency Management
- ▸Consider humoral immunodeficiency in AR with recurrent sinusitis (≥4/year).
- ▸IG therapy reduces infection burden and need for sinus surgery.
Patients with AR and recurrent acute rhinosinusitis (RARS, ≥4/year) should be evaluated for humoral immunodeficiency (CVID, SAD). Immunoglobulin replacement therapy (IVIG/SCIG) reduces sinus infection burden: in a cohort, Lund‑Mackay CT score decreased from 7.6 to 3.5, and need for sinus surgery dropped from 19% to 3.4% [344]B2b. Alternative: azithromycin prophylaxis 5 mg/kg/d 3 days/week × 12 months reduced episodes from 5 to 0.5/year in children with nonallergic rhinitis (NNT=2) [338]A1b.
| Option | Indication | Dose | Outcome | Evidence |
|---|---|---|---|---|
| Immunoglobulin | PID with RARS/CRS | Per standard protocols | Reduced infections, improved LM score | 2b (cohort) [344]B2b |
| Azithromycin | NAR with RARS (children) | 5 mg/kg/d, 3 d/wk × 12 mo | Episodes 5→0.5/yr, NNT=2 | 1b (RCT) [338]A1b |
Pearl: In patients with allergic rhinitis and recurrent or chronic rhinosinusitis, testing for humoral immunodeficiency and initiating immunoglobulin replacement therapy can dramatically reduce infection burden, improve sinus imaging scores, and decrease the need for sinus surgery [344]B2b.
History and Evolution of Treatment
- ▸Intranasal corticosteroid treatment is being refined through delivery devices aimed at reducing irritation and post-nasal drip and improving adherence. [520]
- ▸SCIT remains a disease-modifying option for moderate-to-severe persistent AR, with increasing attention to lower-airway responses and exercise-induced bronchoconstriction. [540]
- ▸Exercise, immunonutritional supplements, and postbiotics are investigational adjuncts; current evidence does not establish them as replacements for standard therapy. [59] [58]
- ▸Biologic treatment is increasingly selected by phenotype and predicted response in children with severe allergic AR and comorbid asthma. [336]
- ▸Early-life nutritional interventions may reduce later allergic manifestations, but evidence applies to prevention and to individually tested formulas rather than to established AR treatment. [318]
- ▸Modern management integrates environmental exposure, structural nasal disease, chronic rhinosinusitis, asthma, immune status, and total allergic burden. [529] [71] [578] [549] [542] [558]
From symptom suppression to individualized, multimodal care
The treatment of allergic rhinitis (AR) has progressively expanded from control of nasal symptoms with topical and systemic pharmacotherapy toward strategies addressing adherence, comorbid lower-airway disease, allergen exposure, immune modulation, and prevention of the atopic march. The supplied 2026 evidence base does not provide a historical chronology of older antihistamine, intranasal corticosteroid, leukotriene-antagonist, or surgical trials; instead, it documents contemporary refinement of these approaches and their integration with adjunctive interventions.
Intranasal corticosteroids: improving delivery and adherence
Intranasal corticosteroid sprays remain an established treatment platform for AR, but unpleasant administration sensations—including post-nasal drip and nasal irritation—may reduce adherence. Ranasinghe et al. evaluated a nasal adaptor for metered-dose inhalers intended to improve tolerability and long-term use. In a crossover design, 16 participants with AR used standard fluticasone nasal spray (50 μg) and fluticasone delivered through the adaptor (125 μg) for 3 weeks each; a parallel postoperative chronic rhinosinusitis group underwent the same comparison. [520] This study represents an evolution from simply prescribing an effective spray to optimizing the patient’s experience and potentially reducing treatment abandonment. [520]
Allergen immunotherapy and airway-wide management
Subcutaneous allergen immunotherapy (SCIT) remains an important disease-modifying treatment for moderate-to-severe persistent AR. Contemporary evaluation increasingly considers associated airway dysfunction rather than nasal symptoms alone. A cross-sectional study of 62 children aged 6–18 years with moderate-to-severe persistent AR receiving early-phase SCIT assessed exercise-induced bronchoconstriction using an exercise challenge and spirometry; children with asthma or asthma symptoms were excluded, and a fall in FEV1 of ≥10% defined a positive response. [540] The study therefore reflects a treatment era in which children receiving immunotherapy are also assessed for clinically relevant lower-airway responses, even when asthma has not been diagnosed. [540]
The “one airway, one disease” concept has also encouraged nonpharmacological adjuncts. In a randomized controlled trial, 18 young adults with physician-confirmed persistent AR were allocated to an 8-week moderate-intensity aerobic-exercise program or comparison care. Participants discontinued antihistamines, corticosteroids, and leukotriene antagonists before and during the study, allowing the effects of exercise on symptoms, nasal airflow, airway inflammation, pulmonary function, and cardiorespiratory outcomes to be examined without concurrent antiallergic medication. [59]A1b
Biologics and treatment of severe type 2 disease
The modern treatment pathway increasingly links AR with allergic asthma and type 2 inflammation. A retrospective cohort of 246 children with moderate-to-severe allergic AR and allergic asthma received omalizumab or dupilumab, with early response assessed at 16 weeks; investigators developed a nomogram using baseline factors to predict response before biologic initiation. [336]B2b This illustrates movement toward biomarker- and phenotype-informed selection rather than uniform escalation.
Dupilumab, which blocks interleukin-4/interleukin-13 receptor signaling, was also evaluated in the prospective REVEAL registry of patients aged ≥12 years initiating treatment for asthma in real-world practice. [577] Although this registry concerns asthma rather than isolated AR, it is relevant to patients whose nasal disease forms part of broader type 2 airway inflammation. Persistent airflow limitation is another important comorbidity consideration: in a multicenter cohort of 849 patients with asthma, 640 (75.4%) had post-bronchodilator persistent airflow limitation defined as FEV1/FVC <0.70. [522]
Adjunctive immunonutrition and prevention
Immunonutritional therapy is being investigated as an adjunct rather than a replacement for established AR treatment. The multicenter INAPRA pilot trial randomized 40 children aged 5–12 years with allergic asthma and AR to a multicomponent immunonutritional supplement containing postbiotics or placebo, assessing clinical and immunomodulatory effects. [58]A1b The exploratory design and small sample size support cautious interpretation and do not establish routine use. [58]A1b
Prevention has shifted toward early-life intervention and interruption of the atopic march. In the double-blind randomized A.R.T. trial follow-up, a specific partially hydrolyzed formula given during the first 6 months of life was compared with standard formula to determine whether an earlier reduction in atopic dermatitis persisted to age 5 years and extended to other allergic manifestations, including food allergy. [318]B2b This evidence concerns prevention of allergic disease rather than treatment of established AR; importantly, the authors emphasize that partially hydrolyzed formulas differ in allergenicity and immunogenicity and must be evaluated individually. [318]B2b
Environmental control and risk-directed care
Environmental management has become more targeted. In a population study of 12,345 participants from northern China, Artemisia pollen exposure was categorized as low, medium, or high, while sensitization and allergic disease were analyzed in relation to host susceptibility and environmental exposure. [529] In children, a Beijing cluster study of 2,132 participants aged 6–12 years examined genetic background, dietary habits, and social behaviors in relation to allergic airway disease using ARIA- and GINA-based classification. [530] A survey of 393 patients with AR found substantial variation in knowledge, attitudes, and practices concerning environmental control and treatment; 42.75% had lived with AR for more than 5 years. [579]
Comorbidity, anatomy, and treatment boundaries
Treatment evolution also recognizes that persistent symptoms may not be caused by allergy alone. A five-year prospective study followed preschool children with chronic rhinosinusitis symptoms, with or without house-dust-mite sensitization, to identify predictors of persistent disease and later HDM-induced AR. [71]B2b The ARHINASD study enrolled 138 children aged 6–14 years with or without nasal septal deviation and assessed AR, sensitization, endoscopy, cytology, and nasal cytokines, reflecting interest in the potentially bidirectional relationship between structural obstruction and mucosal inflammation. [578]
Finally, treatment decisions should account for immune status and multisystem disease. A retrospective cohort examined new chronic rhinosinusitis after rituximab-associated B-cell depletion and hypogammaglobulinemia, excluding patients with pre-existing CRS. [549] Cat sensitization was strongly associated with AR plus asthma in a real-world study of 1,367 patients (1,154 with AR alone and 213 with AR plus asthma); cat sensitization remained prominent after adjustment, with an odds ratio of 3.743. [542] Allergy burden also matters: in 264 treatment-naive children with asthma, a cumulative score incorporating AR, atopic dermatitis, food allergy, drug allergy, and family history was examined against lung function. [558] These developments reinforce that contemporary AR care is individualized, airway-wide, and attentive to prevention, adherence, comorbidity, and competing diagnoses rather than limited to nasal symptom relief.
| Treatment or strategy | Population/design | Clinical significance |
|---|---|---|
| Intranasal fluticasone with nasal adaptor | Crossover trials; 16 AR participants; 3 weeks per treatment; 50 μg spray versus 125 μg MDI delivery | Targets tolerability and adherence. [520] |
| Moderate-intensity aerobic exercise | Randomized trial; 18 young adults; 8 weeks; medication withdrawal | Evaluates nonpharmacological effects on nasal and lower-airway outcomes. [59]A1b |
| SCIT with airway assessment | Cross-sectional study; 62 children aged 6–18 years; EIB threshold ≥10% FEV1 fall | Extends assessment beyond nasal symptoms. [540] |
| Biologics | Retrospective pediatric cohort; 246 patients with AR and allergic asthma; response at 16 weeks | Supports individualized biologic selection. [336]B2b |
| Immunonutritional/postbiotic supplement | Double-blind pilot RCT; 40 children aged 5–12 years | Exploratory adjunctive strategy requiring confirmation. [58]A1b |
| Partially hydrolyzed formula | Follow-up of double-blind randomized A.R.T. trial; intervention during first 6 months; outcomes to age 5 years | Preventive strategy addressing the atopic march. [318]B2b |
Complications, Comorbidities & Iatrogenic Risks
- ▸Poorly controlled or untreated AR may be complicated by asthma, sinusitis, and otitis media with effusion [583].
- ▸Cat-dander sensitization was strongly associated with AR–asthma comorbidity in a real-world cohort (OR **3.743**) [542].
- ▸Children receiving house-dust-mite SCIT require vigilance for systemic reactions, particularly when asthma–AR comorbidity or high allergen-specific IgE is present [576].
- ▸The supplied abstracts do not provide comparative adverse-event estimates for oral therapies, press-needle therapy, Xiangju capsules, or homeopathic treatment; safety should not be presumed from efficacy claims [518,535,159,561].
- ▸Immune-marker changes after bacterial lysate treatment do not by themselves establish clinical efficacy or safety [581].
Clinical burden and upper-airway complications
Allergic rhinitis (AR) is generally not associated with severe outcomes, but poorly controlled or untreated disease may contribute to asthma, sinusitis, and otitis media with effusion. These complications are specifically identified in the 2026 ACE evidence-to-recommendation framework, which focuses mainly on perennial AR and notes that house-dust-mite exposure is a predominant local driver in Singapore [583]. Chronic rhinitis symptoms include nasal obstruction, rhinorrhea, sneezing, and nasal itching; symptom patterns vary between allergic and non-allergic rhinitis subtypes, which can complicate diagnosis and classification [555]C.
Chronic rhinosinusitis (CRS) symptoms in preschool children may persist into school age. In a 5-year prospective cohort of children aged 4–8 years with CRS symptoms, with or without house-dust-mite sensitization, 117 children completed follow-up; the study investigated early clinical and multi-omic predictors of persistent CRS and subsequent AR due to house-dust-mite sensitization [71]B2b. Adenoid hypertrophy (AH) frequently coexists with AR in children. Transcriptomic profiling distinguished children with AH alone from those with AH and AR, although the study was small, comprising 24 participants: 6 healthy controls, 10 with AH, and 8 with AH plus AR [528]C.
Asthma and allergic multimorbidity
AR and asthma commonly coexist and may impose a greater clinical burden than either condition alone. In a real-world study of 1,367 patients, including 1,154 with AR alone and 213 with AR plus asthma, cat-dander sensitization remained a prominent independent factor associated with AR–asthma comorbidity after adjustment, with an odds ratio of 3.743 [542]. Other associated characteristics included a family history of AR or asthma, visual-analogue symptom severity above 3, polysensitization, cat ownership, and age below 18 years [542].
In children with moderate-to-severe allergic asthma and comorbid AR treated with omalizumab or dupilumab, a retrospective cohort of 246 patients developed a nomogram to predict early biologic response at 16 weeks; the study reflects variable treatment response rather than establishing a complication rate [336]B2b. A separate 3-year real-world cohort of 1,208 children receiving individualized liquid-drop sublingual immunotherapy (SLIT) included 954 children with AR and 1,095 with asthma, with assessments at months 6, 12, 18, 24, and 36; its primary outcome was the proportion achieving the predefined minimal clinically important improvement in asthma quality of life at month 6 [525]. In a prospective study of children with AR and/or asthma, subcutaneous immunotherapy (SCIT) was associated with changes in health-related quality of life for children and parental caregivers over 12 months, although the supplied abstract does not provide comparative effect estimates [575].
Other atopic or inflammatory disorders may coexist with allergic disease. A nationwide matched case-control study examined allergic and autoimmune comorbidities in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA), while a country-wide case-control study reported that familial Mediterranean fever was associated with a higher prevalence of atopic disorders [526][582]. These studies support consideration of broader atopic morbidity during assessment but do not establish that AR causes either PFAPA or familial Mediterranean fever [526][582].
Treatment-related and iatrogenic risks
Oral antihistamines and leukotriene receptor antagonists are widely evaluated pediatric options, but evidence regarding their efficacy and safety has historically been limited. A 2026 network meta-analysis of randomized trials in children younger than 12 years with seasonal or perennial AR evaluated nasal and ocular symptom scores, quality of life, adverse events, and serious adverse events associated with oral antihistamines and leukotriene receptor antagonists [518]. The supplied abstract does not report the comparative event estimates; clinicians should therefore avoid assuming that all oral agents have equivalent safety profiles [518].
Subcutaneous allergen immunotherapy carries a risk of systemic reactions. In a retrospective cohort of 250 children receiving house-dust-mite SCIT, 9,244 injections were analyzed for systemic reactions; comorbid allergic asthma, AR with asthma, and high allergen-specific IgE were investigated as potential risk factors [576]C. The study specifically supports heightened vigilance in children with asthma–AR comorbidity or high allergen-specific IgE, although the supplied abstract does not provide the final reaction rate or adjusted effect sizes [576]C.
Evidence for non-standard or adjunctive interventions should be interpreted cautiously. A systematic review and meta-analysis evaluated press-needle therapy in children, including press-needle plus medication versus medication alone and press-needle alone versus medication alone, with safety as an outcome; the supplied abstract does not provide pooled adverse-event estimates [535]. A randomized trial assessed individualized or standardized homeopathic treatment versus placebo in seasonal AR using quality of life, response rate, rescue medication use, and symptom scores, but the supplied abstract does not report the results [561]. A systematic review evaluated Xiangju capsules alone or combined with conventional treatment in randomized trials and assessed efficacy, safety, subgroup stability, and publication bias; the available abstract does not provide definitive safety estimates [159]A1a. Sublingual polyvalent mechanical bacterial lysate was studied in children aged 5–17 years with grass-pollen AR in a randomized, double-blind, placebo-controlled trial, focusing on T-helper-cell transcription factors and cytokines; immunologic modulation should not be equated with proven clinical benefit or absence of adverse effects [581].
Surgical and functional considerations
Nasal obstruction may remain clinically important despite medical treatment. In a prospective multicenter cohort of 212 adults undergoing septorhinoplasty, 57% had AR, 22% had chronic sinusitis, and 22% had obstructive sleep apnea; postoperative assessment at 3–8 months examined obstruction, work productivity, and activity impairment [547]. These findings concern selected surgical patients and should not be extrapolated to routine AR care or interpreted as evidence that septorhinoplasty treats the underlying allergic inflammation [547].
| Domain | Evidence and clinical implication |
|---|---|
| Upper-airway complications | Poor control may contribute to asthma, sinusitis, or otitis media with effusion [583]. |
| CRS and adenoid disease | CRS may persist from preschool to school age; AH frequently coexists with AR [71]B2b[528]C. |
| Asthma comorbidity | Cat sensitization was independently associated with AR plus asthma (OR 3.743) [542]. |
| SCIT systemic reactions | Risk was studied across 250 children and 9,244 injections; asthma–AR comorbidity and high allergen-specific IgE were evaluated as risk factors [576]C. |
| Oral medications | Pediatric randomized evidence assessed adverse and serious adverse events, but comparative results are not available in the supplied abstract [518]. |
| Adjunctive/non-standard therapies | Safety was assessed or planned in studies of press-needle therapy, Xiangju capsules, and homeopathy, but supplied abstracts do not report definitive pooled estimates [535][159]A1a[561]. |
Prognosis & Natural History
- ▸AR follows a heterogeneous and fluctuating course; symptom severity varies by phenotype and exposure, with obstruction, rhinorrhea, sneezing, and itching as core symptoms. [555, 159]
- ▸In children, AR is associated with habitual snoring and SDB, with a pooled habitual-snoring prevalence of 4% and an odds ratio of 2.24 for AR among children with habitual snoring. [184]
- ▸Early CRS symptoms, house-dust-mite sensitization, and complex allergen co-sensitization profiles may help identify children requiring longitudinal monitoring, but causality and individual progression risk remain uncertain. [71, 72]
- ▸Multiallergen immunotherapy reduced combined symptom-and-medication scores versus placebo in polysensitized patients, while pediatric real-world benefit depends on persistence and adherence. [273, 525, 584]
- ▸Most newer pharmacologic, acupuncture, device, and homeopathic studies provide short-term treatment evidence rather than evidence about untreated AR natural history or durable remission. [159, 275, 520, 535, 561]
Overall course
Allergic rhinitis (AR) is a chronic inflammatory disorder whose symptoms can substantially impair quality of life; the available updated evidence describes a fluctuating, heterogeneous course rather than a uniform trajectory. [159]A1a Symptom burden varies across rhinitis subtypes and between individuals, and the principal symptoms are nasal obstruction, rhinorrhea, sneezing, and nasal itching. [555]C Seasonal disease may worsen during relevant pollen periods, while perennial disease may remain persistent with ongoing exposure; however, the supplied evidence does not establish a single predictable pattern of remission or progression. [555]C
The current evidence base is weighted toward symptom burden, comorbidity, and treatment-response studies rather than long-term untreated natural-history cohorts. Consequently, the risk estimates below should be interpreted as associations or prognostic indicators, not proof that AR inevitably progresses to another disease. [71]B2b[72]C4
Childhood persistence and airway progression
In a 5-year prospective cohort of preschool children with chronic rhinosinusitis (CRS) symptoms, with or without immunoglobulin E–mediated house-dust-mite sensitization, investigators assessed early clinical and multi-omics characteristics as predictors of CRS persistence and school-age AR due to house-dust mite. [71]B2b This supports the clinical importance of early phenotyping in children with coexisting CRS symptoms and suspected AR, although the supplied abstract does not provide the final predictor estimates or demonstrate that AR alone causes persistent CRS. [71]B2b
Allergen-sensitization patterns may identify children with broader lower-airway involvement. In a propensity-score-matched pediatric study of 1,206 children with AR or asthma, house-dust-mite sensitization was the leading reported sensitization pattern at 41%, and network and regression analyses were used to investigate factors associated with asthma rather than isolated upper-airway disease. [72]C4 These findings suggest that polysensitization and the structure of co-sensitization networks may help characterize risk, but the retrospective design cannot establish temporal progression from AR to asthma. [72]C4
Sleep, ear, and upper-airway consequences
AR is associated with clinically relevant sleep-disordered breathing (SDB) and habitual snoring in children. A meta-analysis of 17 studies including 32,907 children reported a pooled prevalence of habitual snoring of 4% (95% CI, 2%-7%; I²=98%) and an odds ratio of 2.24 (95% CI, 1.66-3.02) for AR in children with habitual snoring compared with those without habitual snoring. [184]A1a The high heterogeneity indicates that prevalence varies substantially across populations and definitions, and these data do not prove that AR independently causes SDB. [184]A1a
Middle-ear and Eustachian-tube involvement is another potential complication. A systematic review identified six studies with extractable numerator-and-denominator data to estimate objective Eustachian-tube dysfunction, abnormal tympanometry, middle-ear dysfunction, or otitis-media-with-effusion-compatible findings in AR. [523] Because the review emphasized variation in operational definitions and important limitations in the underlying studies, the pooled prevalence should not be treated as a definitive individual prognosis. [523]
Symptom severity and multisystem burden
Seasonal AR severity may extend beyond the nose. In 4,119 patients with seasonal AR assessed during Japanese cedar and cypress pollen seasons, skin symptoms were evaluated in relation to severe seasonal AR using multivariable analyses with inverse-probability weighting. [585] The study supports an association between pollen-season skin manifestations and disease severity, but its cross-sectional design does not determine whether skin symptoms predict future AR persistence or progression. [585]
Allergic multimorbidity may also have consequences later in life. A prospective UK Biobank cohort of adults aged 60 years or older evaluated associations between AR, atopic dermatitis, asthma, allergic-disease coexistence, and incident hospital-recorded osteoporosis or major osteoporotic fracture. [178]B2b This study addresses long-term comorbidity burden in older adults, but the supplied evidence does not provide the effect estimates; therefore, no specific fracture risk should be inferred from the abstract alone. [178]B2b
Prognosis with immunotherapy and adherence
Allergen immunotherapy may modify longer-term symptom and medication burden in selected patients, but its apparent benefit depends on persistence and adherence. A systematic review of seven randomized and seven nonrandomized studies found that multiallergen immunotherapy in polysensitized patients significantly reduced combined symptom-and-medication scores versus placebo (SMD −3.75, 95% CI −5.85 to −1.65; p<0.001); comparisons with single-allergen therapy were also examined, although the supplied abstract does not provide all comparative estimates. [273]B2a
In a 3-year real-world pediatric cohort, individualized liquid-drop sublingual immunotherapy was assessed at baseline and months 6, 12, 18, 24, and 36 in children aged 3-17 years, including 954 children with AR. [525] The study was designed to determine early and longitudinal response across allergic multimorbidity patterns, with clinically meaningful quality-of-life response assessed at month 6; the supplied abstract does not provide the AR-specific response results. [525] A separate prospective pediatric study evaluated 12-month health-related quality of life after subcutaneous immunotherapy versus standard pharmacotherapy in children with AR and/or asthma and their caregivers. [575]
Treatment completion is not guaranteed: a real-world cohort specifically examined persistence and reasons for discontinuation of dust-mite subcutaneous immunotherapy in children treated between 2017 and 2023. [584] Thus, the expected long-term benefit of immunotherapy must be balanced against treatment duration, adherence, and discontinuation. [525][584]
Interpretation of newer treatment evidence
Recent randomized reviews of Xiangju capsules, acupuncture-related therapies, and press-needle therapy in children primarily address short-term efficacy and safety, not untreated natural history or durable remission. [159]A1a[275]D5[535] A randomized placebo-controlled trial of homeopathic medication in seasonal AR assessed quality of life, response, rescue medication use, and symptoms after 3-4 weeks, likewise providing short-term rather than long-term prognostic evidence. [561] A crossover trial of a nasal-spray adaptor focused on tolerability and potential adherence to intranasal corticosteroids over 3-week treatment periods. [520] These studies may inform symptom control and treatment acceptability, but they do not establish whether AR persists, remits, or progresses.
Prognostic summary
The most defensible current conclusion is that AR has a variable course with potentially important sleep, ear, CRS, skin, and lower-airway associations, particularly in children with multimorbidity or complex sensitization profiles. [71]B2b[72]C4[184]A1a[523][585] Long-term outcomes are influenced not only by phenotype and comorbidity but also by the feasibility and persistence of disease-modifying treatment. [273]B2a[525][575][584] Robust individual prediction of remission, CRS persistence, or progression to asthma remains limited by heterogeneity, retrospective designs, inconsistent definitions, and incomplete long-term follow-up. [71]B2b[72]C4[184]A1a[523]
| Domain | Evidence relevant to prognosis | Main limitation |
|---|---|---|
| Symptom course | Variable presentation and severity across rhinitis subtypes. [555]C | Heterogeneous definitions and populations. [555]C |
| Pediatric sleep outcomes | Habitual snoring prevalence 4%; AR associated with habitual snoring, OR 2.24. [184]A1a | High heterogeneity; association does not prove causation. [184]A1a |
| CRS persistence | Five-year cohort evaluated predictors of persistent CRS and school-age HDM-AR. [71]B2b | Abstract does not provide final predictor estimates. [71]B2b |
| Asthma/lower-airway involvement | Sensitization networks and risk factors assessed in matched children with AR or asthma. [72]C4 | Retrospective design cannot establish progression. [72]C4 |
| Immunotherapy trajectory | Reduced combined symptom-medication scores with multiallergen AIT; pediatric cohorts assessed 6-36 months. [273]B2a[525] | Adherence, discontinuation, and incomplete outcome reporting. [525][584] |
Special Populations and Pregnancy
- ▸In pregnancy, second-gen antihistamines and INCS are safe; avoid first-gen and decongestants.
- ▸In elderly, avoid first-gen antihistamines; INCS first-line; SLIT safe.
Pediatrics: First‑line therapy: intranasal corticosteroids (INCS) (e.g., beclomethasone 80‑160 μg/day) [440]A1b. Fixed combination olopatadine‑mometasone (GSP301) effective [439]A1b. SLIT effective and safe; 3 years for immunologic changes [238]C4[444]A1a. Probiotics adjunct with heterogeneous results [62]A1a. Pregnancy: Avoid first‑gen antihistamines and oral decongestants; second‑gen (cetirizine, loratadine, fexofenadine) and INCS (budesonide, fluticasone, mometasone) are safe [193]B2a[198]D5. Continue AIT if initiated before pregnancy; do not start during. Elderly: Avoid first‑gen antihistamines (anticholinergic, fall risk) [466]D5. LAR common (up to 21%) [469]C4. INCS and fixed combinations first‑line; SLIT safe and effective (44% symptom reduction) [445]B2b. Immunocompromised: AIT relatively contraindicated; standard pharmacotherapy considered safe [13]A1c.
Pearl: In elderly patients, first‑generation antihistamines should be avoided due to anticholinergic effects and risk of falls, while intranasal corticosteroids remain first‑line therapy with a favorable safety profile [466]D5.
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Probiotics for prevention of allergic rhinitis | Not effective (OR 0.73 at ≤1 year; OR 0.95 at >1 year) [78]A1a | Reduces atopic sensitization (OR 0.87) and improves symptoms as adjunct [62]A1a | Low to moderate | Probiotics cannot be recommended for primary prevention of AR, but may have a role in symptom management |
| Use of montelukast in pediatric AR | Limited to inadequate response or intolerance to alternatives [198]D5 | Some guidelines consider it for mild disease | Moderate | Montelukast should be reserved for second-line use due to neuropsychiatric safety concerns |
Prevention, Screening & Surveillance
- ▸Use food allergy, parental autoimmune disease, family history, polysensitization, and regional exposure patterns to identify children who may benefit from closer surveillance; these markers do not constitute universal AR screening criteria. [334][508][60][587][591]
- ▸Do not recommend vitamin D supplementation or partially hydrolyzed formula solely for AR prevention without considering the limited, product-specific, or heterogeneous evidence. [318][564]
- ▸Assess asthma symptoms and lower-airway involvement periodically in patients with persistent or severe AR, especially those with cat sensitization, polysensitization, or exercise limitation. [542][540][558]
- ▸During SCIT, monitor efficacy, adherence, and adverse reactions throughout treatment and after completion; published real-world follow-up included **3 years of treatment plus 2 years** post-treatment. [588]
- ▸Reassess environmental-control advice, sleep, household exposures, oral health, and structural nasal obstruction as part of longitudinal care. [515][590][579][61][578]
Prevention: early-life and familial risk
Allergic rhinitis (AR) prevention should focus on risk-informed counseling rather than universal allergen testing. The atopic march may progress from infantile food allergy (FA) to later AR, but this trajectory is not inevitable. In a prospective cohort of 447 infants aged 0–2 years with positive food-allergen testing and follow-up to 6 years, clinical and questionnaire variables were used to develop and validate prediction models for subsequent AR; this supports targeted surveillance of infants with FA, although the abstract does not establish a model suitable for routine population use. [334]B2b
A specific partially hydrolyzed formula (pHF), administered during the first 6 months of life, was evaluated against standard formula in a multicenter, double-blind randomized trial. The investigators assessed whether an earlier reduction in atopic dermatitis persisted to 5 years and whether it extended to other allergic manifestations. Because pHF products differ in allergenicity and immunogenicity, any preventive effect should not be generalized to all hydrolyzed formulas. [318]B2b The available evidence therefore supports discussing the specific studied product only in the clinical context in which it was evaluated, rather than recommending routine pHF for every infant.
Parental autoimmune disease is a potential risk marker: a systematic review and meta-analysis of 12 studies found that maternal autoimmune disease was associated with increased risk of allergic disease in offspring, including asthma, eczema, and AR; included studies were of moderate-to-high methodological quality. [508]B2a This association may justify attention to family history during pediatric risk assessment, but it does not demonstrate that autoimmune disease itself is preventable or that enhanced AR screening improves outcomes. Local sensitization profiles may also be useful for prevention planning because allergen exposure varies by geography, ecology, and behavior; a systematic review from Russia emphasized the emerging role of locally informed, allergen-specific preventive immunization strategies, particularly for respiratory allergy and asthma. [60]D5
Evidence for vitamin D supplementation remains insufficient for routine AR prevention. An umbrella review reassessed meta-analytic evidence on vitamin D levels and supplementation across allergic diseases and specifically examined consistency, prediction intervals, small-study effects, and excess-significance bias; these methods reflect uncertainty and heterogeneity rather than proof of benefit. [564] Vitamin D should therefore be supplemented according to established nutritional indications, not solely to prevent AR.
Environmental and behavioral measures
Environmental counseling should be individualized to documented sensitization and exposure. Population studies show that exposure and host susceptibility both contribute to pollen-related sensitization: a study of 12,345 participants in northern China evaluated Artemisia pollen exposure, specific IgE, sensitization, AR, and acute asthma exacerbation across exposure categories. [529] Hospital-based data from 19,787 patients in Ningbo likewise demonstrate regional variation in sensitization to common inhalant and food allergens, supporting locally tailored testing and avoidance advice rather than a fixed universal allergen panel. [587]
Among 510 children aged 1–15 years with suspected allergic disease in Suzhou, 74.12% were specific-IgE positive; component-resolved testing was additionally performed in a subgroup for house-dust-mite allergens. [591] These findings support age- and region-sensitive interpretation of testing, while emphasizing that sensitization alone must be correlated with symptoms before labeling AR or prescribing extensive avoidance.
Indoor prevention should address potentially modifiable household conditions without implying causality from cross-sectional data. In 9,086 preschool children aged 3–6 years in Wuhan, mixed exposures involving ventilation, device use, and family hygiene practices were analyzed in relation to asthma, AR, and eczema using weighted quantile sum regression. [590] A Beijing survey of 2,132 children aged 6–12 years similarly examined genetic background, diet, and social behaviors in relation to allergic airway disease using ARIA- and GINA-based classification. [530] Patients should receive practical advice on ventilation, pollutant reduction, and exposure-specific control, while avoiding unsupported “hygiene” or dietary prescriptions.
Sleep and circadian health may be relevant preventive targets. A UK Biobank prospective cohort including 256,945 participants for shift-work analyses and 374,672 for sleep-pattern analyses linked self-reported night-shift work and sleep behaviors with incident AR identified through hospital records; multivariable Cox models and mediation analyses were used. [515]B2b These observational findings support counseling on regular, adequate sleep and avoidance of unnecessary circadian disruption, but they do not establish that sleep modification prevents AR.
Screening and surveillance after AR diagnosis
Routine screening should assess the full allergic-airway phenotype. AR is associated with asthma, and cumulative allergic burden in children with asthma—including AR, atopic dermatitis, FA, drug allergy, and family history—was evaluated against lung function in 264 treatment-naive children aged 4–16 years using dose-response and restricted-cubic-spline analyses. [558] Children with persistent, severe, polysensitized, or lower-airway symptoms warrant periodic asthma review, including symptom assessment and objective lung-function testing when age-appropriate.
Cat sensitization is a particularly important comorbidity marker. In a real-world study of 1,154 patients with AR alone and 213 with AR plus asthma, cat-dander sensitization remained a prominent factor associated with comorbid asthma (OR 3.743), alongside family history, polysensitization, cat ownership, symptom burden, and younger age. [542] Exposure history and sensitization testing should therefore be revisited when asthma symptoms emerge.
Children with moderate-to-severe persistent AR should also be asked about exertional respiratory symptoms. In 62 children aged 6–18 years without diagnosed asthma or asthma symptoms who were undergoing early subcutaneous allergen immunotherapy (SCIT), exercise testing used the ATS/ERS protocol; exercise-induced bronchoconstriction was defined by a ≥10% fall in FEV1 from baseline. [540] This supports targeted—not universal—exercise assessment in symptomatic patients.
Allergen immunotherapy surveillance
SCIT requires monitoring for local and systemic adverse reactions, adherence, symptom response, and asthma development. In a real-world cohort of 889 patients completing 3 years of dust-mite SCIT followed by 2 years after treatment, efficacy and adverse reactions were compared between 544 children and 345 adults using multivariable analysis. [588] Age-related differences in treatment response and safety should therefore be considered during shared decision-making and follow-up. A separate cohort found that children and adults completing SCIT differed in baseline burden, smoking and alcohol exposure, and AR duration, reinforcing the need to interpret outcomes in clinical context. [588]
Nasal septal deviation may complicate symptom surveillance. In the prospective ARHINASD study of 138 children aged 6–14 years, participants with and without septal deviation underwent assessment of AR, sensitization, nasal endoscopy, cytology, nasal-fluid cytokines, and nasal airflow-related features. [578] Persistent obstruction despite appropriate anti-inflammatory treatment should prompt examination for structural disease rather than automatic escalation of allergy therapy.
Dental health should be included in long-term review because a systematic review, meta-analysis, and Mendelian-randomization investigation examined associations between AR and dental caries, including prevalence and severity outcomes. [61]B2a The evidence concerns association and potential causality, not a proven AR-prevention intervention; oral-hygiene counseling and dental referral remain appropriate components of comprehensive care. [61]B2a
Practical surveillance priorities
At each review, document symptom control, medication use, sleep, school or work impact, exposure changes, asthma symptoms, exercise limitation, and treatment adverse effects. Environmental-control knowledge and adherence may be limited: a Chinese KAP survey of 393 patients evaluated knowledge, attitudes, and practices regarding environmental control and AR treatment, including relationships among these domains. [579] Reassess counseling comprehension rather than assuming that written advice has been implemented. AR has also been studied in relation to androgenetic alopecia and second-generation antihistamine exposure in a Taiwanese cohort using national insurance data; this is an exploratory association and does not alter AR surveillance recommendations. [514]B2b Recurrent wheezing after lower respiratory infection in children aged ≤5 years may signal later respiratory disease and warrants follow-up, although the cited study addressed recurrent wheezing rather than AR directly. [589]
| Clinical situation | Suggested focus | Evidence |
|---|---|---|
| Infant with food allergy | Follow for later AR and other atopic manifestations; avoid assuming inevitable atopic march | Prospective cohort followed children to 6 years [334]B2b |
| Persistent or severe AR | Screen clinically for asthma, exercise limitation, sleep disruption, and cumulative allergic burden | [558][540][515]B2b |
| Cat exposure or sensitization | Review asthma symptoms and exposure-control options | Cat sensitization associated with comorbid asthma, OR 3.743 [542] |
| Starting or receiving SCIT | Monitor efficacy, adherence, local/systemic reactions, and respiratory status | Age-comparative real-world SCIT data [588] |
| Persistent unilateral or refractory obstruction | Examine for septal deviation or other structural disease | Pediatric ARHINASD study [578] |
| Regionally variable exposure | Use local sensitization and pollen data to guide testing and counseling | [60]D5[529][587][591] |
References
- [1]
Brożek JL, Bousquet J, Agache I et al.. “Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision.” The Journal of allergy and clinical immunology (2017). PMID: 28602936 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [2]
Brozek JL, Bousquet J, Baena-Cagnani CE et al.. “Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.” The Journal of allergy and clinical immunology (2010). PMID: 20816182 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prevention, Screening & Surveillance - [3]
Sousa-Pinto B, Bousquet J, Vieira RJ et al.. “Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.” Allergy (2025). PMID: 41324154 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [4]
Roberts G, Pfaar O, Akdis CA et al.. “EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.” Allergy (2017). PMID: 28940458 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [5]
Vieira RJ, Sousa-Pinto B, Bousquet J et al.. “Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.” Allergy (2026). PMID: 41877472 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [6]
Arshad H, Lack G, Durham SR et al.. “Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37844847 ↗
L5RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance - [7]
Sousa-Pinto B, Vieira RJ, Brozek J et al.. “Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.” The Journal of allergy and clinical immunology (2024). PMID: 38685482 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [8]
Xu X, Li S, Chen Y et al.. “Association between allergic diseases and mental health conditions: An umbrella review.” The Journal of allergy and clinical immunology (2024). PMID: 39521284 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type - [9]
Sousa-Pinto B, Vieira RJ, Bognanni A et al.. “Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.” Allergy (2024). PMID: 39548801 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway - [10]
Licari A, Magri P, De Silvestri A et al.. “Epidemiology of Allergic Rhinitis in Children: A Systematic Review and Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37236349 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [11]
Torres MI, Gil-Mata S, Bognanni A et al.. “Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39251016 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks - [12]
Gil-Mata S, Vieira RJ, Borowiack E et al.. “Intranasal Treatments for Allergic Rhinitis in Preschool- and School-Age Children: Network Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40675325 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [13]
Scadding GK, Kariyawasam HH, Scadding G et al.. “BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007).” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017). PMID: 30239057 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy - [14]
Walker SM, Durham SR, Till SJ et al.. “Immunotherapy for allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2011). PMID: 21848757 ↗
L1GUIDELINECited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [15]
Creticos PS, Schroeder JT, Hamilton RG et al.. “Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis.” The New England journal of medicine (2006). PMID: 17021320 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [16]
Liu QD, Pan GX, Yan YJ et al.. “Metabolomic profiles in allergic rhinitis: A systematic review and meta-analysis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 39824455 ↗
L3SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [17]
Knudgaard MH, Andreasen TH, Ravnborg N et al.. “Rhinitis prevalence and association with atopic dermatitis: A systematic review and meta-analysis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33684526 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [18]
Chalmers JR, Haines RH, Bradshaw LE et al.. “Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.” Lancet (London, England) (2020). PMID: 32087126 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance - [19]
Mårtensson A, Nordström FU, Cervin-Hoberg C et al.. “Nasal administration of a probiotic assemblage in allergic rhinitis: A randomised placebo-controlled crossover trial.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022). PMID: 35075723 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [20]
Srivastava D, Singh BP, Arora N et al.. “Clinico-immunologic study on immunotherapy with mixed and single insect allergens.” Journal of clinical immunology (2009). PMID: 19533313 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [21]
Berni Canani R, Carucci L, Coppola S et al.. “Ultra-processed foods, allergy outcomes and underlying mechanisms in children: An EAACI task force report.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 39254357 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Special Populations & Pregnancy - [22]
Venter C, Tan W, Pickett-Nairne K et al.. “Systematic review on maternal dietary patterns during pregnancy and offspring allergy.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 39673331 ↗
L5SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification, Special Populations & Pregnancy - [23]
Venter C, Agostoni C, Arshad SH et al.. “Dietary factors during pregnancy and atopic outcomes in childhood: A systematic review from the European Academy of Allergy and Clinical Immunology.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32524677 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [24]
Lisik D, Ermis SSÖ, Ioannidou A et al.. “Siblings and risk of allergic rhinitis: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2023). PMID: 37492922 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [25]
Bousquet J, Schünemann HJ, Togias A et al.. “Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.” The Journal of allergy and clinical immunology (2019). PMID: 31627910 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification - [26]
Hellings PW, Steelant B. “Epithelial barriers in allergy and asthma.” The Journal of allergy and clinical immunology (2020). PMID: 32507228 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism - [27]
Matricardi PM, van Hage M, Custovic A et al.. “Molecular allergy diagnosis enabling personalized medicine.” The Journal of allergy and clinical immunology (2025). PMID: 39855360 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [28]
Pacheco SE, Guidos-Fogelbach G, Annesi-Maesano I et al.. “Climate change and global issues in allergy and immunology.” The Journal of allergy and clinical immunology (2021). PMID: 34688774 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification - [29]
Zhang Y, Lan F, Zhang L. “Advances and highlights in allergic rhinitis.” Allergy (2021). PMID: 34379805 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [30]
Zhang Y, Lan F, Zhang L. “Update on pathomechanisms and treatments in allergic rhinitis.” Allergy (2022). PMID: 35892225 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [31]
Ogulur I, Pat Y, Ardicli O et al.. “Advances and highlights in biomarkers of allergic diseases.” Allergy (2021). PMID: 34519063 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [32]
Datsi A, Steinhoff M, Ahmad F et al.. “Interleukin-31: The "itchy" cytokine in inflammation and therapy.” Allergy (2021). PMID: 33629401 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism - [33]
Ponda P, Carr T, Rank MA et al.. “Nonallergic Rhinitis, Allergic Rhinitis, and Immunotherapy: Advances in the Last Decade.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36152989 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [34]
Conway AE, Verdi M, Kartha N et al.. “Allergic Diseases and Mental Health.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38851487 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Complications, Comorbidities & Iatrogenic Risks - [35]
Klimek L, Mullol J, Ellis AK et al.. “Current Management of Allergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38851250 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [36]
Akar-Ghibril N, Casale T, Custovic A et al.. “Allergic Endotypes and Phenotypes of Asthma.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32037107 ↗
L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [37]
Bielory L, Delgado L, Katelaris CH et al.. “ICON: Diagnosis and management of allergic conjunctivitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2019). PMID: 31759180 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [38]
Linton S, Hossenbaccus L, Ellis AK. “Evidence-based use of antihistamines for treatment of allergic conditions.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 37517656 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy - [39]
Scelo G, Torres-Duque CA, Maspero J et al.. “Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 37640263 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks - [40]
Bensch GW. “Safety of intranasal corticosteroids.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2016). PMID: 27979016 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment, Prevention, Screening & Surveillance - [41]
Linton S, Burrows AG, Hossenbaccus L et al.. “Future of allergic rhinitis management.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33971355 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [42]
Arshad SH. “Does allergen immunotherapy for allergic rhinitis prevent asthma?” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35500864 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History - [43]
D'Amato G, Murrieta-Aguttes M, D'Amato M et al.. “Pollen respiratory allergy: Is it really seasonal?” The World Allergy Organization journal (2023). PMID: 37520612 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [44]
Morais-Almeida M, Canonica GW, Giavina-Bianchi P et al.. “Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action.” The World Allergy Organization journal (2026). PMID: 42058161 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type - [45]
Di Cara G, Carelli A, Latini A et al.. “Severity of allergic rhinitis and asthma development in children.” The World Allergy Organization journal (2015). PMID: 26023322 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Severity, Grading & Risk Stratification - [46]
Wang H, Tu J, Zhang J et al.. “Integrated multi-omics profiling reveals shared mechanistic pathways in asthma-allergic rhinitis comorbidity: A hybrid machine learning framework leveraging Mendelian randomization for precision diagnostics.” The World Allergy Organization journal (2025). PMID: 41049388 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation - [47]
Xu Z, Lai M, Luo X et al.. “The clinical characteristics and inflammatory endotypes of chronic rhinosinusitis with nasal polyps in Southern China: A multi-center, cross sectional study.” The World Allergy Organization journal (2025). PMID: 40822746 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type - [48]
Larenas-Linnemann DE, Mayorga-Butrón JL, Maza-Solano J et al.. “Global expert views on the diagnosis, classification and pharmacotherapy of allergic rhinitis in clinical practice using a modified Delphi panel technique.” The World Allergy Organization journal (2023). PMID: 37520611 ↗
L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type - [49]
Zhao Z, Chen H, Liu T et al.. “Efficacy predictions for omalizumab treatment based on basophil CD203c expression in patients with allergic rhinitis by basophil activation test -- a real-life, pilot study.” The World Allergy Organization journal (2026). PMID: 42058162 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type - [50]
Justicia JL, Padró C, Roger A et al.. “Immunological parameters as biomarkers of response to MicroCrystalline Tyrosine-adjuvanted mite immunotherapy.” The World Allergy Organization journal (2021). PMID: 34178239 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type - [51]
Wheatley LM, Togias A. “Clinical practice. Allergic rhinitis.” The New England journal of medicine (2015). PMID: 25629743 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [52]
Guttman-Yassky E, Renert-Yuval Y, Brunner PM. “Atopic dermatitis.” Lancet (London, England) (2025). PMID: 39955121 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks - [53]
Langan SM, Irvine AD, Weidinger S. “Atopic dermatitis.” Lancet (London, England) (2020). PMID: 32738956 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance - [54]
Greiner AN, Hellings PW, Rotiroti G et al.. “Allergic rhinitis.” Lancet (London, England) (2011). PMID: 21783242 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [55]
Weidinger S, Novak N. “Atopic dermatitis.” Lancet (London, England) (2015). PMID: 26377142 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Prognosis & Natural History, Prevention, Screening & Surveillance - [56]
Huang K, Yang T, Xu J et al.. “Prevalence, risk factors, and management of asthma in China: a national cross-sectional study.” Lancet (London, England) (2019). PMID: 31230828 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment, Special Populations & Pregnancy - [57]
Shaaban R, Zureik M, Soussan D et al.. “Rhinitis and onset of asthma: a longitudinal population-based study.” Lancet (London, England) (2008). PMID: 18805333 ↗
L2OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment, Prevention, Screening & Surveillance - [58]
Caldaria E, Iorio R, Marziali D et al.. “Exploratory pilot trial of a multicomponent immunonutritional supplement in children with allergic asthma and rhinitis: The INAPRA study.” International immunopharmacology (2026). PMID: 42202393 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Special Populations & Pregnancy - [59]
Kerdkaew K, Rattanathamma P, Tongtako W et al.. “Effects of Moderate-Intensity Aerobic Exercise on Clinical Symptoms and Physiological Outcomes in Young Adults with Persistent Allergic Rhinitis: A Randomized Controlled Trial.” International journal of environmental research and public health (2026). PMID: 42196705 ↗
L1RCTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [60]
Dubovets A, Lukashevichus A, Artemova V et al.. “Towards Sensitization Profiling for Allergy Prevention in Russia: A Systematic Review.” International journal of molecular sciences (2026). PMID: 42353054 ↗
L5SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance - [61]
Yu Q, Lan L, Li Y et al.. “Association between asthma, allergic rhinitis, atopic dermatitis, and dental caries: evidence from systematic review with meta-analysis and Mendelian randomisation investigation.” Journal of global health (2026). PMID: 42246314 ↗
L2SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance - [62]
Bakhshi A, Poursadegh F, Salari M et al.. “Effect of probiotics on allergic rhinitis in children; A systematic review and meta-analysis.” European journal of pediatrics (2026). PMID: 42209809 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy - [63]
Inpan R, Kantasa T, Hanprasertpong N et al.. “Ginger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.” Pharmaceutical biology (2026). PMID: 42183789 ↗
L1SR_OBSCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks - [64]
Eifan AO, Durham SR. “Pathogenesis of rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2016). PMID: 27434218 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [65]
Wang N, Yao Y, Liu YH et al.. “Allergic Rhinitis in China: Trends, Challenges and Implications Over the Past Two Decades.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2025). PMID: 40676746 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance - [66]
Moitra S, Mahesh PA, Moitra S. “Allergic rhinitis in India.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023). PMID: 36856159 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [67]
Page C, Pitchford S. “Platelets and allergic inflammation.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2014). PMID: 24708345 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors - [68]
Campo P, Rondón C, Gould HJ et al.. “Local IgE in non-allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2015). PMID: 25495772 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [69]
Liao EC, Ho CM, Lin MY et al.. “Dermatophagoides pteronyssinus and Tyrophagus putrescentiae allergy in allergic rhinitis caused by cross-reactivity not dual-sensitization.” Journal of clinical immunology (2010). PMID: 20683648 ↗
L4OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance - [70]
Qiu S, Du Y, Duan X et al.. “B cell immunity in allergic nasal mucosa induces T helper 2 cell differentiation.” Journal of clinical immunology (2012). PMID: 22454245 ↗
L3OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [71]
Dobrakowski Ł, Kalisiak M, Majak J et al.. “Predicting the course of chronic rhinosinusitis in young children-5-year prospective study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42418237 ↗
L2COHORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [72]
Zou P, Fan Y, Xie C et al.. “Allergen Sensitization Profiles and Co-Sensitization Networks in Children with Allergic Rhinitis and Asthma: A Propensity Score-Matched Retrospective Study.” Journal of asthma and allergy (2026). PMID: 42333264 ↗
L4COHORTCited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Grading & Risk Stratification, Prognosis & Natural History, Special Populations & Pregnancy - [73]
Kalb B, Khaleva E, Giovannini M et al.. “Trajectories of allergic diseases in children: Destination unknown?” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2025). PMID: 40589146 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History, Prevention, Screening & Surveillance - [74]
Papadopoulos NG, Aggelides X, Stamataki S et al.. “New concepts in pediatric rhinitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33475171 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy - [75]
Zicari AM, De Castro G, Leonardi L et al.. “Update on rhinitis and rhinosinusitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32017218 ↗
L5OTHERCited in: Definition, Classification & Hypersensitivity Mechanism Type, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [76]
Schoos AM. “Atopic diseases-Diagnostics, mechanisms, and exposures.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 39016386 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Hypersensitivity Mechanism Type, Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Prevention, Screening & Surveillance - [77]
Corren J, Larson D, Altman MC et al.. “Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.” The Journal of allergy and clinical immunology (2022). PMID: 36223848 ↗
L1RCTCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History - [78]
Xiao Z, Luo H, Liu H et al.. “Probiotic supplementation during pregnancy or infancy for the prevention of allergic rhinitis in infants: A systematic review and meta-analysis of Randomized controlled trials.” The World Allergy Organization journal (2025). PMID: 41079137 ↗
L1SR_MA_RCTCited in: Pathophysiology & Immune Mechanism, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [79]
Liu X, Zhou J, Chen J et al.. “Risk of Asthma and Allergies in Children Delivered by Cesarean Section: A Comprehensive Systematic Review.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38908434 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism - [80]
Chokevittaya P, Jirattikanwong N, Thongngarm T et al.. “Factors Associated With Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39265658 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History - [81]
Halken S, Larenas-Linnemann D, Roberts G et al.. “EAACI guidelines on allergen immunotherapy: Prevention of allergy.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017). PMID: 28902467 ↗
L1GUIDELINECited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prevention, Screening & Surveillance - [82]
Patou J, De Smedt H, van Cauwenberge P et al.. “Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2006). PMID: 16911353 ↗
L5SR_OBSCited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks - [83]
Tan W, Amara S, Venter M et al.. “Systematic review of maternal dietary patterns during pregnancy and offspring allergy.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2025). PMID: 41054961 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History, Special Populations & Pregnancy - [84]
Pacheco-González RM, García-Marcos L, Morales E. “Prenatal vitamin D status and respiratory and allergic outcomes in childhood: A meta-analysis of observational studies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2018). PMID: 29444346 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Special Populations & Pregnancy - [85]
Oh Y, Hong SJ, Park YJ et al.. “Association between phthalate exposure and risk of allergic rhinitis in children: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 39229646 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism, Prevention, Screening & Surveillance - [86]
Kristiansen M, Dhami S, Netuveli G et al.. “Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27653623 ↗
L2SR_OBSCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History, Prevention, Screening & Surveillance - [87]
Paller AS, Spergel JM, Mina-Osorio P et al.. “The atopic march and atopic multimorbidity: Many trajectories, many pathways.” The Journal of allergy and clinical immunology (2018). PMID: 30458183 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History - [88]
Lawson LP, Parameswaran S, Panganiban RA et al.. “Update on the genetics of allergic diseases.” The Journal of allergy and clinical immunology (2025). PMID: 40139464 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors - [89]
Fang ZF, Fu Y, Yi F et al.. “Neural control of the pathophysiology of allergic airway disease and its clinical implications: A focus on allergic rhinitis and asthma.” The Journal of allergy and clinical immunology (2025). PMID: 40447196 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism - [90]
Iinuma T, Kiuchi M, Hirahara K et al.. “Single-cell immunoprofiling after immunotherapy for allergic rhinitis reveals functional suppression of pathogenic TH2 cells and clonal conversion.” The Journal of allergy and clinical immunology (2022). PMID: 35863510 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [91]
Spergel J, Aceves SS. “Allergic components of eosinophilic esophagitis.” The Journal of allergy and clinical immunology (2018). PMID: 29980277 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [92]
Matricardi PM, Dramburg S, Potapova E et al.. “Molecular diagnosis for allergen immunotherapy.” The Journal of allergy and clinical immunology (2019). PMID: 30850070 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [93]
Siracusa MC, Kim BS, Spergel JM et al.. “Basophils and allergic inflammation.” The Journal of allergy and clinical immunology (2013). PMID: 24075190 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment - [94]
Bousquet J, Melén E, Haahtela T et al.. “Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.” Allergy (2023). PMID: 36799120 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Severity, Grading & Risk Stratification - [95]
Hellings PW, Klimek L, Cingi C et al.. “Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology.” Allergy (2017). PMID: 28474799 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Severity, Grading & Risk Stratification, Special Populations & Pregnancy - [96]
Huang ZQ, Liu J, Sun LY et al.. “Updated epithelial barrier dysfunction in chronic rhinosinusitis: Targeting pathophysiology and treatment response of tight junctions.” Allergy (2024). PMID: 38372149 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, History and Evolution of Treatment, Prognosis & Natural History - [97]
Gao YD, Wang ZJ, Ogulur I et al.. “The Evolution, Immunopathogenesis and Biomarkers of Type 2 Inflammation in Common Allergic Disorders.” Allergy (2025). PMID: 40586319 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, History and Evolution of Treatment - [98]
Moldaver D, Larché M. “Immunotherapy with peptides.” Allergy (2011). PMID: 21507007 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [99]
Fernández-Gallego N, Castillo-González R, Méndez-Barbero N et al.. “The impact of type 2 immunity and allergic diseases in atherosclerosis.” Allergy (2022). PMID: 35781885 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [100]
Stevens WW, Schleimer RP, Kern RC. “Chronic Rhinosinusitis with Nasal Polyps.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27393770 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism - [101]
Wise SK, Damask C, Greenhawt M et al.. “A Synopsis of Guidance for Allergic Rhinitis Diagnosis and Management From ICAR 2023.” The journal of allergy and clinical immunology. In practice (2023). PMID: 36894277 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Special Populations & Pregnancy - [102]
Baroody FM, Gevaert P, Smith PK et al.. “Nonallergic Rhinopathy: A Comprehensive Review of Classification, Diagnosis, and Treatment.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38467330 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [103]
Smallwood D, Ledford D, Kennedy D et al.. “Postnasal Drip.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38677587 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History - [104]
Campo P, Canonica GW. “Local Allergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38641133 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [105]
Diver S, Russell RJ, Brightling CE. “Cough and Eosinophilia.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31279462 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prognosis & Natural History - [106]
Bose S, Grammer LC, Peters AT. “Infectious Chronic Rhinosinusitis.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27393772 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [107]
Ellis AK, Tenn MW. “Advances in rhinitis: Models and mechanisms.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 29157860 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway - [108]
Pierre Z, Mattos JL. “Smell and the sinuses.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2026). PMID: 42219147 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [109]
Lowe AJ, Leung DYM, Tang MLK et al.. “The skin as a target for prevention of the atopic march.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 29413338 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prevention, Screening & Surveillance - [110]
Dimou MV, Xepapadaki P, Lakoumentas J et al.. “Levels of IgE sensitization drive symptom thresholds in allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 38679157 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism - [111]
Ho JSS, Li CH, Wang A et al.. “It is no skin off my nose: The relationship between the skin and allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33901674 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism - [112]
Howell MD, Fitzsimons C, Smith PA. “JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 29454096 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism - [113]
DeVore SB, Gonzalez T, Sherenian MG et al.. “On the surface: Skin microbial exposure contributes to allergic disease.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32853786 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Prevention, Screening & Surveillance - [114]
Rouadi PW, Idriss SA, Bousquet J et al.. “WAO - ARIA consensus on chronic cough: Executive summary.” The World Allergy Organization journal (2025). PMID: 40093560 ↗
L1REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [115]
Cheng Q, Fei J, Liao Y et al.. “Identification of immune-associated biomarkers in diagnosing allergic rhinitis.” The World Allergy Organization journal (2025). PMID: 40761581 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History - [116]
Giulia D, Paola DF, Armando DL et al.. “Applications of basophil activation test in paediatric allergic diseases.” The World Allergy Organization journal (2024). PMID: 39734398 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Prognosis & Natural History, Special Populations & Pregnancy - [117]
Ridolo E, Nicoletta F, Lombardi C et al.. “Eosinophilic esophagitis and inhalant antigens: Pointing out the roles of allergic rhinitis, immunotherapy and biologic treatment.” The World Allergy Organization journal (2024). PMID: 39386073 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History - [118]
Rouadi PW, Idriss SA, Naclerio RM et al.. “Immunopathological features of air pollution and its impact on inflammatory airway diseases (IAD).” The World Allergy Organization journal (2020). PMID: 33042360 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Prognosis & Natural History - [119]
Gelardi M, Guglielmi AV, Iannuzzi L et al.. “Local allergic rhinitis: entopy or spontaneous response?” The World Allergy Organization journal (2016). PMID: 27980704 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment - [120]
Liu Z, Li Y, Zhao X et al.. “LncRNA PELATON regulates Th2 cell differentiation by miR-10b-5p/GATA3 axis in allergic rhinitis.” The World Allergy Organization journal (2025). PMID: 41048563 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [121]
Van Bever HP, Samuel ST, Lee BW. “Halting the allergic march.” The World Allergy Organization journal (2008). PMID: 23283392 ↗
L5OTHERCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance - [122]
Dollner R, Taraldsrud E, Iversen K et al.. “Non-allergic, mastocytosis-associated rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2013). PMID: 23517036 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism - [123]
Campo P, Eguiluz-Gracia I, Bogas G et al.. “Local allergic rhinitis: Implications for management.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018). PMID: 29900607 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [124]
Cao PP, Shi LL, Xu K et al.. “Dendritic cells in inflammatory sinonasal diseases.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2016). PMID: 27159777 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation - [125]
Allan K, Kelly FJ, Devereux G. “Antioxidants and allergic disease: a case of too little or too much?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2009). PMID: 19968654 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [126]
Lopez DJ, Lodge CJ, Bui DS et al.. “Establishing subclasses of childhood eczema, their risk factors and prognosis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022). PMID: 35347774 ↗
L2REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment, Prevention, Screening & Surveillance - [127]
O'Regan GM, Irvine AD. “The role of filaggrin in the atopic diathesis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2010). PMID: 20642575 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Complications, Comorbidities & Iatrogenic Risks - [128]
Liu Y, Zeng M, Liu Z. “Th17 response and its regulation in inflammatory upper airway diseases.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2015). PMID: 25048954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism - [129]
Liang X, Liu W, Qi H et al.. “Allergen Sensitization Characteristics and Temporal Trends in Allergic Rhinitis: A Single-Center Retrospective Study of 2,482 Patients in Beijing.” Respiratory medicine (2026). PMID: 42349726 ↗
L4COHORTCited in: Pathophysiology & Immune Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification - [130]
Marseglia G, Miraglia Del Giudice M, Licari A et al.. “Azelastine-fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 41755501 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks - [131]
Sponholz W, Steinert C, Monnati F et al.. “IgE to cyclophilin Bet v 7 triggers mast cell activation and mediates cross-reactivity with Ara h 18 in children with seasonal allergic rhinitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 41781362 ↗
L4OTHERCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [132]
Li J, Zhang Y, Zhang L. “[Effects of baseline clinical characteristics on the efficacy of stapokibart in patients with seasonal allergic rhinitis: a post-hoc subgroup analysis].” Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery (2026). PMID: 42402684 ↗
L2RCTCited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [133]
Zhou Y, Wang T, Fan Y et al.. “Therapy of allergic rhinitis using ribavirin spray to clear nasal commensal viruses.” Signal transduction and targeted therapy (2026). PMID: 42350364 ↗
L4RCTCited in: Pathophysiology & Immune Mechanism, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [134]
Zhang W, Li P, Zhao S et al.. “Microbiome and metabolome integrated analysis reveals oral microbiota alterations and associated metabolic pathways in allergic rhinitis.” Journal of oral microbiology (2026). PMID: 42428783 ↗
L3OTHERCited in: Pathophysiology & Immune Mechanism - [135]
Li E, Shi M, Huang S. “New-onset allergic diseases after SARS-CoV-2 infection: mechanistic hypotheses and emerging strategies for risk stratification.” Frontiers in immunology (2026). PMID: 42421939 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Immune Mechanism, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [136]
Ní Chaoimh C, Lad D, Nico C et al.. “Early initiation of short-term emollient use for the prevention of atopic dermatitis in high-risk infants-The STOP-AD randomised controlled trial.” Allergy (2022). PMID: 35997592 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [137]
Eapen AA, Shankhwar S, von Mutius E et al.. “Environmental risk factors and asthma primary prevention: From birth cohort studies to clinical trials.” The Journal of allergy and clinical immunology (2025). PMID: 40659121 ↗
L5TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [138]
Arrais M, Maricoto T, Nwaru BI et al.. “Helminth infections and allergic diseases: Systematic review and meta-analysis of the global literature.” The Journal of allergy and clinical immunology (2021). PMID: 34968529 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [139]
Sun Y, Vonk JM, Kersten ETG et al.. “Genome-Wide Association Study Reveals a Causal Relationship Between Allergic Rhinitis and Hazelnut Allergy.” Allergy (2024). PMID: 39673378 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [140]
Tsai SY, Gaffin JM, Hawryluk EB et al.. “Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.” Allergy (2024). PMID: 39166365 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Special Populations & Pregnancy - [141]
Pfaar O, Richter H, Müller T et al.. “Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany.” The World Allergy Organization journal (2025). PMID: 40861800 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [142]
Chang CL, Ali GB, Pham J et al.. “Childhood body mass index trajectories and asthma and allergies: A systematic review.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023). PMID: 37401045 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [143]
Conlan N, Maher GM, Al Khalaf SY et al.. “Association between hypertensive disorders of pregnancy and the risk of asthma, eczema and allergies in offspring: A systematic review and meta-analysis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020). PMID: 33037716 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Special Populations & Pregnancy - [144]
Kim YH, Kim KW, Kim MJ et al.. “Vitamin D levels in allergic rhinitis: a systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27188226 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [145]
Çelebi Sözener Z, Treffeisen ER, Özdel Öztürk B et al.. “Global warming and implications for epithelial barrier disruption and respiratory and dermatologic allergic diseases.” The Journal of allergy and clinical immunology (2023). PMID: 37689250 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification - [146]
Biagini JM, Kroner JW, Baatyrbek Kyzy A et al.. “Longitudinal atopic dermatitis endotypes: An atopic march paradigm that includes Black children.” The Journal of allergy and clinical immunology (2021). PMID: 34673050 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [147]
Perry TT, Grant TL, Dantzer JA et al.. “Impact of socioeconomic factors on allergic diseases.” The Journal of allergy and clinical immunology (2023). PMID: 37967769 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [148]
Rondón C, Campo P, Togias A et al.. “Local allergic rhinitis: concept, pathophysiology, and management.” The Journal of allergy and clinical immunology (2012). PMID: 22516477 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [149]
Shin YH, Hwang J, Kwon R et al.. “Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019.” Allergy (2023). PMID: 37431853 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [150]
Arnau-Soler A, Tremblay BL, Sun Y et al.. “Food Allergy Genetics and Epigenetics: A Review of Genome-Wide Association Studies.” Allergy (2024). PMID: 39698764 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [151]
Celebi Sozener Z, Ozdel Ozturk B, Cerci P et al.. “Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease.” Allergy (2022). PMID: 35108405 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification - [152]
Berni Canani R, Caminati M, Carucci L et al.. “Skin, gut, and lung barrier: Physiological interface and target of intervention for preventing and treating allergic diseases.” Allergy (2024). PMID: 38439599 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [153]
Yang L, Lin Z, Gao T et al.. “The Role of Skin-Gut-Lung Microbiome in Allergic Diseases.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40320144 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks - [154]
Thien F, Davies JM, Douglass JA et al.. “Thunderstorm Asthma: Current Perspectives and Emerging Trends.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40199421 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [155]
Kim J, Rouadi PW. “The Relationship of Climate Change to Rhinitis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38636591 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [156]
Conroy ER, Banzon TM, Simoneau T et al.. “An Overview of Adherence-What It Is and Why It Is Important.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39074603 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [157]
Modi S, Norris MR, Nguyen V et al.. “Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2023). PMID: 36736954 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [158]
Zeiger RS, Schatz M, Zhou B et al.. “Risk Factors for Moderate-Severe Asthma in Children Ages 5-11 Years With Early-Onset Atopic Dermatitis.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40752737 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [159]
Chen M, Lu YW, Shi J et al.. “Efficacy and safety of Xiangju capsules for allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in pharmacology (2026). PMID: 42292827 ↗
L1SR_MA_RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [160]
Narla S, Silverberg JI. “Current updates in the epidemiology and comorbidities of atopic dermatitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 40350074 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification - [161]
Rackerby N, Ahn C, Ball BD et al.. “Evolving paradigms of treatment of allergic and nonallergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 40245980 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks - [162]
Gabryszewski SJ, Hill DA. “One march, many paths: Insights into allergic march trajectories.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 33971364 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Prevention, Screening & Surveillance - [163]
Kazancioglu A, Ozdemiral C, Gur Cetinkaya P et al.. “Long-term risk of allergic diseases after allergic proctocolitis: A clinical perspective.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 40701364 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [164]
Spergel JM. “From atopic dermatitis to asthma: the atopic march.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2010). PMID: 20674819 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [165]
Ker J, Hartert TV. “The atopic march: what's the evidence?” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2009). PMID: 19852191 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [166]
Chen C, Song X, Murdock DJ et al.. “Association between allergic conditions and COVID-19 susceptibility and outcomes.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024). PMID: 38242353 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Grading & Risk Stratification - [167]
Cheng Y, Liu Q, Li M et al.. “First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.” Frontiers in immunology (2026). PMID: 42292382 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [168]
Rosário Filho NA, Urrutia-Pereira M, D'Amato G et al.. “Air pollution and indoor settings.” The World Allergy Organization journal (2021). PMID: 33510831 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [169]
Chong SN, Chew FT. “Epidemiology of allergic rhinitis and associated risk factors in Asia.” The World Allergy Organization journal (2018). PMID: 30128063 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation - [170]
Higashida-Konishi M, Izumi K, Shimada T et al.. “Allergic disorders and their risk factors in primary Sjögren's syndrome.” The World Allergy Organization journal (2023). PMID: 36788991 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors - [171]
Gómez RM, Croce VH, Zernotti ME et al.. “Active smoking effect in allergic rhinitis.” The World Allergy Organization journal (2021). PMID: 33510834 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Complications, Comorbidities & Iatrogenic Risks - [172]
Li H, Zong Y, He L et al.. “Mendelian randomization analysis reveals causal relationship between allergic diseases and influenza.” The World Allergy Organization journal (2025). PMID: 40529241 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [173]
Krishna MT, Mahesh PA, Vedanthan P et al.. “An appraisal of allergic disorders in India and an urgent call for action.” The World Allergy Organization journal (2020). PMID: 32774662 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [174]
Zhang X, Zhang M, Sui H et al.. “Prevalence and risk factors of allergic rhinitis among Chinese adults: A nationwide representative cross-sectional study.” The World Allergy Organization journal (2023). PMID: 37008533 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [175]
Mahesh PA, Moitra S, Mabalirajan U et al.. “Allergic diseases in India - Prevalence, risk factors and current challenges.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022). PMID: 36181726 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [176]
Yue H, Umehara Y, Trujillo-Paez JV et al.. “Exogenous factors in the pathogenesis of atopic dermatitis: Irritants and cutaneous infections.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021). PMID: 33394511 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors - [177]
Irmak S, Dedeoglu S, Toprak SF et al.. “Intranasal Corticosteroids Versus Second-Generation Antihistamines for Allergic Rhinitis in Adolescents: A Prospective Cohort Study of Quality of Life and School Attendance.” Journal of asthma and allergy (2026). PMID: 42305426 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications, Comorbidities & Iatrogenic Risks, Special Populations & Pregnancy - [178]
Peng C, Chen B, Chen Z et al.. “Associations of allergic diseases with incident hospital-recorded osteoporosis and major osteoporotic fracture in older adults: a prospective cohort study in the UK Biobank.” BMC geriatrics (2026). PMID: 42249315 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History - [179]
Duse M, Caminiti S, Zicari AM. “Rhinosinusitis: prevention strategies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2007). PMID: 17767614 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance - [180]
Lee SY, Nakano T, Shimojo N et al.. “Asian birth cohort studies on allergic diseases: The A2BC network initiative.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 39560177 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [181]
Mastrorilli C, Posa D, Cipriani F et al.. “Asthma and allergic rhinitis in childhood: what's new.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27862336 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [182]
Wong GWK, Li J, Bao YX et al.. “Pediatric allergy and immunology in China.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2017). PMID: 29047174 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Special Populations & Pregnancy - [183]
De Filippo M, Votto M, Caminiti L et al.. “Safety of allergen-specific immunotherapy in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 35080302 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [184]
Li Q, Zhong Q, Kong X et al.. “Allergic rhinitis in children in relation to sleep breathing disorders: a meta-analysis.” International journal of pediatric otorhinolaryngology (2026). PMID: 42302637 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Pregnancy - [185]
Vliagoftis H, Kouranos VD, Betsi GI et al.. “Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2008). PMID: 19119700 ↗
L1SR_MA_RCTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Prevention, Screening & Surveillance - [186]
Oppenheimer J, Casale TB, Spergel JM et al.. “Pharmacokinetics and Pharmacodynamics Following Repeat Dosing of neffy (Epinephrine Nasal Spray) Versus Intramuscular Injection During Induced Allergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41687867 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [187]
Li X, Wang X, Yang Q et al.. “A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39746515 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment, Complications, Comorbidities & Iatrogenic Risks - [188]
Durham SR, Penagos M. “Sublingual or subcutaneous immunotherapy for allergic rhinitis?” The Journal of allergy and clinical immunology (2016). PMID: 26853126 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [189]
Vieira RJ, Gil-Mata S, Ferreira A et al.. “Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2026). PMID: 41707943 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks - [190]
Caimmi D, Abouelfath A, Lassalle R et al.. “Patient-Perceived Benefits of Named-Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real-World Cohort Study.” Allergy (2026). PMID: 41795228 ↗
L3COHORTCited in: Clinical Presentation, Prognosis & Natural History - [191]
Ridolo E, Montagni M, Incorvaia C et al.. “Orphan immunotherapies for allergic diseases.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2016). PMID: 26837608 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [192]
Bielory L, Gross GN, Letierce A et al.. “Ocular symptoms improvement from intranasal triamcinolone compared with placebo and intranasal fluticasone propionate: A meta-analysis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32004698 ↗
L2SR_OBSCited in: Clinical Presentation - [193]
Gómez RM, Moreno P, Compalati E et al.. “Update meta-analysis on the efficacy and safety issues of fexofenadine.” The World Allergy Organization journal (2023). PMID: 37546236 ↗
L2SR_OBSCited in: Clinical Presentation, Prognosis & Natural History, Special Populations & Pregnancy - [194]
Wen YS, Lin CY, Yang KD et al.. “Nasal nitric oxide is a useful biomarker for acute unilateral maxillary sinusitis in pediatric allergic rhinitis: A prospective observational cohort study.” The World Allergy Organization journal (2019). PMID: 31193296 ↗
L3COHORTCited in: Clinical Presentation - [195]
Margaritte-Jeannin P, Budu-Aggrey A, Ege M et al.. “Identification of OCA2 as a novel locus for the co-morbidity of asthma-plus-eczema.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021). PMID: 34155719 ↗
L2SR_OBSCited in: Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks - [196]
Yeo BSY, Guan EJ, Ng K et al.. “Association of Abnormal Body Weight and Allergic Rhinitis-A Systematic Review and Meta-Analysis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2024). PMID: 39602830 ↗
L2SR_OBSCited in: Clinical Presentation, Severity, Grading & Risk Stratification - [197]
Barnes ML, Vaidyanathan S, Williamson PA et al.. “The minimal clinically important difference in allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2009). PMID: 19895590 ↗
L2SR_OBSCited in: Clinical Presentation, Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [198]
Dykewicz MS, Wallace DV, Amrol DJ et al.. “Rhinitis 2020: A practice parameter update.” The Journal of allergy and clinical immunology (2020). PMID: 32707227 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Special Populations & Pregnancy - [199]
Dykewicz MS, Hamilos DL. “Rhinitis and sinusitis.” The Journal of allergy and clinical immunology (2010). PMID: 20176255 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [200]
Ruysseveldt E, Steelant B, Wils T et al.. “The nasal basal cell population shifts toward a diseased phenotype with impaired barrier formation capacity in allergic rhinitis.” The Journal of allergy and clinical immunology (2024). PMID: 38705259 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [201]
Augé J, Vent J, Agache I et al.. “EAACI Position paper on the standardization of nasal allergen challenges.” Allergy (2018). PMID: 29377177 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [202]
Woehlk C, Stranzl T, Contoli M et al.. “Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma.” Allergy (2025). PMID: 41031547 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance - [203]
Bousquet J, Sousa-Pinto B, Vieira RJ et al.. “Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024-2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms.” Allergy (2025). PMID: 41268627 ↗
L5OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [204]
Okubo Y, Kuwabara Y, Sato S et al.. “Real-World Effectiveness for Sublingual Allergen Immunotherapy Among School-Aged Children and Adolescents.” Allergy (2025). PMID: 40631972 ↗
L3OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [205]
Mullol J, Del Cuvillo A, Lockey RF. “Rhinitis Phenotypes.” The journal of allergy and clinical immunology. In practice (2020). PMID: 32389274 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification - [206]
Blaiss MS, Steven GC, Bender B et al.. “Shared decision making for the allergist.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 30201469 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [207]
Kaliner MA. “Azelastine and olopatadine in the treatment of allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2009). PMID: 19927534 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway - [208]
Sacha JJ, Quinn JM. “The environment, the airway, and the athlete.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2011). PMID: 21277508 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [209]
He G, Meng Q, Yuan X et al.. “A multicenter randomized study: safety of an optimized accelerated house dust mite immunotherapy for patients with allergic rhinitis in China (PERFECT study).” Frontiers in immunology (2026). PMID: 42039184 ↗
L1RCTCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [210]
Devillier P, Okano M, Canonica GW et al.. “Allergic rhinitis activity and efficacy of 300 IR house dust mite sublingual immunotherapy tablet in pediatrics.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 41968360 ↗
L2RCTCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [211]
Braido F, Scichilone N, Lavorini F et al.. “Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN).” The World Allergy Organization journal (2016). PMID: 27800118 ↗
L5OTHERCited in: Clinical Presentation - [212]
El-Sayed ZA, El-Ghoneimy DH, Ortega-Martell JA et al.. “Allergic manifestations of inborn errors of immunity and their impact on the diagnosis: A worldwide study.” The World Allergy Organization journal (2022). PMID: 35783543 ↗
L4OTHERCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [213]
Huang Y, Wang C, Zhang Y et al.. “Developing nomograms for identifying allergic rhinitis among chronic rhinitis: A real-world study.” The World Allergy Organization journal (2021). PMID: 33912321 ↗
L4OTHERCited in: Clinical Presentation, History and Evolution of Treatment, Prevention, Screening & Surveillance - [214]
Rouadi PW, Idriss SA, Bousquet J et al.. “WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation - Updates in COVID-19.” The World Allergy Organization journal (2021). PMID: 34963794 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [215]
Feijen J, Seys SF, Steelant B et al.. “Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma.” The World Allergy Organization journal (2020). PMID: 32642023 ↗
L4OTHERCited in: Clinical Presentation - [216]
Rotiroti G, Roberts G, Scadding GK. “Rhinitis in children: common clinical presentations and differential diagnoses.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2015). PMID: 25616224 ↗
L5CASE_REPORTCited in: Clinical Presentation, Complications, Comorbidities & Iatrogenic Risks - [217]
Gane SB, Scadding GK. “Diseases mimicking allergic rhinitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19744218 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [218]
Jacob J, Fong A, Joyce C et al.. “Cost-Effectiveness of Allergen Immunotherapy for Allergic Rhinitis: A Systematic Review.” Allergy (2026). PMID: 42093212 ↗
L2SR_OBSCited in: Clinical Presentation, Acute Management & Anaphylaxis Pathway - [219]
Demidova A, Kiknavelidze N, Purtskhvanidze K et al.. “'What' and 'How' to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2026). PMID: 41974646 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prognosis & Natural History - [220]
Cianferoni A, Votto M. “COVID-19 and allergy: How to take care of allergic patients during a pandemic?” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 33236431 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [221]
Anastasiou E, Xepapadaki P, Asllani J et al.. “Update on the treatment of allergic rhinitis in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 41918374 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [222]
Crestani E, Harb H, Benamar M et al.. “Metabolomic and immunological signatures of asthma severity in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2025). PMID: 41195700 ↗
L4OTHERCited in: Clinical Presentation, Severity, Grading & Risk Stratification - [223]
Xiao X, Feng G, Zhang Y et al.. “Young Children Allergic Rhinitis Questionnaire is a novel tool for allergy screening in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 35212036 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [224]
Meyer R, Fox AT, Chebar Lozinsky A et al.. “Non-IgE-mediated gastrointestinal allergies-Do they have a place in a new model of the Allergic March.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019). PMID: 30403301 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment - [225]
Briskey D, Pellow J, Beatson G et al.. “Efficacy and safety of a particulate yeast β-glucan preparation in the treatment of seasonal allergic rhinitis (BETALL): a randomised placebo-controlled crossover trial protocol.” Trials (2026). PMID: 41998746 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History - [226]
Lucas D, Greta G, Bygvraa DA et al.. “Occupational allergic diseases among harvesting fishermen on the open sea: A systematic review.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 37116652 ↗
L2SR_OBSCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [227]
Hamed A, Preston DC, Eschenbacher W et al.. “Nasal IgE production in allergic rhinitis: Impact of rhinovirus infection.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2019). PMID: 30776162 ↗
L4TRIAL_NONRANDOMCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [228]
Li C, Zhou H, Zhang W et al.. “Bacterial lysate treatment in allergic disease: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 34097747 ↗
L1SR_OBSCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [229]
Yuan X, Xie S, Liu L et al.. “Complement C3 links epithelial remodeling and macrophage metabolic reprogramming in allergic rhinitis.” The Journal of allergy and clinical immunology (2026). PMID: 41759749 ↗
L3OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [230]
Breiteneder H, Peng YQ, Agache I et al.. “Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.” Allergy (2020). PMID: 32893900 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [231]
Fu QW, Liu P, Ruan Y et al.. “International Evidence-Based Guidelines for Traditional Chinese Medicine Management of Allergic Rhinitis.” Allergy (2025). PMID: 40944470 ↗
L1OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway - [232]
Asano K, Ueki S, Tamari M et al.. “Adult-onset eosinophilic airway diseases.” Allergy (2020). PMID: 33040364 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [233]
Richards M, Ferber J, Li DK et al.. “Cesarean delivery and the risk of allergic rhinitis in children.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32387533 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Special Populations & Pregnancy - [234]
Potter PC. “Update on sublingual immunotherapy.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16496508 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [235]
Popov TA, Passalacqua G, González-Díaz SN et al.. “Medical devices in allergy practice.” The World Allergy Organization journal (2020). PMID: 33024482 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway, Prevention, Screening & Surveillance - [236]
Segal M, Stokes JR, Casale TB. “Anti-immunoglobulin e therapy.” The World Allergy Organization journal (2008). PMID: 23282676 ↗
L5OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [237]
Eckrich J, Hinkel J, Fischl A et al.. “Nasal IgE in subjects with allergic and non-allergic rhinitis.” The World Allergy Organization journal (2020). PMID: 32612737 ↗
L3OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [238]
Zeng Y, Xiao H, Gao S et al.. “Efficacy and immunological changes of sublingual immunotherapy in pediatric allergic rhinitis.” The World Allergy Organization journal (2023). PMID: 37520614 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Special Populations & Pregnancy - [239]
Gherasim A, Dietsch F, Beck M et al.. “Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season.” The World Allergy Organization journal (2023). PMID: 37520615 ↗
L2OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [240]
Sheha DS, El-Korashi LA, AbdAllah AM et al.. “Dyslipidemia among allergic rhinitis patients: Frequency and risk factors.” The World Allergy Organization journal (2021). PMID: 33747342 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment - [241]
Huang W, Chen X, Liu Z et al.. “Sphk1 regulates HMGB1 via HDAC4 and mediates epithelial pyroptosis in allergic rhinitis.” The World Allergy Organization journal (2024). PMID: 39295955 ↗
L5OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [242]
Gelardi M, Iannuzzi L, Quaranta N et al.. “NASAL cytology: practical aspects and clinical relevance.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2016). PMID: 27009397 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [243]
Stewart MG. “Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2008). PMID: 18419620 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, Acute Management & Anaphylaxis Pathway - [244]
Prieto A, Rondón C, Eguiluz-Gracia I et al.. “Systematic evaluation of allergic phenotypes of rhinitis in children and adolescents.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33598969 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [245]
Soyak Aytekin E, Unsal H, Sahiner UM et al.. “IgE mediated legume allergy in east Mediterranean children: A reflection of multiple food allergies.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 35470935 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [246]
Malizia V, Cilluffo G, Fasola S et al.. “Endotyping allergic rhinitis in children: A machine learning approach.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 35080305 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup, History and Evolution of Treatment - [247]
Guo B, Xiong P, Zhang Z et al.. “Predictors of the Efficacy of Focused Ultrasound for Moderate-to-Severe Persistent Allergic Rhinitis: A Retrospective Cohort Study.” Ultrasound in medicine & biology (2026). PMID: 42144291 ↗
L4COHORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [248]
Gaddikeri R, Shah P. “Case 347: Tracheobronchial Smooth Muscle Atrophy and Separation.” Radiology (2026). PMID: 42377126 ↗
L4CASE_REPORTCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [249]
Shoup J, Sadle C, Buckley A et al.. “Oxytocin and RAGE signaling at the intersection of social neurodevelopment and inflammation.” Journal of translational medicine (2026). PMID: 42415063 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [250]
Ye F, Tao Y, Chen J et al.. “Pharmacological silencing of nasal TRPV1+ nociceptors ameliorates eosinophilic infiltration but exacerbates neutrophilic infiltration in murine models of allergic rhinitis.” Rhinology (2026). PMID: 42411335 ↗
L5OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [251]
Huang L, Zhao X, Zhou J et al.. “Pandemic-Associated Sensitization Patterns and Burden in Chinese Children with Allergic Rhinitis: A Retrospective Phase-Stratified Study.” Journal of asthma and allergy (2026). PMID: 42403887 ↗
L4OTHERCited in: Diagnosis & Immunodiagnostics: Allergy Testing and Immune-Function Workup - [252]
Rosenzwajg M, Gherasim A, Dietsch F et al.. “Low-dose IL-2 in birch pollen allergy: A phase-2 randomized double-blind placebo-controlled trial.” The Journal of allergy and clinical immunology (2024). PMID: 39532189 ↗
L1RCTCited in: Severity, Grading & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History - [253]
Zhang J, Yang X, Chen G et al.. “Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2023). PMID: 37913839 ↗
L1RCTCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks - [254]
Muhammad Danial Song HJJ, Min Lee CT, Ci Ng FY et al.. “Childhood Acid Suppressants May Increase Allergy Risk-A Systematic Review and Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36257597 ↗
L2SR_OBSCited in: Severity, Grading & Risk Stratification, Special Populations & Pregnancy - [255]
Ambrosino P, Parrella P, Formisano R et al.. “Clinical application of nasal nitric oxide measurement in allergic rhinitis: A systematic review and meta-analysis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32663599 ↗
L3SR_OBSCited in: Severity, Grading & Risk Stratification - [256]
Lee MS, Pittler MH, Shin BC et al.. “Acupuncture for allergic rhinitis: a systematic review.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2009). PMID: 19441597 ↗
L1SR_OBSCited in: Severity, Grading & Risk Stratification, Prevention, Screening & Surveillance - [257]
Guo R, Pittler MH, Ernst E. “Herbal medicines for the treatment of allergic rhinitis: a systematic review.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 18219828 ↗
L1SR_OBSCited in: Severity, Grading & Risk Stratification - [258]
Ahlbeck L, Ahlberg E, Björkander J et al.. “Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022). PMID: 35332591 ↗
L1RCTCited in: Severity, Grading & Risk Stratification, Prognosis & Natural History - [259]
Mullol J, Bartra J, del Cuvillo A et al.. “Specialist-based treatment reduces the severity of allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2013). PMID: 23786279 ↗
L2TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification - [260]
Calderon MA, Penagos M, Sheikh A et al.. “Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2011). PMID: 21848759 ↗
L1SR_OBSCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [261]
Walter S, Ho J, Alvarado R et al.. “Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020). PMID: 32808380 ↗
L2SR_OBSCited in: Severity, Grading & Risk Stratification - [262]
Liu W, Zeng Q, He C et al.. “Compliance, efficacy, and safety of subcutaneous and sublingual immunotherapy in children with allergic rhinitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32810884 ↗
L2TRIAL_NONRANDOMCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [263]
Kuniyoshi Y, Tsujimoto Y, Banno M et al.. “Neonatal jaundice, phototherapy and childhood allergic diseases: An updated systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33475191 ↗
L2SR_OBSCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Prognosis & Natural History, Special Populations & Pregnancy - [264]
Mitselou N, Hallberg J, Stephansson O et al.. “Adverse pregnancy outcomes and risk of later allergic rhinitis-Nationwide Swedish cohort study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2020). PMID: 32060962 ↗
L2COHORTCited in: Severity, Grading & Risk Stratification - [265]
Bousquet J, Schünemann HJ, Sousa-Pinto B et al.. “Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024).” The journal of allergy and clinical immunology. In practice (2024). PMID: 38971567 ↗
L5REVIEW_NARRATIVECited in: Severity, Grading & Risk Stratification - [266]
Gonzalez-Diaz SN, Martin B, Villarreal-Gonzalez RV et al.. “Psychological impact of the COVID-19 pandemic on patients with allergic diseases.” The World Allergy Organization journal (2021). PMID: 33520081 ↗
L4OTHERCited in: Severity, Grading & Risk Stratification - [267]
Carpagnano GE, Bonini M, Latorre M et al.. “Profile of mild/moderate asthma patients: Baseline data from the MANI cohort.” The World Allergy Organization journal (2025). PMID: 40689384 ↗
L2OTHERCited in: Severity, Grading & Risk Stratification, Acute Management & Anaphylaxis Pathway, Complications, Comorbidities & Iatrogenic Risks - [268]
Meng Y, Lu H, Wang C et al.. “Naso-ocular neuropeptide interactions in allergic rhinoconjunctivitis, rhinitis, and conjunctivitis.” The World Allergy Organization journal (2021). PMID: 34035875 ↗
L3OTHERCited in: Severity, Grading & Risk Stratification - [269]
Rogkakou A, Villa E, Garelli V et al.. “Persistent Allergic Rhinitis and the XPERT Study.” The World Allergy Organization journal (2011). PMID: 23282334 ↗
L5OTHERCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks - [270]
Sima Y, Wang X, Zhang T et al.. “Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis.” The World Allergy Organization journal (2026). PMID: 41732343 ↗
L1OTHERCited in: Severity, Grading & Risk Stratification - [271]
Kurita J, Yonekura S, Iinuma T et al.. “Evaluation of shoseiryuto for seasonal allergic rhinitis, using an environmental challenge chamber.” The World Allergy Organization journal (2022). PMID: 35399817 ↗
L1OTHERCited in: Severity, Grading & Risk Stratification - [272]
Sih T, Mion O. “Allergic rhinitis in the child and associated comorbidities.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19664013 ↗
L5CASE_REPORTCited in: Severity, Grading & Risk Stratification - [273]
Shi Y, Pan Z, Tian X et al.. “Multiallergen Immunotherapy for Polysensitized Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis.” Journal of asthma and allergy (2026). PMID: 42403890 ↗
L2SR_OBSCited in: Severity, Grading & Risk Stratification, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [274]
Wang H, Zhang Q, Hu M et al.. “Periostin in allergic rhinitis: from pathogenic mediator to predictive biomarker and therapeutic target.” Frontiers in pharmacology (2026). PMID: 42394977 ↗
L5SR_OBSCited in: Severity, Grading & Risk Stratification - [275]
Ma J, Peng M, Song YG et al.. “Efficacy and safety of acupuncture-related therapies in the treatment of allergic rhinitis: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 42245938 ↗
L5SR_OBSCited in: Severity, Grading & Risk Stratification, Complications, Comorbidities & Iatrogenic Risks, Prognosis & Natural History - [276]
Worm M, Demoly P, Okamoto Y et al.. “Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data.” The World Allergy Organization journal (2024). PMID: 39035788 ↗
L2TRIAL_NONRANDOMCited in: Acute Management & Anaphylaxis Pathway - [277]
Ahlbeck L, Ahlberg E, Stuivers L et al.. “Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023). PMID: 37013723 ↗
L1RCTCited in: Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment, Prognosis & Natural History - [278]
Kulalert P, Phinyo P, Lao-Araya M. “Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis.” The World Allergy Organization journal (2022). PMID: 36119654 ↗
L1SR_OBSCited in: Acute Management & Anaphylaxis Pathway - [279]
Das RR, Naik SS. “Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2014). PMID: 25229699 ↗
L2SR_OBSCited in: Acute Management & Anaphylaxis Pathway - [280]
Shamji MH, Sharif H, Layhadi JA et al.. “Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma.” The Journal of allergy and clinical immunology (2022). PMID: 35093483 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [281]
Frew AJ. “Allergen immunotherapy.” The Journal of allergy and clinical immunology (2010). PMID: 20176266 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [282]
Creticos PS, Gunaydin FE, Nolte H et al.. “Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38685477 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [283]
Larenas-Linnemann D, Diamant Z, Jesenak M et al.. “Combination of Allergen-Specific Immunotherapy With Biologics in Severe Asthma: Counterintuitive or Rational?” The journal of allergy and clinical immunology. In practice (2025). PMID: 40349962 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Prognosis & Natural History - [284]
Oppenheimer JJ, Dinakar C, Fineman SM. “AllergyWatch.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2019). PMID: 31247305 ↗
L5OTHERCited in: Acute Management & Anaphylaxis Pathway - [285]
Zhang S, Chen Y, Zhao J et al.. “Neurectomy Versus Ablation of Posterior Nasal and Anterior Ethmoidal Nerve for Allergic Rhinitis: A Prospective Randomized Comparative Study.” American journal of rhinology & allergy (2026). PMID: 41847828 ↗
L1RCTCited in: Acute Management & Anaphylaxis Pathway - [286]
Gawlik R, Pitsch T, Dubuske L. “Anaphylaxis as a manifestation of horse allergy.” The World Allergy Organization journal (2009). PMID: 23283110 ↗
L5OTHERCited in: Acute Management & Anaphylaxis Pathway - [287]
Machnes-Maayan D, Yahia SH, Frizinsky S et al.. “A clinical pathway for the diagnosis of sesame allergy in children.” The World Allergy Organization journal (2022). PMID: 36440465 ↗
L4OTHERCited in: Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [288]
Florido-López JF, Andreu-Balaguer C, Escudero C et al.. “Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study.” The World Allergy Organization journal (2020). PMID: 33376572 ↗
L2OTHERCited in: Acute Management & Anaphylaxis Pathway - [289]
Alzughaibi BH, Michaelis LJ, Pearce MS et al.. “Pediatric IgE mediated food allergies and ethnic group inequalities: A scoping review.” The World Allergy Organization journal (2026). PMID: 42179758 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway - [290]
Chua NYM, Tay E, Chua RL et al.. “Pharmacotherapeutic Medication Adherence in Patients With Allergic Rhinitis: A Systematic Review and Meta-Analysis.” Current allergy and asthma reports (2026). PMID: 42133217 ↗
L2SR_OBSCited in: Acute Management & Anaphylaxis Pathway - [291]
Gupta N, Mohan RK, Reddy UN et al.. “Rational Allergy Practice Guidelines by the Indian Academy of Pediatrics (IAP) and IAP-Allergy and Applied Immunology Chapter.” Indian pediatrics (2026). PMID: 41949750 ↗
L1GUIDELINECited in: Acute Management & Anaphylaxis Pathway, History and Evolution of Treatment - [292]
Dantzer JA, Wood RA. “The use of omalizumab in allergen immunotherapy.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018). PMID: 29315922 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [293]
Saranz RJ, Lozano A, Lozano NA et al.. “Subclinical lower airways correlates of chronic allergic and non-allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017). PMID: 28421631 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [294]
Salib RJ, Harries PG, Nair SB et al.. “Mechanisms and mediators of nasal symptoms in non-allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2008). PMID: 18201248 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway - [295]
Passalacqua G, Baiardini I, Senna G et al.. “Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2013). PMID: 23278877 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway - [296]
Wraith DC, Krishna MT. “Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021). PMID: 33529435 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [297]
Castagnoli R, Votto M, Taietti I et al.. “Bridging Rare to Common Diseases: Precision Medicine and the Transforming Landscape of Pediatric Allergy and Immunology.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42324659 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Anaphylaxis Pathway, Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [298]
Shang X, Yang Y, Deng W. “Thunderstorm-Associated Asthma in Shenzhen, China: A Retrospective Case-Control Study of Risk Factors, Clinical Characteristics, and Management Approaches.” Journal of asthma and allergy (2026). PMID: 41970277 ↗
L3CASE_CONTROLCited in: Acute Management & Anaphylaxis Pathway - [299]
Wan WJ, Xu QY, Lu MP et al.. “Patient compliance to sublingual immunotherapy for mite-induced allergic rhinitis: A retrospective study.” The World Allergy Organization journal (2024). PMID: 39040084 ↗
L4COHORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [300]
Schutzmeier P, Kutzora S, Mittermeier I et al.. “Non-pharmacological interventions for pollen-induced allergic symptoms: Systematic literature review.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 34717016 ↗
L2SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [301]
de Bot CM, Moed H, Berger MY et al.. “Sublingual immunotherapy in children with allergic rhinitis: quality of systematic reviews.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2011). PMID: 21919934 ↗
L5SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [302]
Jutel M, Agache I, Bonini S et al.. “International consensus on allergy immunotherapy.” The Journal of allergy and clinical immunology (2015). PMID: 26162571 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [303]
Casale TB, Stokes JR. “Immunotherapy: what lies beyond.” The Journal of allergy and clinical immunology (2014). PMID: 24581428 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [304]
Penagos M, Durham SR. “Allergen immunotherapy for long-term tolerance and prevention.” The Journal of allergy and clinical immunology (2022). PMID: 35085663 ↗
L5OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance - [305]
Casale TB, Stokes JR. “Future forms of immunotherapy.” The Journal of allergy and clinical immunology (2010). PMID: 21094518 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [306]
Zhang Y, Li J, Li X et al.. “Chinese Position Paper on Biologic Therapy for Allergic Rhinitis.” Allergy (2026). PMID: 41872701 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [307]
Layhadi JA, Lalioti A, Palmer E et al.. “Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37996041 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [308]
Kappen JH, Agache I, Jutel M et al.. “Allergen Immunotherapy for Asthma.” The journal of allergy and clinical immunology. In practice (2023). PMID: 38013158 ↗
L5OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [309]
Nelson HS. “The Art of Immunotherapy.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37898175 ↗
L5OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [310]
Sotoudeh S, Choudhry H, Cantillo JF et al.. “Cat, Dog, and Exotic Animal Allergy.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40848832 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [311]
Carnés J, Iraola V, Cho SH et al.. “Mite allergen extracts and clinical practice.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2017). PMID: 28284531 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [312]
Wagenmann M, Gehrt F, Scheckenbach K. “Remission and Meaningful Outcomes in Chronic Rhinitis and Rhinosinusitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2026). PMID: 42364847 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [313]
Bonini M, Di Maria G, Paggiaro P et al.. “Potential benefit of omalizumab in respiratory diseases.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 25442695 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [314]
Waserman S, Shah A, Avilla E. “Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2021). PMID: 34029713 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [315]
Nelson HS. “Efficacy and safety of allergen immunotherapy in children.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16496504 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [316]
Steven GC. “Shared decision making in allergic rhinitis: An approach to the patient.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32615266 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [317]
Cox L, Cohn JR. “Duration of allergen immunotherapy in respiratory allergy: when is enough, enough?” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2007). PMID: 17521025 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [318]
Sekkidou M, Karglani E, Pancheva R et al.. “Nutritional intervention with a partially hydrolyzed formula during the first 6 months of life may reduce the risk of food allergy and atopic dermatitis up to the age of 5 years.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42154372 ↗
L2RCTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment, Special Populations & Pregnancy, Prevention, Screening & Surveillance - [319]
Furci F, Caminati M, Crisafulli E et al.. “The intriguing possibility of using probiotics in allergen-specific immunotherapy.” The World Allergy Organization journal (2023). PMID: 36852412 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History - [320]
Yu L, Zhang H, Pan J et al.. “Pediatric usage of Omalizumab: A promising one.” The World Allergy Organization journal (2021). PMID: 34963793 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prognosis & Natural History, Special Populations & Pregnancy - [321]
Larenas-Linnemann D, Rodríguez-Pérez N, Luna-Pech JA et al.. “Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines.” The World Allergy Organization journal (2020). PMID: 32884611 ↗
L1REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [322]
Jordakieva G, Jensen-Jarolim E. “The impact of allergen exposure and specific immunotherapy on circulating blood cells in allergic rhinitis.” The World Allergy Organization journal (2018). PMID: 30128065 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [323]
Cardona-Villa R, Del Pozo S, Uribe-García S et al.. “Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae.” The World Allergy Organization journal (2025). PMID: 40822748 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [324]
Koca Kalkan I, Ates H, Aksu K et al.. “Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic.” The World Allergy Organization journal (2021). PMID: 34122718 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [325]
Varghese M, Glaum MC, Lockey RF. “Drug-induced rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2010). PMID: 20210811 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, History and Evolution of Treatment - [326]
Pechsrichuang P, Jacquet A. “Molecular approaches to allergen-specific immunotherapy: Are we so far from clinical implementation?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2020). PMID: 32078207 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [327]
Smith SA, Stone CA, Jacquet A. “Allergen-Specific Human Monoclonal IgG Antibodies for Use in Passive Allergy Immunotherapy.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2025). PMID: 41061743 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [328]
Votto M, De Filippo M, Caminiti L et al.. “Eosinophilic gastrointestinal disorders and allergen immunotherapy: Lights and shadows.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33503273 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Complications, Comorbidities & Iatrogenic Risks - [329]
Liour SS, Tom A, Chan YH et al.. “Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27090058 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [330]
Huoman J, Papapavlou G, Pap A et al.. “Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019). PMID: 30803044 ↗
L2OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [331]
Tsai YG, Yang KD, Wen YS et al.. “Allergen-specific immunotherapy enhances CD8+ CD25+ CD137+ regulatory T cells and decreases nasal nitric oxide.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019). PMID: 30968455 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [332]
Liu Q, Zhu W, Sun Y et al.. “A meta-analysis of acupuncture at the sphenopalatine ganglion for the treatment of allergic rhinitis.” Frontiers in allergy (2026). PMID: 42211436 ↗
L1SR_OBSCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [333]
Tharpe C, Davidson J, Mardaga K et al.. “Real-world outcomes of personalized sublingual immunotherapy for environmental allergies delivered through a telemedicine platform: a retrospective longitudinal cohort study.” Frontiers in allergy (2026). PMID: 42358593 ↗
L2COHORTCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [334]
Jia X, Tao Q, Hu H et al.. “Prediction of future onset of allergic rhinitis and analysis of risk factors in children with food allergy during infancy.” European journal of pediatrics (2026). PMID: 42429983 ↗
L2OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics, Prevention, Screening & Surveillance - [335]
Huang L, Wang Y, Huang S. “Existential distress and social alienation in adolescents with allergic rhinitis: the serial mediating roles of psychological inflexibility and experiential avoidance.” Frontiers in public health (2026). PMID: 42415749 ↗
L4OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [336]
Wang L, Kang Z, Ma J et al.. “A Clinical Nomogram for Predicting Early Response to Biologics in Pediatric Allergic Asthma with Comorbid Allergic Rhinitis.” Journal of asthma and allergy (2026). PMID: 42403888 ↗
L2OTHERCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [337]
Liu X, Zhao W. “Advances in Nanotechnology-Based Immunomodulatory Strategies for the Treatment of Allergic Rhinitis.” International journal of nanomedicine (2026). PMID: 42368400 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [338]
Veskitkul J, Wongkaewpothong P, Thaweethamchareon T et al.. “Recurrent Acute Rhinosinusitis Prevention by Azithromycin in Children with Nonallergic Rhinitis.” The journal of allergy and clinical immunology. In practice (2017). PMID: 28438539 ↗
L1RCTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution, Prevention, Screening & Surveillance - [339]
Han X, Krempski JW, Nadeau K. “Advances and novel developments in mechanisms of allergic inflammation.” Allergy (2020). PMID: 33068299 ↗
L5REVIEW_NARRATIVECited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [340]
Nemet S, Elbirt D, Cohen R et al.. “IgE deficiency (<2.5 IU/mL) in children: Clinical insights from a population-based study of 123,393 subjects.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2025). PMID: 40285341 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [341]
Gartenberg A, Petrie A. “Mixed connective tissue disease-myositis overlap syndrome presenting as an allergic disease process to the emergency department: A case report.” The American journal of emergency medicine (2023). PMID: 38142167 ↗
L4CASE_REPORTCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [342]
Marbet L, Gujer E, Münger MH et al.. “Allergic manifestations in inborn errors of immunity: a systematic scoping review.” Frontiers in immunology (2025). PMID: 41142799 ↗
L2REVIEW_NARRATIVECited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [343]
Vaseghi-Shanjani M, Samra S, Yousefi P et al.. “Primary atopic disorders: inborn errors of immunity causing severe allergic disease.” Current opinion in immunology (2025). PMID: 40020536 ↗
L5REVIEW_NARRATIVECited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [344]
Makary CA, Behnke J, Peppers B et al.. “Outcome of Immunoglobulin Replacement Therapy in Adults With Rhinosinusitis.” The Laryngoscope (2021). PMID: 34146351 ↗
L2OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [345]
Li G, Li S, Ye F et al.. “Construction of an Indole-induced Transgenic System and Its Therapeutic Effects on Allergic Rhinitis.” American journal of respiratory cell and molecular biology (2025). PMID: 40305665 ↗
L5OTHERCited in: Immunodeficiency Management: Immunoglobulin Replacement, Prophylaxis and Immune Reconstitution - [346]
Blaiss MS. “Management of rhinitis and asthma in pregnancy.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2003). PMID: 12839108 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [347]
Bai L, Xu Y, Pan T et al.. “Leukotriene Receptor Antagonists and Risk of Neuropsychiatric Entities: A Meta-Analysis of Observational Studies.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36473625 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [348]
Gappa M, Gagnon R, Horak F et al.. “The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial.” Allergy (2024). PMID: 39495086 ↗
L1RCTCited in: History and Evolution of Treatment - [349]
Holzmann C, Karg J, Reiger M et al.. “Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial.” Allergy (2025). PMID: 40242867 ↗
L1RCTCited in: History and Evolution of Treatment - [350]
Scadding GK, Durham SR, Mirakian R et al.. “BSACI guidelines for the management of allergic and non-allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2008). PMID: 18081563 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Special Populations & Pregnancy - [351]
Yonekura S, Gotoh M, Kaneko S et al.. “Disease-Modifying Effect of Japanese Cedar Pollen Sublingual Immunotherapy Tablets.” The journal of allergy and clinical immunology. In practice (2021). PMID: 34333190 ↗
L1RCTCited in: History and Evolution of Treatment - [352]
Lloyd M, Ashley S, Chawla SS et al.. “Impact of Participant Baseline Factors on Exposure-Adjusted Incidence of Treatment-Related Adverse Events During Peanut Oral Immunotherapy.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40976354 ↗
L1RCTCited in: History and Evolution of Treatment - [353]
Creticos PS, Reed CE, Norman PS et al.. “Ragweed immunotherapy in adult asthma.” The New England journal of medicine (1996). PMID: 8559203 ↗
L1RCTCited in: History and Evolution of Treatment - [354]
Durham SR, Walker SM, Varga EM et al.. “Long-term clinical efficacy of grass-pollen immunotherapy.” The New England journal of medicine (1999). PMID: 10441602 ↗
L1RCTCited in: History and Evolution of Treatment - [355]
Knapp HR. “Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.” The New England journal of medicine (1990). PMID: 1701029 ↗
L1RCTCited in: History and Evolution of Treatment - [356]
Terreehorst I, Hak E, Oosting AJ et al.. “Evaluation of impermeable covers for bedding in patients with allergic rhinitis.” The New England journal of medicine (2003). PMID: 12867607 ↗
L1RCTCited in: History and Evolution of Treatment - [357]
Pipkorn U, Proud D, Lichtenstein LM et al.. “Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids.” The New England journal of medicine (1987). PMID: 2438553 ↗
L1RCTCited in: History and Evolution of Treatment - [358]
Kalliomäki M, Salminen S, Arvilommi H et al.. “Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial.” Lancet (London, England) (2001). PMID: 11297958 ↗
L1RCTCited in: History and Evolution of Treatment - [359]
Skoner DP. “Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis.” The Journal of allergy and clinical immunology (2001). PMID: 11449200 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [360]
Simons FE, Simons KJ. “Histamine and H1-antihistamines: celebrating a century of progress.” The Journal of allergy and clinical immunology (2011). PMID: 22035879 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [361]
Mullarkey MF. “Eosinophilic nonallergic rhinitis.” The Journal of allergy and clinical immunology (1988). PMID: 3057047 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [362]
Kaplan AP, Ferrer Puga M, Sabate-Bresco M. “Endotypes in chronic spontaneous urticaria.” The Journal of allergy and clinical immunology (2026). PMID: 42134608 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prevention, Screening & Surveillance - [363]
Corren J. “Allergic rhinitis and asthma: how important is the link?” The Journal of allergy and clinical immunology (1997). PMID: 9042071 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [364]
Pratt C, Brown AM, Rampe D et al.. “Cardiovascular safety of fexofenadine HCl.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1999). PMID: 10444240 ↗
L5RCTCited in: History and Evolution of Treatment - [365]
Bousquet J. “Rapid symptom relief in rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1999). PMID: 10209702 ↗
L5RCTCited in: History and Evolution of Treatment - [366]
Tohidinik HR, Mallah N, Takkouche B. “History of allergic rhinitis and risk of asthma; a systematic review and meta-analysis.” The World Allergy Organization journal (2019). PMID: 31660100 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [367]
Zuberbier T. “Urticaria.” Allergy (2003). PMID: 14616095 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [368]
Bachert C. “Persistent rhinitis - allergic or nonallergic?” Allergy (2004). PMID: 14984551 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [369]
Tubita V, Callejas-Díaz B, Roca-Ferrer J et al.. “Role of microRNAs in inflammatory upper airway diseases.” Allergy (2020). PMID: 33314198 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [370]
Dykewicz MS, Wallace DV, Bandi S et al.. “Patient-Reported Outcome Measures in Rhinitis and Chronic Rhinosinusitis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 39004415 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [371]
Nelson HS, Sowers T, Plunkett G et al.. “The Art of Dosing for Subcutaneous Immunotherapy in North America.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37385447 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [372]
Bousquet J, Ansotegui IJ, Anto JM et al.. “Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?” The journal of allergy and clinical immunology. In practice (2019). PMID: 31445223 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [373]
Calderon MA, Casale TB, Nelson HS et al.. “Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States.” The journal of allergy and clinical immunology. In practice (2022). PMID: 36343885 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [374]
Skoner DP, Golant AK, Norton AE et al.. “Is This Medication Safe for My Child? How to Discuss Safety of Commonly Used Medications With Parents.” The journal of allergy and clinical immunology. In practice (2022). PMID: 35963511 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [375]
Lieberman P. “The basics of histamine biology.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2010). PMID: 21277530 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [376]
Slavin RG. “Occupational rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2003). PMID: 12772943 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [377]
Sly RM. “Changing prevalence of allergic rhinitis and asthma.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (1999). PMID: 10094214 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [378]
Berger WE. “Overview of allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2003). PMID: 12839106 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [379]
Bousquet J, Demoly P, Michel FB. “Specific immunotherapy in rhinitis and asthma.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2001). PMID: 11476474 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [380]
Keil T, Bockelbrink A, Reich A et al.. “The natural history of allergic rhinitis in childhood.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2010). PMID: 20487364 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment, Prognosis & Natural History - [381]
Song KB, Park MJ, Choi EJ et al.. “Food allergy in early childhood increases the risk of oral allergy syndrome in schoolchildren: A birth cohort study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2022). PMID: 35616894 ↗
L2COHORTCited in: History and Evolution of Treatment - [382]
Lund V. “Allergic rhinitis--making the correct diagnosis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1998). PMID: 9988431 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [383]
Lundbäck B. “Epidemiology of rhinitis and asthma.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (1998). PMID: 9678821 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [384]
Xu X, Li J, Zhang X et al.. “Blood and local eosinophil levels in chronic rhinitis: Observations during seasonal allergen exposure and non-exposure.” The World Allergy Organization journal (2024). PMID: 39157197 ↗
L4OTHERCited in: History and Evolution of Treatment - [385]
Devillier P, Saf S, Rolland C et al.. “Respiratory allergic diseases and allergen immunotherapy: A French patient survey before and during the COVID-19 pandemic.” The World Allergy Organization journal (2024). PMID: 38623320 ↗
L4OTHERCited in: History and Evolution of Treatment - [386]
Alnahas S, Abouammoh N, Althagafi W et al.. “Prevalence, severity, and risk factors of allergic rhinitis among schoolchildren in Saudi Arabia: A national cross-sectional study, 2019.” The World Allergy Organization journal (2023). PMID: 37859757 ↗
L4OTHERCited in: History and Evolution of Treatment - [387]
Bernstein JA. “Characteristics of nonallergic vasomotor rhinitis.” The World Allergy Organization journal (2009). PMID: 24228982 ↗
L5OTHERCited in: History and Evolution of Treatment - [388]
Gabet S, Rancière F, Just J et al.. “Asthma and allergic rhinitis risk depends on house dust mite specific IgE levels in PARIS birth cohort children.” The World Allergy Organization journal (2019). PMID: 31641405 ↗
L2OTHERCited in: History and Evolution of Treatment - [389]
Sayyeda F, Hyder Ali IA, Harun SN et al.. “Asthma and chronic obstructive disease overlap (ACO), a systematic review of prevalence and co-morbidity factors based on diagnostic criteria.” Journal of pharmaceutical policy and practice (2026). PMID: 42052098 ↗
L2SR_OBSCited in: History and Evolution of Treatment - [390]
Sears MR, Burrows B, Flannery EM et al.. “Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.” The New England journal of medicine (1991). PMID: 1891008 ↗
L2OTHERCited in: History and Evolution of Treatment - [391]
Agosti JM, Sprenger JD, Lum LG et al.. “Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation.” The New England journal of medicine (1988). PMID: 3059190 ↗
L4OTHERCited in: History and Evolution of Treatment - [392]
Huggins KG, Brostoff J. “Local production of specific IgE antibodies in allergic-rhinitis patients with negative skin tests.” Lancet (London, England) (1975). PMID: 49744 ↗
L4OTHERCited in: History and Evolution of Treatment - [393]
Schwartz LB, Bradford TR, Rouse C et al.. “Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis.” Journal of clinical immunology (1994). PMID: 7929694 ↗
L5OTHERCited in: History and Evolution of Treatment - [394]
Weissmann S, Amitai N, Honig E et al.. “Gestational Diabetes Mellitus Increases the Risk of Atopic Dermatitis in Children: A National Retrospective Study with Analysis by Treatment Modality.” Dermatology and therapy (2026). PMID: 41975143 ↗
L3COHORTCited in: History and Evolution of Treatment - [395]
Hu L, He W, Li J et al.. “The role of adenoid immune phenotype in polysensitized children with allergic rhinitis and adenoid hypertrophy.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2024). PMID: 38822736 ↗
L4OTHERCited in: History and Evolution of Treatment - [396]
Arasi S, Pajno GB, Lau S et al.. “Local allergic rhinitis: A critical reappraisal from a paediatric perspective.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27098888 ↗
L5OTHERCited in: History and Evolution of Treatment - [397]
Dondi A, Tripodi S, Panetta V et al.. “Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2013). PMID: 24236692 ↗
L4OTHERCited in: History and Evolution of Treatment - [398]
Yavuz ST, Oksel Karakus C, Custovic A et al.. “Four subtypes of childhood allergic rhinitis identified by latent class analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 34310772 ↗
L4OTHERCited in: History and Evolution of Treatment - [399]
Jiang X, Shen C, Dai Y et al.. “Early food allergy and respiratory allergy symptoms and attention-deficit/hyperactivity disorder in Chinese children: A cross-sectional study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2018). PMID: 29524252 ↗
L4OTHERCited in: History and Evolution of Treatment - [400]
Nakanishi M, Carbone LFB, Aggarwal V et al.. “Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials.” Brazilian journal of otorhinolaryngology (2026). PMID: 41985293 ↗
L1TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [401]
Weinstein SF, Katial R, Jayawardena S et al.. “Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.” The Journal of allergy and clinical immunology (2018). PMID: 29355679 ↗
L1RCTCited in: Complications, Comorbidities & Iatrogenic Risks - [402]
Stuck BA, Hummel T. “Olfaction in allergic rhinitis: A systematic review.” The Journal of allergy and clinical immunology (2015). PMID: 26409662 ↗
L2SR_OBSCited in: Complications, Comorbidities & Iatrogenic Risks - [403]
Dretzke J, Meadows A, Novielli N et al.. “Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison.” The Journal of allergy and clinical immunology (2013). PMID: 23557834 ↗
L1SR_OBSCited in: Complications, Comorbidities & Iatrogenic Risks - [404]
Calderón MA, Casale TB, Demoly P. “Validation of Patient-Reported Outcomes for Clinical Trials in Allergic Rhinitis: A Systematic Review.” The journal of allergy and clinical immunology. In practice (2019). PMID: 30797777 ↗
L2TRIAL_NONRANDOMCited in: Complications, Comorbidities & Iatrogenic Risks - [405]
Lai YR, Liao YH, Huang L et al.. “Clinical Effects of Polyphenolic Compounds on Allergic Rhinitis: A Systematic Review and Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2025). PMID: 40618891 ↗
L1SR_OBSCited in: Complications, Comorbidities & Iatrogenic Risks - [406]
Rodrigo GJ, Yañez A. “The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16802764 ↗
L1SR_OBSCited in: Complications, Comorbidities & Iatrogenic Risks - [407]
De Corso E, Cantone E, Galli J et al.. “Otitis media in children: Which phenotypes are most linked to allergy? A systematic review.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2021). PMID: 33336435 ↗
L2SR_OBSCited in: Complications, Comorbidities & Iatrogenic Risks - [408]
Bachert C, Gevaert E. “Advances in rhinitis and rhinosinusitis in 2015.” The Journal of allergy and clinical immunology (2016). PMID: 27817798 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance - [409]
Koinis-Mitchell D, Craig T, Esteban CA et al.. “Sleep and allergic disease: a summary of the literature and future directions for research.” The Journal of allergy and clinical immunology (2012). PMID: 22867694 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks - [410]
Blaiss MS, Hammerby E, Robinson S et al.. “The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 29626629 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks - [411]
Santos CB, Pratt EL, Hanks C et al.. “Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 17165263 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks - [412]
Naclerio RM, Ansotegui IJ, Canonica GW et al.. “Twenty-five years: The fexofenadine clinical experience.” The World Allergy Organization journal (2024). PMID: 39252789 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks - [413]
Paoletti G, Giua C, Marti A et al.. “ARIA-Italy managing allergic rhinitis and asthma in a changing world: The role of the Pharmacist.” The World Allergy Organization journal (2025). PMID: 40642300 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks, Prevention, Screening & Surveillance - [414]
Guida G, Scelo G, Friston DA et al.. “Longitudinal observation of severe asthma comorbidities and oral corticosteroids use from SANI and ISAR registries.” The World Allergy Organization journal (2026). PMID: 41783626 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks - [415]
Cvetkovski B, Muscat D, Bousquet J et al.. “The future of allergic rhinitis management: A partnership between healthcare professionals and patients.” The World Allergy Organization journal (2024). PMID: 38463017 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks - [416]
Passalacqua G, Canonica GW, Baiardini I. “Rhinitis, rhinosinusitis and quality of life in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2007). PMID: 17767607 ↗
L5REVIEW_NARRATIVECited in: Complications, Comorbidities & Iatrogenic Risks - [417]
Georgalas C, Terreehorst I, Fokkens W. “Current management of allergic rhinitis in children.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2009). PMID: 19744219 ↗
L5OTHERCited in: Complications, Comorbidities & Iatrogenic Risks - [418]
Ng CSY, Chan CHY, Fung YL et al.. “Impact of comorbid allergic diseases on health-related quality of life of Hong Kong schoolchildren.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2023). PMID: 37232280 ↗
L2OTHERCited in: Complications, Comorbidities & Iatrogenic Risks - [419]
Wongsa C, Phinyo P, Sompornrattanaphan M et al.. “Efficacy and Safety of House Dust Mite Sublingual Immunotherapy Tablet in Allergic Asthma: A Systematic Review of Randomized Controlled Trials.” The journal of allergy and clinical immunology. In practice (2022). PMID: 35181547 ↗
L1SR_MA_RCTCited in: Prognosis & Natural History - [420]
Layhadi JA, Starchenka S, De Kam PJ et al.. “Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.” Allergy (2025). PMID: 40626378 ↗
L1RCTCited in: Prognosis & Natural History - [421]
Bożek A, Kołodziejczyk K, Jarząb J. “Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 29273130 ↗
L1RCTCited in: Prognosis & Natural History - [422]
Pastacaldi C, Lewis P, Howarth P. “Staphylococci and staphylococcal superantigens in asthma and rhinitis: a systematic review and meta-analysis.” Allergy (2010). PMID: 21087214 ↗
L2SR_OBSCited in: Prognosis & Natural History - [423]
Anolik R, Schwartz AM, Sajjan S et al.. “Patient initiation and persistence with allergen immunotherapy.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 24814759 ↗
L2TRIAL_NONRANDOMCited in: Prognosis & Natural History - [424]
Rosario Filho NA, Satoris RA, Scala WR. “Allergic rhinitis aggravated by air pollutants in Latin America: A systematic review.” The World Allergy Organization journal (2021). PMID: 34471459 ↗
L2SR_OBSCited in: Prognosis & Natural History - [425]
Bager P, Wohlfahrt J, Westergaard T. “Caesarean delivery and risk of atopy and allergic disease: meta-analyses.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2008). PMID: 18266879 ↗
L2SR_OBSCited in: Prognosis & Natural History - [426]
Kuper P, Hasenpusch C, Proebstl S et al.. “Timing of complementary feeding for early childhood allergy prevention: An overview of systematic reviews.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023). PMID: 37779264 ↗
L2SR_OBSCited in: Prognosis & Natural History, Prevention, Screening & Surveillance - [427]
Campbell BE, Lodge CJ, Lowe AJ et al.. “Exposure to 'farming' and objective markers of atopy: a systematic review and meta-analysis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2015). PMID: 25270644 ↗
L2SR_OBSCited in: Prognosis & Natural History, Prevention, Screening & Surveillance - [428]
El Didi HS, Pereira AM, Jácome C et al.. “Control of Allergic Rhinitis and Asthma Test for Children (CARATkids): A systematic review and meta-analysis of its measurement properties.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2025). PMID: 40898383 ↗
L2SR_OBSCited in: Prognosis & Natural History - [429]
Zhang GQ, Liu B, Li J et al.. “Fish intake during pregnancy or infancy and allergic outcomes in children: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 27590571 ↗
L2SR_OBSCited in: Prognosis & Natural History - [430]
Rondón C, Bogas G, Barrionuevo E et al.. “Nonallergic rhinitis and lower airway disease.” Allergy (2016). PMID: 27439024 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [431]
Bousquet J, Pfaar O, Togias A et al.. “2019 ARIA Care pathways for allergen immunotherapy.” Allergy (2019). PMID: 30955224 ↗
L1REVIEW_NARRATIVECited in: Prognosis & Natural History - [432]
Van Gerven L, Steelant B, Hellings PW. “Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge.” Allergy (2018). PMID: 29624710 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [433]
Miliordos K, Triga M, Tranou MK et al.. “Natural history and clinical characteristics of fish-induced food protein-induced enterocolitis syndrome (FPIES) in Greek children.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2026). PMID: 41763605 ↗
L4OTHERCited in: Prognosis & Natural History - [434]
Neuman-Sunshine DL, Eckman JA, Keet CA et al.. “The natural history of persistent peanut allergy.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2011). PMID: 22541403 ↗
L4OTHERCited in: Prognosis & Natural History - [435]
Zhou J, Margiotta FM, Duca ED et al.. “Comorbidities of atopic dermatitis: Emerging evidence and clinical considerations.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2026). PMID: 42009218 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History - [436]
Lou Z, Yang H, Zhao C et al.. “Efficacy and Safety of Simultaneous Bilateral Nasal Cauterization in Pediatric Recurrent Anterior Epistaxis: A Prospective Randomized Controlled Trial.” American journal of rhinology & allergy (2026). PMID: 41940820 ↗
L1RCTCited in: Prognosis & Natural History - [437]
Hansen S, Strøm M, Maslova E et al.. “Fish oil supplementation during pregnancy and allergic respiratory disease in the adult offspring.” The Journal of allergy and clinical immunology (2016). PMID: 27246522 ↗
L1RCTCited in: Special Populations & Pregnancy - [438]
Ma J, Palmer DJ, Geddes D et al.. “Maternal Allergic Disease Phenotype and Infant Birth Season Influence the Human Milk Microbiome.” Allergy (2024). PMID: 39723602 ↗
L4RCTCited in: Special Populations & Pregnancy - [439]
Prenner BM, Amar NJ, Hampel FC et al.. “Efficacy and safety of GSP301 nasal spray in children aged 6 to 11 years with seasonal allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35926824 ↗
L1RCTCited in: Special Populations & Pregnancy - [440]
Storms WW, Segall N, Mansfield LE et al.. “Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2013). PMID: 24125150 ↗
L1RCTCited in: Special Populations & Pregnancy - [441]
Tareke AA, Hadgu AA, Ayana AM et al.. “Prenatal vitamin D supplementation and child respiratory health: A systematic review and meta-analysis of randomized controlled trials.” The World Allergy Organization journal (2020). PMID: 33294117 ↗
L1SR_MA_RCTCited in: Special Populations & Pregnancy - [442]
Cait A, Wedel A, Arntz JL et al.. “Prenatal antibiotic exposure, asthma, and the atopic march: A systematic review and meta-analysis.” Allergy (2022). PMID: 35689800 ↗
L2SR_OBSCited in: Special Populations & Pregnancy - [443]
Grabenhenrich LB, Keil T, Reich A et al.. “Prediction and prevention of allergic rhinitis: A birth cohort study of 20 years.” The Journal of allergy and clinical immunology (2015). PMID: 25976706 ↗
L2COHORTCited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance - [444]
Penagos M, Compalati E, Tarantini F et al.. “Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2006). PMID: 16937742 ↗
L1SR_OBSCited in: Special Populations & Pregnancy - [445]
Bozek A, Ignasiak B, Filipowska B et al.. “House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2013). PMID: 23331565 ↗
L2RCTCited in: Special Populations & Pregnancy - [446]
Yamamoto-Hanada K, Yang L, Ishitsuka K et al.. “Allergic profiles of mothers and fathers in the Japan Environment and Children's Study (JECS): a nationwide birth cohort study.” The World Allergy Organization journal (2017). PMID: 28811862 ↗
L2COHORTCited in: Special Populations & Pregnancy - [447]
Patil VK, Kurukulaaratchy RJ, Venter C et al.. “Changing prevalence of wheeze, rhinitis and allergic sensitisation in late childhood: findings from 2 Isle of Wight birth cohorts 12 years apart.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2015). PMID: 25809555 ↗
L2TRIAL_NONRANDOMCited in: Special Populations & Pregnancy - [448]
Flanigan C, Sheikh A, DunnGalvin A et al.. “Prenatal maternal psychosocial stress and offspring's asthma and allergic disease: A systematic review and meta-analysis.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2018). PMID: 29331049 ↗
L2SR_OBSCited in: Special Populations & Pregnancy - [449]
Venter C, Pickett K, Starling A et al.. “Advanced glycation end product intake during pregnancy and offspring allergy outcomes: A Prospective cohort study.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2021). PMID: 34610188 ↗
L2COHORTCited in: Special Populations & Pregnancy - [450]
Konishi S, Ng CF, Stickley A et al.. “Pollinosis and all-cause mortality among middle-aged and elderly Japanese: a population-based cohort study.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2016). PMID: 26366720 ↗
L2COHORTCited in: Special Populations & Pregnancy - [451]
Lampi J, Canoy D, Jarvis D et al.. “Farming environment and prevalence of atopy at age 31: prospective birth cohort study in Finland.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2011). PMID: 21575087 ↗
L2COHORTCited in: Special Populations & Pregnancy - [452]
Abdel-Aziz MI, Hashimoto S, Neerincx AH et al.. “Metabotypes are linked to uncontrolled childhood asthma, gut microbiota, and systemic inflammation.” The Journal of allergy and clinical immunology (2025). PMID: 40280190 ↗
L2OTHERCited in: Special Populations & Pregnancy - [453]
Hamilos DL. “Chronic rhinosinusitis: epidemiology and medical management.” The Journal of allergy and clinical immunology (2011). PMID: 21890184 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [454]
Jensen SK, Fischer-Rasmussen K, Eliasen A et al.. “From genotype to phenotype in early childhood asthma.” The Journal of allergy and clinical immunology (2026). PMID: 41500470 ↗
L2OTHERCited in: Special Populations & Pregnancy - [455]
Sultan T, Brustad N, Kyvsgaard JN et al.. “Dominance of IL-5 and CCL17 in nasal cytokine profiles of children with type 2 inflammation.” The Journal of allergy and clinical immunology (2025). PMID: 41352441 ↗
L2OTHERCited in: Special Populations & Pregnancy - [456]
DeBrosse CW, Franciosi JP, King EC et al.. “Long-term outcomes in pediatric-onset esophageal eosinophilia.” The Journal of allergy and clinical immunology (2011). PMID: 21636117 ↗
L3OTHERCited in: Special Populations & Pregnancy - [457]
Pfaller B, Bendien S, Ditisheim A et al.. “Management of allergic diseases in pregnancy.” Allergy (2021). PMID: 34427919 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [458]
Sastre J. “Ebastine in allergic rhinitis and chronic idiopathic urticaria.” Allergy (2008). PMID: 19032340 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [459]
Straumann A, Aceves SS, Blanchard C et al.. “Pediatric and adult eosinophilic esophagitis: similarities and differences.” Allergy (2012). PMID: 22313241 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [460]
Dramburg S, Grittner U, Potapova E et al.. “Heterogeneity of sensitization profiles and clinical phenotypes among patients with seasonal allergic rhinitis in Southern European countries-The @IT.2020 multicenter study.” Allergy (2024). PMID: 38311961 ↗
L4OTHERCited in: Special Populations & Pregnancy - [461]
Leskien M, Thiering E, Yu Z et al.. “Childhood Asthma and Allergy Are Related to Accelerated Epigenetic Aging.” Allergy (2025). PMID: 40346984 ↗
L2OTHERCited in: Special Populations & Pregnancy - [462]
Mustafa SS, Huang J, Perrotta K et al.. “COVID-19 and Pregnancy: Interrelationships With Asthma and Allergy.” The journal of allergy and clinical immunology. In practice (2023). PMID: 37604428 ↗
L5OTHERCited in: Special Populations & Pregnancy - [463]
Gentile D, Bartholow A, Valovirta E et al.. “Current and future directions in pediatric allergic rhinitis.” The journal of allergy and clinical immunology. In practice (2013). PMID: 24565478 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [464]
Anderson HM, Wood RA, Busse WW. “Dust Mite-Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27665384 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [465]
Shusterman D, Baroody FM, Craig T et al.. “Role of the Allergist-Immunologist and Upper Airway Allergy in Sleep-Disordered Breathing.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27923646 ↗
L4REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [466]
Bousquet J, Ventura MT, Taborda-Barata L et al.. “Allergic rhinitis in the elderly. In collaboration with ARIA guidelines.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42309322 ↗
L5OTHERCited in: Special Populations & Pregnancy - [467]
Wang HT, Warren CM, Gupta RS et al.. “Prevalence and Characteristics of Shellfish Allergy in the Pediatric Population of the United States.” The journal of allergy and clinical immunology. In practice (2020). PMID: 31917365 ↗
L4OTHERCited in: Special Populations & Pregnancy - [468]
Rachelefsky G, Farrar JR. “Are you comfortable with over-the-counter intranasal steroids for children? A call to action.” The journal of allergy and clinical immunology. In practice (2014). PMID: 24811016 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [469]
Bozek A, Ignasiak B, Kasperska-Zajac A et al.. “Local allergic rhinitis in elderly patients.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2015). PMID: 25744906 ↗
L4OTHERCited in: Special Populations & Pregnancy - [470]
Hussien H, Moore DL, Nimri S et al.. “The age of eczema onset and multiple food allergies.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025). PMID: 41349694 ↗
L2OTHERCited in: Special Populations & Pregnancy - [471]
Larenas-Linnemann D, Blaiss M, Van Bever HP et al.. “Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2013). PMID: 23706708 ↗
L1REVIEW_NARRATIVECited in: Special Populations & Pregnancy - [472]
Sherrey J, Biggs S, Dorrian J et al.. “Allergic disease, sleep problems, and psychological distress in children recruited from the general community.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2022). PMID: 35598883 ↗
L4OTHERCited in: Special Populations & Pregnancy - [473]
Ventura MT, Gelardi M, D'Amato A et al.. “Clinical and cytologic characteristics of allergic rhinitis in elderly patients.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2012). PMID: 22374194 ↗
L4OTHERCited in: Special Populations & Pregnancy - [474]
Della Giustina A, Landi M, Bellini F et al.. “Vitamin D, allergies and asthma: focus on pediatric patients.” The World Allergy Organization journal (2014). PMID: 25829979 ↗
L5REVIEW_NARRATIVECited in: Special Populations & Pregnancy, Prevention, Screening & Surveillance - [475]
Imoto Y, Sakashita M, Tokunaga T et al.. “Recent prevalence of allergic rhinitis caused by house dust mites among the pediatric population in Fukui, Japan.” The World Allergy Organization journal (2024). PMID: 39114286 ↗
L4OTHERCited in: Special Populations & Pregnancy - [476]
Lu HY, Chiu CW, Kao PH et al.. “Association between maternal age at delivery and allergic rhinitis in schoolchildren: A population-based study.” The World Allergy Organization journal (2020). PMID: 32612736 ↗
L2OTHERCited in: Special Populations & Pregnancy - [477]
Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗
L2COHORTCited in: Special Populations & Pregnancy - [478]
Merkle T, Curley C, Wambold D et al.. “Association of Nasal and Inhalant Corticosteroids With Pediatric Perioral Dermatitis: A TriNetX Retrospective Cohort Study.” Pediatric dermatology (2026). PMID: 42107964 ↗
L2COHORTCited in: Special Populations & Pregnancy - [479]
Smiley K, Galli L, Grippen Goddard A et al.. “Clinical characteristics, type 2 comorbidities, and treatment responses in pediatric and adult chronic spontaneous urticaria: A multicenter retrospective cohort study.” Allergy and asthma proceedings (2026). PMID: 42050840 ↗
L2COHORTCited in: Special Populations & Pregnancy - [480]
Chia XY, Cai J, Dai D et al.. “Efficacy and safety of Tuina therapy for children with combined allergic rhinitis and asthma syndrome in remission: a randomized controlled trial protocol.” Frontiers in medicine (2026). PMID: 42415810 ↗
L5OTHERCited in: Special Populations & Pregnancy - [481]
Wheatley LM, Wood R, Nadeau K et al.. “Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID/AHRQ Workshop.” The Journal of allergy and clinical immunology (2019). PMID: 30731123 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [482]
Jaakkola MS, Quansah R, Hugg TT et al.. “Association of indoor dampness and molds with rhinitis risk: a systematic review and meta-analysis.” The Journal of allergy and clinical immunology (2013). PMID: 24028857 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [483]
Yepes-Nuñez JJ, Brożek JL, Fiocchi A et al.. “Vitamin D supplementation in primary allergy prevention: Systematic review of randomized and non-randomized studies.” Allergy (2017). PMID: 28675776 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [484]
Venter C, Meyer RW, Greenhawt M et al.. “Role of dietary fiber in promoting immune health-An EAACI position paper.” Allergy (2022). PMID: 35801383 ↗
L5SR_OBSCited in: Prevention, Screening & Surveillance - [485]
Anandan C, Nurmatov U, Sheikh A. “Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta-analysis.” Allergy (2009). PMID: 19392990 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [486]
Brick T, Hettinga K, Kirchner B et al.. “The Beneficial Effect of Farm Milk Consumption on Asthma, Allergies, and Infections: From Meta-Analysis of Evidence to Clinical Trial.” The journal of allergy and clinical immunology. In practice (2019). PMID: 31770653 ↗
L2TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [487]
Schmitt J, Schwarz K, Stadler E et al.. “Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study.” The Journal of allergy and clinical immunology (2015). PMID: 26371838 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [488]
Lo JE, Huang YH, Bhattacharyya N et al.. “Allergic Rhinitis and Keratoconus: A Systematic Review and Meta-Analysis.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38851486 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [489]
Arroyave WD, Rabito FA, Carlson JC et al.. “Impermeable dust mite covers in the primary and tertiary prevention of allergic disease: a meta-analysis.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2014). PMID: 24484971 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [490]
Ellis AK, Tsitoura DC, Quint D et al.. “Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017). PMID: 28681506 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [491]
Baumann LM, Romero KM, Robinson CL et al.. “Prevalence and risk factors for allergic rhinitis in two resource-limited settings in Peru with disparate degrees of urbanization.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2015). PMID: 25059756 ↗
L4TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [492]
Nwaru BI, Ohlsson C, Bygdell M et al.. “Pubertal BMI change and adult-onset asthma in men: Population-based cohort study in Sweden.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2019). PMID: 31732997 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [493]
Rosas-Salazar C, Gebretsadik T, Seibold MA et al.. “Impact of nasal and inhaled corticosteroids on SARS-CoV-2 infection susceptibility.” The Journal of allergy and clinical immunology (2025). PMID: 40701496 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [494]
Hong H, Liao S, Chen F et al.. “Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation.” Allergy (2020). PMID: 32737888 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [495]
Biedermann T, Winther L, Till SJ et al.. “Birch pollen allergy in Europe.” Allergy (2019). PMID: 30829410 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [496]
Ordak M, Zemelka-Wiacek M, Kosowska A et al.. “Trace Elements in Allergy: Narrative Review.” Allergy (2026). PMID: 42083298 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [497]
Cardona V, Luengo O, Labrador-Horrillo M. “Immunotherapy in allergic rhinitis and lower airway outcomes.” Allergy (2016). PMID: 27439141 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [498]
Schatz M, Sicherer SH, Zeiger RS. “The Journal of Allergy and Clinical Immunology: In Practice 2017 Year in Review.” The journal of allergy and clinical immunology. In practice (2018). PMID: 29397373 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [499]
Pepper AN, Calderón MA, Casale TB. “Sublingual Immunotherapy for the Polyallergic Patient.” The journal of allergy and clinical immunology. In practice (2016). PMID: 27452888 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [500]
Fiocchi A, Cabana MD, Mennini M. “Current Use of Probiotics and Prebiotics in Allergy.” The journal of allergy and clinical immunology. In practice (2022). PMID: 35792336 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [501]
Shaker M, Mauger D, Fuhlbrigge AL. “Value-Based, Cost-Effective Care: The Role of the Allergist-Immunologist.” The journal of allergy and clinical immunology. In practice (2022). PMID: 35944893 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [502]
Kyvsgaard JN, Hesselberg LM, Sunde RB et al.. “Burden and Subtypes of Early Life Infections Increase the Risk of Asthma.” The journal of allergy and clinical immunology. In practice (2024). PMID: 38609018 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [503]
Chipps BE, Murphy KR, Oppenheimer J. “2020 NAEPP Guidelines Update and GINA 2021-Asthma Care Differences, Overlap, and Challenges.” The journal of allergy and clinical immunology. In practice (2021). PMID: 34718214 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [504]
Lau S, Matricardi PM, Wahn U et al.. “Allergy and atopy from infancy to adulthood: Messages from the German birth cohort MAS.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2018). PMID: 29803707 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [505]
Sugita K, Soyka MB, Wawrzyniak P et al.. “Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.” Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2020). PMID: 32454094 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [506]
Xu H, Wen Y, Zheng H et al.. “Allergic disease and keratoconus: A two-sample univariable and multivariable Mendelian randomization study.” The World Allergy Organization journal (2024). PMID: 39650195 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [507]
Xu Y, Li Y. “Association between lipid-lowering drugs and allergic diseases: A Mendelian randomization study.” The World Allergy Organization journal (2024). PMID: 38623319 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [508]
Ai Y, Zhu T, Gan J. “Parental autoimmune diseases and offspring's allergic disease: A systematic review and meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 41930403 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [509]
Islam N, Chu AWL, Sheriff F et al.. “Risk Factors for the Development of Food Allergy in Infants and Children: A Systematic Review and Meta-Analysis.” JAMA pediatrics (2026). PMID: 41661638 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [510]
Liu Y, Ge J, Xu G et al.. “Burden and risk of asthma and rhinitis in people with atopic dermatitis: global estimates from a hierarchical Bayesian model.” The British journal of dermatology (2026). PMID: 41641462 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [511]
Sousa-Pinto B, Jankin S, Vieira RJ et al.. “English tweets on allergy: Content analysis and association with surveillance data.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2024). PMID: 38567657 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [512]
Shifti DM, Pitt E, Versteegh L et al.. “Mapping the Burden and Risk Factors of Allergic Diseases and Asthma Among Aboriginal and Torres Strait Islander People: A Scoping Review.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2025). PMID: 40836867 ↗
L2REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [513]
Valbert F, Neusser S, Pfaar O et al.. “Care with allergen immunotherapy for allergic respiratory diseases in Germany-Predictors and deficits.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022). PMID: 35524545 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [514]
Zhang HW, Chang YT, Kuo YJ et al.. “Androgenetic alopecia risk in allergic rhinitis: A cohort study of immune and antihistamine effects.” The World Allergy Organization journal (2026). PMID: 42028243 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [515]
Lyu W, Wen Y, Chen L et al.. “Unhealthy sleep patterns and irregular night shift work are associated with increased risk of allergic rhinitis: a large prospective cohort study.” BMC public health (2026). PMID: 41776521 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [516]
Tham EH, Rajakulendran M, Lee BW et al.. “Epicutaneous sensitization to food allergens in atopic dermatitis: What do we know?” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2019). PMID: 31541586 ↗
L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [517]
Kaplan F, Gülyüz A. “Mucous Stools in Infancy as an Early Marker of the Atopic March: A Four-Year Cohort Study of Respiratory Atopy Risk.” Children (Basel, Switzerland) (2026). PMID: 41749622 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [518]
Thomander T, Gil-Mata S, Riera-Serra P et al.. “Efficacy and safety of oral treatments for allergic rhinitis in children: A network meta-analysis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42596864 ↗
L1aCited in: Definition, Classification & Hypersensitivity Mechanism Type - [519]
Esmaeel SE, Alanazi RIS, Albladi OOA et al.. “Efficacy and safety of nasal saline irrigation for allergic rhinitis in children and adolescents: A systematic review and meta-analysis with GRADE assessment.” International journal of pediatric otorhinolaryngology (2026). PMID: 42579992 ↗
L1aCited in: Definition, Classification & Hypersensitivity Mechanism Type - [520]
Ranasinghe S, Berger X, Kimita W et al.. “A Novel Device to Improve the Tolerability of Intranasal Corticosteroid Sprays for Allergic Rhinitis and Postoperative Chronic Rhinosinusitis: A Crossover Trial.” Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery (2026). PMID: 42363677 ↗
L1bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [521]
Teng ZP, Han QQ, Shen XF. “Haemophilus abundance is associated with response to sublingual immunotherapy in children with allergic rhinitis.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42487293 ↗
L4Cited in: Definition, Classification & Hypersensitivity Mechanism Type - [522]
Lee JK, Lee HW, Lee CH et al.. “Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long-term Outcomes from a Multicenter Cohort Study.” Journal of asthma and allergy (2026). PMID: 42445813 ↗
L2bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [523]
Kan D, Cheng H, Zhou Q. “Prevalence and Associated Factors of Eustachian Tube Dysfunction in Allergic Rhinitis with Middle-Ear Disease-Related Outcomes: A Systematic Review and Meta-analysis.” International archives of allergy and immunology (2026). PMID: 42579640 ↗
L2aCited in: Definition, Classification & Hypersensitivity Mechanism Type - [524]
Petre AM, Costin R, Anghel I. “Allergic Rhinitis and Allergic Sensitization in Pediatric Otitis Media with Effusion: A Systematic Review and Meta-Analysis with Narrative Synthesis of Eustachian Tube Dysfunction.” Children (Basel, Switzerland) (2026). PMID: 42509917 ↗
L2aCited in: Definition, Classification & Hypersensitivity Mechanism Type - [525]
Gonzalez-Uribe V, Prieto-Gomez J, Moreno-Castro S et al.. “Early and longitudinal response to sublingual immunotherapy across pediatric allergic multimorbidity patterns: A 3-year real-world cohort study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42596760 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [526]
Berkun Y, Magen E, Merzon E et al.. “Allergic but not autoimmune comorbidities in children with PFAPA: A nationwide matched case-control cohort study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42452886 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [527]
Choudhary H, Kaur H, R S et al.. “Fractional Exhaled Nitric Oxide Cut-off Values for Discriminating Asthma Exacerbation and Control in Indian Children with Coexisting Allergic Rhinitis: A Prospective Observational Cohort Study.” Indian journal of pediatrics (2026). PMID: 42536317 ↗
L2bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [528]
Pu S, Zhu Y, Zhou J et al.. “Nasopharyngeal swab transcriptomics identifies divergent molecular signatures in adenoid hypertrophy and allergic rhinitis comorbidity.” Frontiers in immunology (2026). PMID: 42591655 ↗
L4Cited in: Definition, Classification & Hypersensitivity Mechanism Type - [529]
Cui L, Li L, Li J et al.. “Relative contributions of environmental pollen exposure and host susceptibility to Artemisia-related sensitisation and allergy in a high-exposure region of Northern China: a population-based cross-sectional study.” Frontiers in immunology (2026). PMID: 42564215 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [530]
Sha L, Ye S, Li T et al.. “Clinical characteristics and associated factors of airway allergic diseases among children: a cross-sectional study in a district of Beijing.” Frontiers in public health (2026). PMID: 42535047 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [531]
Torun T, Baris HE, Us MC et al.. “Allergic diseases and early childhood insomnia: A cross-sectional study.” Sleep medicine (2026). PMID: 42531837 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [532]
Dumycz K, Zygadło J, Panczyk M et al.. “Phenotypes of atopic dermatitis in Polish children-Latent class analysis of cross-sectional questionnaire-based study.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42400111 ↗
L3bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [533]
Yang J, Ma N, Tian F et al.. “Development and validation of the childhood allergy comprehensive screening questionnaire and Its application in a cross-sectional survey of allergic diseases among children aged 0-6 Years in Shanghai, China.” Frontiers in public health (2026). PMID: 42591591 ↗
L4Cited in: Definition, Classification & Hypersensitivity Mechanism Type - [534]
Yan B, Fang H. “Low-temperature plasma adenoidectomy versus conservative treatment for children with adenoid hypertrophy and allergic rhinitis: A non-randomized observational study.” Science progress (2026). PMID: 42549919 ↗
L1bCited in: Definition, Classification & Hypersensitivity Mechanism Type - [535]
Du H, Lu S, Cai D et al.. “Efficacy and safety of press-needle therapy for allergic rhinitis in children: A systematic review and meta-analysis.” International journal of pediatric otorhinolaryngology (2026). PMID: 42503260 ↗
L1aCited in: Pathophysiology & Immune Mechanism - [536]
Deng B, Zhao Y, Liu J. “Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis.” Immunotherapy (2026). PMID: 42550205 ↗
L1bCited in: Pathophysiology & Immune Mechanism - [537]
Altamirano-Jara JB, Acosta-España JD, Zambrano LI et al.. “The Dermatologic Burden of Flooding: A Systematic Review of Epidemiology, Clinical Manifestations, and Management in a Warming World.” International journal of dermatology (2026). PMID: 42467553 ↗
L2aCited in: Pathophysiology & Immune Mechanism - [538]
Zhu KZ, He C, Zhu SZ et al.. “Enhanced Early Detection of Allergic Rhinitis: A Prospective Study on a Symptom-Based Predictive Model.” World journal of otorhinolaryngology - head and neck surgery (2026). PMID: 42500099 ↗
L2bCited in: Pathophysiology & Immune Mechanism - [539]
Koyama K, Kidoguchi M, Adachi N et al.. “Nasal Corynebacterium depletion is associated with polysensitization to inhalant allergens in adults.” Allergology international : official journal of the Japanese Society of Allergology (2026). PMID: 42595650 ↗
L3bCited in: Pathophysiology & Immune Mechanism - [540]
Yılmaz E, Köker Özer N, Topal E. “Exercise-Induced Bronchoconstriction in Non-Asthmatic Children with Moderate-to-Severe Persistent Allergic Rhinitis Undergoing Subcutaneous Allergen Immunotherapy: Prevalence and Risk Factors.” Journal of clinical medicine (2026). PMID: 42590047 ↗
L3bCited in: Pathophysiology & Immune Mechanism - [541]
Al-Ahmad M, Ali A, Talat W. “Impact of Overweight and Obesity in Severe Asthma Patients and Its Influence on Achieving Clinical Remission.” Journal of asthma and allergy (2026). PMID: 42518874 ↗
L3bCited in: Pathophysiology & Immune Mechanism - [542]
Wang WH, Luo X, Xiao ZH et al.. “Association of Cat Sensitization With Comorbid Asthma in Patients With Allergic Rhinitis: A Real-World Study.” World journal of otorhinolaryngology - head and neck surgery (2026). PMID: 42500084 ↗
L3bCited in: Pathophysiology & Immune Mechanism - [543]
Yılmaz E, Topal E. “Small Airway Dysfunction Assessed by Impulse Oscillometry in Non-Asthmatic Children with Moderate-to-Severe Persistent Allergic Rhinitis During the Early Phase of Allergen Immunotherapy.” Journal of clinical medicine (2026). PMID: 42513532 ↗
L3bCited in: Pathophysiology & Immune Mechanism - [544]
Wang Z, Lu Y. “Efficacy of probiotics on immunological and clinical outcomes in allergic rhinitis: an umbrella review and updated meta-analysis of RCTs in children and adults.” BMC immunology (2026). PMID: 42469658 ↗
L1aCited in: Pathophysiology & Immune Mechanism - [545]
Çelik E, Yüksel Bulut H. “Respiratory Pathogens and Clinical Characteristics of Asthma Exacerbations in Hospitalized Children at a Tertiary Hospital in Türkiye.” Children (Basel, Switzerland) (2026). PMID: 42509879 ↗
L4Cited in: Pathophysiology & Immune Mechanism - [546]
Tang Z, Zhao Y. “Case Report: Bullous erythema multiforme induced by omalizumab.” Frontiers in medicine (2026). PMID: 42539369 ↗
L4Cited in: Pathophysiology & Immune Mechanism - [547]
Bhatnagar K, Bartho M, Pua E et al.. “The Impact of Septorhinoplasty on Work Productivity and Activity Impairment: A Multi-Institutional, Prospective Cohort.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2026). PMID: 42549734 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [548]
Liu J, Lodge CJ, Perret JL et al.. “FEF25-75% trajectories from age 7 to 53 years, associations with childhood and parental preconception factors, and midlife COPD risk: a prospective cohort study.” The Lancet. Respiratory medicine (2026). PMID: 42480573 ↗
L2bCited in: Epidemiology, Etiology & Risk Factors - [549]
Walker K, Valencia-Sanchez BA, Wilson P et al.. “Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab.” Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2026). PMID: 42605935 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [550]
Su JA, Chang SJ, Yang YH et al.. “Association of maternal depression and antidepressant use during pregnancy with child allergic risk: A nationwide cohort study.” Psychiatry research (2026). PMID: 42585799 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [551]
Silverberg JI, Martins B, Du M et al.. “Healthcare resource utilization and costs in pediatric patients under 6 years old with atopic dermatitis in the United States: A retrospective, observational, cross-sectional study.” JAAD international (2026). PMID: 42564562 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [552]
Koriyama M, Okamoto Y, Kurokawa T et al.. “Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study.” Allergology international : official journal of the Japanese Society of Allergology (2026). PMID: 42538191 ↗
L3bCited in: Epidemiology, Etiology & Risk Factors - [553]
Azzi A, Alotaibi AS, Alamri MS et al.. “The Efficacy of Probiotics in Treating Upper Respiratory Tract Infections, Allergic Rhinitis, and Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis.” Microorganisms (2026). PMID: 42197372 ↗
L1aCited in: Clinical Presentation - [554]
Wang J, Zhu X, Ding Z. “Predicting sublingual immunotherapy efficacy in allergic rhinitis.” BMC pulmonary medicine (2026). PMID: 42265665 ↗
L1bCited in: Clinical Presentation - [555]
Ripp AT, Patel PA, Nguyen SA et al.. “Variations in the Severity of Rhinitis Symptoms: A Systematic Review and Meta-Analysis.” World journal of otorhinolaryngology - head and neck surgery (2025). PMID: 42500067 ↗
L4Cited in: Clinical Presentation - [556]
O'Connor MB, Patel RD, Soltani H et al.. “Congenital Ichthyosis is Associated with Increased Risk of Allergic Disorders.” The Journal of allergy and clinical immunology (2026). PMID: 42562187 ↗
L3bCited in: Clinical Presentation - [557]
Aremu S. “Chronic Humidity and Nasal Mucosal Dysfunction in Tropical Climates: Implications for Sinonasal Health in Sub-Saharan Africa and the Developing World - A Systematic Review.” Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria (2026). PMID: 42537028 ↗
L1aCited in: Clinical Presentation - [558]
Zhao J, Wang Z, Wang Y et al.. “Allergy burden score and lung function impairment in children with asthma: a dose-response cross-sectional study.” European journal of pediatrics (2026). PMID: 42337151 ↗
L3bCited in: Clinical Presentation - [559]
Wang W, Wang J, Song G et al.. “Trends in Asthma-Rhinitis Allergic Multimorbidity and Polysensitization in China: The CARRAD Study.” MedComm (2026). PMID: 42253935 ↗
L3bCited in: Clinical Presentation - [560]
Pfaar O, Demoly P, Gevaert P et al.. “Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis.” Clinical and translational allergy (2026). PMID: 42579775 ↗
L1bCited in: Severity, Grading & Risk Stratification - [561]
Siewert J, Cramer H, Ortiz M et al.. “Homeopathic medication for seasonal allergic rhinitis-a randomised placebo-controlled trial.” Frontiers in allergy (2026). PMID: 42539590 ↗
L1bCited in: Severity, Grading & Risk Stratification - [562]
Gagnon R, Dalgaard T, Ortving GS et al.. “Efficacy and safety of the tree sublingual immunotherapy tablet in the subpopulation of Canadian children with allergic rhinitis and/or conjunctivitis: phase III trial results.” Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2026). PMID: 42432760 ↗
L1bCited in: Severity, Grading & Risk Stratification - [563]
Salimi S, Amiri S, Karimi SA et al.. “Effect of glucocorticoids on smell sensation in patients with non-traumatic olfactory disorders: a systematic review and meta-analysis.” European journal of clinical pharmacology (2026). PMID: 42507165 ↗
L2aCited in: Severity, Grading & Risk Stratification - [564]
Hou Y, Zhang Q, Xu X et al.. “Effects of vitamin D levels and vitamin D supplementation on allergic diseases: an umbrella review.” Frontiers in allergy (2026). PMID: 42445461 ↗
L2aCited in: Severity, Grading & Risk Stratification - [565]
Olsen RF, Svendsen K, Graf T et al.. “Birch Rust Spore Exposure and Upper Airway Symptom Dynamics in a Subarctic Region: Indications for a Novel Seasonal Allergen.” Clinical and translational allergy (2026). PMID: 42572169 ↗
L3bCited in: Severity, Grading & Risk Stratification - [566]
Liu B, Hu S, Xiao M. “Improvement in nasal signs and eosinophils following 3 years of sublingual immunotherapy for allergic rhinitis.” Frontiers in immunology (2026). PMID: 42131321 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway - [567]
Lourenço-Silva N, Sousa-Pinto B, Bognanni A et al.. “Comparison of Allergic Rhinitis Treatments on Utilities and Quality of Life: A MASK-air Study.” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2026). PMID: 42087806 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway - [568]
Magen E, Magen I, Merzon E et al.. “Comorbidity burden in patients with anaphylaxis: A 25-year nationwide population-based matched case-control study.” Allergy and asthma proceedings (2026). PMID: 42050834 ↗
L2bCited in: Acute Management & Anaphylaxis Pathway - [569]
Lim MN, Park JS, Kwon JW. “How Pregnancy Affects Asthma in Korea: Risk Factors and Adherence Decline.” Allergy, asthma & immunology research (2026). PMID: 42223035 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway - [570]
Zhang H, Li X, Guo T et al.. “Knowledge, attitudes, and practices regarding intranasal corticosteroid use in adult outpatients with allergic rhinitis: a cross-sectional study in Sichuan Province, China.” Frontiers in public health (2026). PMID: 42205446 ↗
L3bCited in: Acute Management & Anaphylaxis Pathway - [571]
Liu J, Pang S, Lu Y et al.. “Multi-target mechanisms of Chinese herbal medicine in the treatment of allergic rhinitis.” Journal of ethnopharmacology (2026). PMID: 42061564 ↗
L1aCited in: Acute Management & Anaphylaxis Pathway - [572]
Nurpeissov T, Tabynov K, Zhubanturliyeva A et al.. “Ultra-short recombinant Art v 1 immunotherapy induces rapid immune modulation in mugwort allergy: A Phase I trial.” Allergology international : official journal of the Japanese Society of Allergology (2026). PMID: 42336691 ↗
L4Cited in: Acute Management & Anaphylaxis Pathway - [573]
Li L, Xu Y, Bian S et al.. “Comparison of the efficacy of different doses of omalizumab (150 mg vs 300 mg) in patients with seasonal allergic rhinitis and low total IgE: A randomized, double-blind, controlled study.” The World Allergy Organization journal (2026). PMID: 42256022 ↗
L1bCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [574]
Luan H, Gao S, Ma Y et al.. “Interleukin-Mediated Macrophage Polarization in Allergic Rhinitis Inflammation: A Systematic Review.” Journal of inflammation research (2026). PMID: 42445359 ↗
L2aCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [575]
Zhou W, Guo X, Ding B et al.. “Impact of Allergen-Specific Subcutaneous Immunotherapy on 12-Month Health-Related Quality of Life in Children and Their Parental Caregivers.” Allergy, asthma & immunology research (2026). PMID: 42547470 ↗
L3bCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [576]
Wang Q, Dong X, Zhu S et al.. “Comorbidity of Allergic Asthma and Rhinitis and High Allergen-Specific IgE are Risk Factors for Systemic Reactions to House Dust Mite Immunotherapy in Children.” Journal of asthma and allergy (2026). PMID: 42326971 ↗
L4Cited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [577]
Máspero JF, Arnaout RK, Vargas-Ramírez L et al.. “Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry.” Advances in therapy (2026). PMID: 42268495 ↗
L3bCited in: Long-term & Definitive Management: Avoidance, Immunotherapy, Biologics - [578]
Carucci L, Nocerino R, Cantone E et al.. “Allergic rhinitis and nasal septum deviation in children: cause, consequence, or bidirectional relationship? Insights from the ARHINASD study.” Frontiers in medicine (2026). PMID: 42328578 ↗
L3bCited in: History and Evolution of Treatment - [579]
Yu L, Zhang P, Shang X et al.. “Knowledge, Attitudes, and Practices on Allergic Rhinitis Environmental Control and Treatment in China.” Journal of asthma and allergy (2026). PMID: 42403891 ↗
L3bCited in: History and Evolution of Treatment - [580]
Atar Bese S, Mercan A, Koksal ZG et al.. “Medium-term pulmonary outcomes (<6 months) after pediatric COVID-19 infection evaluated using impulse oscillometry and spirometry.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2026). PMID: 42086504 ↗
L4Cited in: History and Evolution of Treatment - [581]
Janeczek K, Grzegorzewska W, Zarobkiewicz M et al.. “Intervention with Polyvalent Bacterial Lysate Modulates T Helper Cell Subsets in Polish Children with Grass Pollen-Induced Allergic Rhinitis.” Biomedicines (2026). PMID: 42512095 ↗
L1bCited in: Complications, Comorbidities & Iatrogenic Risks - [582]
Ovadia A, Gavze RP, Lev-Shalem L et al.. “Familial Mediterranean Fever Is Associated with Higher Atopic Morbidity: Evidence from a Country-Wide Case-Control Study.” The journal of allergy and clinical immunology. In practice (2026). PMID: 42492811 ↗
L3bCited in: Complications, Comorbidities & Iatrogenic Risks - [583]
Goh SLE, Yang JX, Kan SJ et al.. “Evidence-to-Recommendation Framework for 2026 ACE Clinical Guideline on allergic rhinitis - diagnosis and management.” Singapore medical journal (2026). PMID: 42434879 ↗
L1cCited in: Complications, Comorbidities & Iatrogenic Risks - [584]
Song Z, He J, Li S et al.. “Persistence and Reasons for Discontinuation of Subcutaneous Immunotherapy in Children with Dust Mite Allergy: A Real-World Cohort from Hangzhou, China.” Journal of asthma and allergy (2026). PMID: 42109536 ↗
L3bCited in: Prognosis & Natural History - [585]
Simamura A, Sato S, Matsuoka T et al.. “Skin symptoms during the pollen seasons and their association with the severity of seasonal allergic rhinitis in Yamanashi, Japan.” Allergology international : official journal of the Japanese Society of Allergology (2026). PMID: 42309866 ↗
L3bCited in: Prognosis & Natural History - [586]
Zou H, Han P, Yin J et al.. “Follow-up study on factors influencing the persistence of asthma in discharged children.” BMC pediatrics (2026). PMID: 42471639 ↗
L3bCited in: Prognosis & Natural History - [587]
Tu J, Li J, Xie Q et al.. “Hospital-based patterns of allergen sensitization among 19,787 patients with suspected allergic diseases in Ningbo, China.” Frontiers in public health (2026). PMID: 42110272 ↗
L3bCited in: Prevention, Screening & Surveillance - [588]
Jia J, Yuan X, Liu L et al.. “Age-Related Differences in Efficacy and Safety of Subcutaneous Immunotherapy in Allergic Rhinitis: A Real-World Study.” OTO open (2026). PMID: 41948692 ↗
L3bCited in: Prevention, Screening & Surveillance - [589]
Kiatvitchukul T, Dokkham P, Jeephet K et al.. “Understanding recurrent wheezing: A parent's guide.” World journal of clinical pediatrics (2026). PMID: 41884034 ↗
L3bCited in: Prevention, Screening & Surveillance - [590]
Zhou Z, Ren Q, Tang H et al.. “Associations of mixed exposure to family hygiene practices, indoor ventilation, and device use with childhood allergic diseases: A cross-sectional study in Wuhan, China.” Journal of exposure science & environmental epidemiology (2026). PMID: 42082716 ↗
L3bCited in: Prevention, Screening & Surveillance - [591]
Xu Q, Zhao H, Dong Y et al.. “Polysensitization Patterns and Age-Dependent Allergen Profiles in Children from Suzhou, China: A Component-Resolved Cross-Sectional Study.” Journal of asthma and allergy (2026). PMID: 41868538 ↗
L3bCited in: Prevention, Screening & Surveillance